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Abstract 
Embryonic stem (ES) cells exist in a pluripotent state and have the ability to 
differentiate into all adult cell types. Numerous molecular mechanisms are 
responsible for both maintaining pluripotency and directing differentiation. One of 
these mechanisms is epigenetics, the heritable regulation of gene expression profiles 
without changes to the underlying DNA sequence. This has recently been the focus 
of a large amount of research. The Polycomb group (PcG) proteins have been 
identified as major epigenetic regulators. Recent research has shown that PcG 
proteins are involved in silencing genes in ES cells which play a key role in 
development and cell fate decisions. PcG proteins function in two main complexes, 
the Polycomb repressive complexes (PRC), PRC1 and PRC2. Here I explore the 
mechanisms involved in the regulation of PcG proteins in ES cells and how these 
proteins contribute to the maintenance of ES cell pluripotency. 
 
Analysis of the expression levels of PRC2 genes showed them to be significantly 
reduced in differentiated cells compared to undifferentiated ES cells. The differences 
observed in PRC2 expression are due to a regulation at the transcriptional level by 
key ES cell transcription factors such as Oct4 and Sox2. Interestingly, ES cell lines 
which are mutant for PcG members failed to silence genes expressed in distinct 
lineages of the mouse embryo and show a greater tendency to differentiate. In 
particular, Ring1A/B proteins from the PRC1 complex were shown to be essential for 
maintaining a poised form of RNAPII at silenced ES cell promoters, thus contributing 
to the maintenance of pluripotency in ES cells.  
 
Recent data has shown that the Polycomblike protein (Pcl) interacts with the 
canonical PRC2 complex. To further characterise this interaction I have used an 
affinity purification strategy to isolate novel Pcl2 complexes from ES cells and 
identify potential interactors and recruitment factors. The affinity purification of Pcl2 
confirmed it to be a bona fide member of a PRC2 sub-complex and identified 
additional interactor proteins which will be further characterised. The knockdown of 
Pcl2 does not have a severe impact on the stability of ES cells but affects the 
recruitment of Ezh2 and Suz12 to the promoters of PRC2 target genes leading to a 
small reduction on H3K27me3 levels but no changes in gene expression. In addition 
Pcl2 plays a key role in the recruitment of PRC2 to the inactive X chromosome and 
enrichment of H3K27me3. These observations suggest that Pcl2 plays an important 
role in PRC2 mediated epigenetic control. 
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Chapter 1. Introduction 
 
1.1. Epigenetics  
1.1.1. Historical overview of epigenetics 
With the completion of the human genome sequencing (Lander et al., 2001; 
McPherson et al., 2001), it became clear that sequences are only the tip of the 
iceberg for understanding how genetic information is interpreted. Superimposed 
upon the DNA sequence exist several layers of heritable information that we are only 
beginning to understand. The vast majority of cells in a multicellular organism share 
the same genetic information, yet a multitude of specialised cell types each using a 
unique subset of genes is generated throughout development. Using a book analogy, 
all the cells in an organism have the same “instruction manual” written as the 
primary DNA sequence. Different cell types that arise through the development of a 
given organism use only the information contained in certain chapters of this book. 
How this information is chosen, interpreted and maintained throughout 
development is the focus of epigenetics.  
 
Epigenetics is a term that was first introduced by C. H. Waddington in 1942 as a 
portmanteau of the words “genetics” and “epigenesis” (Waddington, 1942). 
Epigenesis is a theory first conceptualized by Aristotle and re-introduced in the late 
eighteenth century, which postulates that cells differentiate from an 
undifferentiated mass of cells during embryonic development, a view that dethroned 
the creationist theory of preformation. When Waddington first coined Epigenetics, 
the physical nature of genes and their role in heredity was not known. He used it as a 
conceptual model to explain how genes interact with the environment to produce a 
phenotype throughout development (Waddington, 1942). Later, Waddington 
described cellular differentiation as an epigenetic phenomenon, essentially governed 
by changes in what he called the “epigenetic landscape” rather than alterations in 
genetic inheritance (Waddington, 1957) (Figure 1.1).  
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Figure 1.1. The Epigenetic Landscape. In 1957, Conrad Waddington introduced the concept of an 
epigenetic landscape to describe how a cell makes decisions throughout development. In this 
dynamic visual metaphor, the cell (represented by a ball) can follow different trajectories that will 
produce different outcomes or cellular fates. Adapted from (Waddington, 1957). 
 
 
Since Waddington first used the term epigenetics, its definition has evolved 
significantly and became more narrowly linked to specific molecular phenomena 
occurring in organisms (Roloff and Nuber, 2005). Today, epigenetics refer to 
heritable traits that are passed over several rounds of cell division or even from one 
generation to the other and that do not involve changes to the underlying DNA 
sequence (Martienssen, 1996). Epigenetic traits exist on top of or in addition to the 
traditional genetic models of inheritance. In a broader sense, epigenetics is what 
bridges the genotype to the phenotype, a phenomenon that changes the final 
outcome of a locus or chromosome without any genetic change (Goldberg et al., 
2007).  
 
In recent years, there has been an explosion of interest in epigenetics. In part this 
has been fuelled by progress in understanding classical examples of epigenetic 
phenomena such as paramutation in maize, first observed in 1958, in which one 
allele cause epigenetic heritable changes at the other allele in the same locus 
16 
 
(Chandler and Stam, 2004) and position effect variegation (PEV) in the fruit fly 
Drosophila, which was initially described in 1930 by Muller (Muller and Altenburg, 
1930) and where it was shown that the local genomic environment of a gene can 
affect its expression in a heritable manner. Similarly, parental imprinting, in which 
certain genes are expressed in a parent-of-origin manner in mammals and flowering 
plants (Feil and Berger, 2007) and X chromosome inactivation in female mammals, 
first described in 1961 (Lyon, 1961), where one of the two X chromosome is entirely 
inactivated during early embryo development (Heard, 2005), are classical epigenetic 
phenomena that have provided powerful models to study the molecular basis of 
these processes. But undoubtedly, the explosion of epigenetics is also closely tied to 
advances in two other major fields: the increased appreciation of the role of 
chromatin in gene regulation and stem cell biology in the context of genome 
plasticity. 
 
1.1.2. Molecular basis of epigenetics 
But what is the molecular basis of epigenetics? How are epigenetic processes 
triggered and maintained? There is no obvious or easy answer. Epigenetic heritable 
changes can be triggered and maintained by many different molecular mechanisms. 
A major focus of current research is centred around the study of covalent 
modifications of DNA, specifically cytosine methylation and post-translational 
modification of histones with a view to understanding the impact of such 
modifications on chromatin structure (Bernstein et al., 2007). There are however 
other important players in epigenetic processes. For example, it has became evident 
recently that RNA, particularly noncoding RNAs, also play an important role in 
controlling multiple epigenetic phenomena (Bernstein and Allis, 2005) ranging from 
X-inactivation and imprinting to the silencing of genes and repetitive DNA sequences 
by post-transcriptional and transcriptional RNA interference (RNAi) related pathways 
respectively (Zaratiegui et al., 2007).  
 
The different known epigenetic mechanisms can function independently but also can 
overlap. In S. pombe, the biochemical purification of the RNA Interference (RNAi) 
17 
 
machinery revealed the existence of an interaction between RNAi pathway and 
proteins involved in chromatin modification, such as Chp1 (Grewal and Jia, 2007). 
Another example is the silencing of the inactive X chromosome. In this process, the 
non-coding RNA Xist (X-inactivation-specific-transcript) triggers the inactivation of an 
entire chromosome that involves extensive changes in DNA methylation and histone 
modifications (Heard, 2005). Further examples are the observation that DNA 
methyltransferases (DNMTs), which catalyse the transfer of a methyl group onto 
DNA, act in part by directly or indirectly interacting with different enzymes which 
regulate and modify chromatin (Dobosy and Selker, 2001; Fuks et al., 2001) and that 
DNMT3L is able to interpret patterns of histone modifications (Freitag and Selker, 
2005). These findings give rise to the idea of a global network of gene expression 
regulation where different genetic and epigenetic processes are brought together to 
provide fine tuned control of cellular phenotype. 
 
In this introduction, I will first discuss the dynamic structure of chromatin and the 
major epigenetic modifications that have been described, as well as the mechanisms 
and factors involved in their targeting in the context of chromatin, illustrating the 
facts with recent examples from the literature. I will then focus on the highly 
conserved Polycomb group (PcG) proteins, important players in epigenetic control 
mechanisms in development and cellular differentiation. 
 
1.2. Chromatin – a dynamic “scaffold” 
1.2.1. Chromatin composition 
In the nuclei of all eukaryotic cells, the genomic information is divided between a set 
of different chromosomes. The genome is large, each human cell contains around 
three metres of DNA that needs to be highly compacted and ordered to fit within the 
nucleus. In eukaryotic genomes this is achieved by the interaction of DNA with 
histone and non-histone proteins to form a dynamic polymer called chromatin 
(Figure 1.2). Chromatin is defined as the material that makes up chromosomes (Finch 
et al., 1977; Kornberg, 1977). The notion of chromatin emerged with the 
development of microscopy and cytology techniques at the end of the nineteenth 
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century. Flemming around 1880 was the first to stain the cell nucleus and named the 
material he observed chromatin (“khroma” in Greek means colour) (Olins and Olins, 
2003).  
 
The dynamic organisation of chromatin is dependent on the higher order structuring 
of nucleosomes, the basic repeating unit of chromatin. The nucleosome is composed 
of an octamer of core histone proteins formed by a central heterotetramer of 
histones H3 and H4, flanked by two heterodimers of histone H2A and H2B. This 
octamer is then wrapped by approximately 147 base pair (bp) of DNA (Luger et al., 
1997) (Figure 1.2). While the length of DNA wrapped around the nucleosome is 
constant, the length of DNA separating nucleosomes varies between 10 and 80bp. 
Many proteins were identified and shown to be involved in the dynamic regulation 
of nucleosome positioning and/or structure (Henikoff, 2008). A large number of 
these proteins are ATPases that often function as subunits of large chromatin 
remodelling complexes, including SWI/SNF, ISWI and CDH complexes (Saha et al., 
2006; Tsukiyama, 2002). Together with additional chromatin associated proteins and 
linker histones (H1, H5) that bind to both DNA on the outer surface of nucleosomes 
and to linker DNA, arrays of nucleosomes are packed and organised into higher order 
chromatin structures that allow for the compaction of the DNA by a 30-40 fold factor 
(Widom, 1989).  
 
Although DNA can be packed in a very orderly fashion into chromatin, this polymer 
has to maintain the ability of dynamically responding to different stimuli, allowing 
for different cellular processes to occur such as transcription, replication and DNA 
repair. Recent studies have indeed revealed that chromatin possesses a highly 
dynamic nature that is important in the regulation of gene expression (Misteli, 
2007).  
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Figure 1.2. Chromatin organisation and epigenetic regulation. The genetic information of eukaryotic 
cells is contained within the nucleus and compacted into chromosomes, which constitute the highest 
order of chromatin organisation. Chromatin is composed of DNA wrapped around an octamer of 
histones that form the nucleosome and constitute the traditional “beads on a string” structure. 
Histone proteins are subjected to a number of covalent post-translational modifications [acetylation 
(Ac), methylation (Me), phosphorylation (P) and ubiquitylation (Ub)] that dictate the underlying 
chromatin status, defining domains of active and condensed chromatin. The DNA molecule can also 
be modified by addition of a methyl group to the carbon-5 position of a cytosine (C) residue in the 
context of a cytosine-guanine dinucleotide. Together, these represent several layers of epigenetic 
regulation of gene expression. Adapted from (Baylin and Schuebel, 2007) and (Sparmann and van 
Lohuizen, 2006). 
 
 
1.2.3. Histones and histone variants 
Histones were amongst the first proteins to be studied, mainly because of the 
relative ease to isolate them. The term “histone” was first used by Albrecht Kossel in 
1884 when he isolated acid-soluble proteins from bird erythrocyte nuclei. Initially 
considered to be essentially structural proteins, their importance was overlooked 
with the discovery of the DNA and the genetic code. Soon though, the importance of 
histones in several biological processes became evident. Histones are small proteins 
with molecular masses ranging from 10-22 kDa. They are amongst the most basic 
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naturally occurring proteins known (Lindner, 2008). Histones organise and compact 
DNA in eukaryotes to form chromatin and are, in fact, the major protein component 
of chromatin. Histone proteins, in particular core histones, are highly conserved 
through evolution (Baxevanis and Landsman, 1997). The core histones have a folded 
globular domain, which is necessary for their interaction with DNA and are thought 
to be responsible for the structural organisation of the nucleosome. The N-terminal 
“tails” of core histones are unstructured and protrude from the nucleosome (Luger 
and Richmond, 1998). 
 
A striking feature of histones, and particularly of their tails, is that they are known to 
be extensively post-translationally modified. Different types of histone modification 
can be found. These are lysine acetylation, lysine and arginine methylation, serine 
and threonine phosphorylation, ubiquitylation, sumoylation, ADP-ribosylation of 
glutamic acid, deimination (conversion of arginine to a citrulline), proline 
isomerisation (conformational change of proline from cis to trans) and glycosylation 
(Kouzarides, 2007; Lindner, 2008). Selected modifications will be discussed in more 
detail in section 1.5. Histone modifications are thought to modulate chromatin 
structure and the biological role of the underlying DNA. They have key roles in 
transcription, DNA repair, replication and condensation. The modifications can act in 
a synergistic or antagonistic manner or control other modifications, thus constituting 
a “histone code”, which is then interpreted by other proteins to produce distinct 
biological responses (Jenuwein and Allis, 2001; Rice and Allis, 2001). 
 
To add to the complexity of histones and histone regulation, each family of histone 
proteins shows a remarkable diversity. In mammals, all classes of histones known 
(with the exception of H4) consist of non-allelic primary sequence variants and sub-
types. While the incorporation of core histones seems to take place during DNA 
replication, most of the histone variants are incorporated throughout the cell cycle. 
The incorporation of different histone variants can affect nucleosome stability and 
chromatin function, partitioning chromatin into regions that have particular 
properties (Henikoff and Ahmad, 2005). Examples of how histone variants impact 
different biological processes include the H3 histone variant CENP-A, which is 
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essential for kinetochore assembly or the H2A histone variant macroH2A, which is 
involved in X chromosome inactivation (reviewed in (Sarma and Reinberg, 2005)). 
Together with the evidence for post-translational modifications, histones and 
histone variants create an enormous potential for chromatin and nuclear 
organisation regulation that has only just started to be understood.  
 
1.2.4. Chromatin structure 
In 1928, work of the botanist Emil Heitz on cell cycle was essential to define two 
types of chromatin (Heitz, 1928). Using DNA stains on interphase nuclei, he observed 
regions that stay condensed throughout the cell cycle, which he called 
heterochromatin; distinct from euchromatin corresponding to regions of chromatin 
that goes through decondensation cycles between cell division. Since these 
observations, chromatin has been the focus of many studies and our understanding 
of chromatin has progressed considerably. The two types of chromatin defined by 
Heitz, heterochromatin and euchromatin, can now be distinguished from each other 
on a structural, functional and cytological basis. 
 
1.2.4.1. Euchromatin 
Euchromatin is the lightly packaged form of chromatin. Because of its unfolded 
structure, euchromatin is highly accessible to transcription factors and RNA 
polymerases. Thus it is enriched for active genes and usually replicates early in S-
phase (Kornberg and Lorch, 1999; Sun et al., 2001). Histone modifications associated 
with active transcription, like the methylation of histone H3 on lysine 4 (Lachner et 
al., 2003; Noma et al., 2001; Santos-Rosa et al., 2002) and the hyperacetylation of 
histones H3 and H4 (Grunstein, 1997; Roth et al., 2001) are general marks of 
euchromatin.   
 
1.2.4.2. Heterochromatin 
Heterochromatin is the tightly packed form of chromatin. It is relatively inaccessible 
to transcription factors and usually replicates late in S phase (Hennig, 1999). 
Constitutive heterochromatin regions are generally gene-poor and enriched in 
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repeated sequences and transposable elements. These regions are mainly located at 
centromeres, pericentric regions and telomeres. They have been shown to be 
essential for the integrity of the genome, being involved in chromosome 
condensation and segregation. These regions are generally associated with gene 
silencing as was initially demonstrated by studies on position effect variegation 
(PEV). In this phenomenon, the integration of genes that are normally found in 
euchromatin, close to heterochromatic regions, often results in sporadic gene 
silencing, giving rise to a mosaic pattern of expression within a given tissue. This 
heritable phenomenon was first observed in Drosophila (Muller and Altenburg, 
1930) and has since been identified in many other organisms from yeast to human 
(Dillon and Festenstein, 2002; Schotta et al., 2003).  
 
Distinct from constitutive heterochromatin, there are also regions of 
heterochromatin which are not always present, termed facultative heterochromatin. 
Facultative heterochromatin retains the ability to become transcriptionally activated 
throughout development and can be found in a heterochromatic or euchromatic 
conformation in different cell types of the organism. A classical example of 
facultative heterochromatin is the inactivation of one of the two X-chromosomes in 
early embryonic development of mammalian females (Arney and Fisher, 2004; 
Heard, 2005).  
 
1.2.5. Nuclear organisation and chromosomal territories 
In addition to the complex arrangement of the genetic information within the 
nucleus, the cellular factors that interpret this information and act upon it are 
organised in sophisticated patterns within the nucleus of a cell (Lamond and Spector, 
2003; Misteli, 2005). Many transcription factors, chromatin proteins and RNA 
processing factors are distributed in discreet compartments in the nucleus. For 
example, processes such as transcription and replication occur in spatially defined 
regions of the nucleus. Therefore, the organisation and architecture of the genome 
should not be ignored when considering processes involved on the maintenance of 
cellular function and nuclear integrity. The appropriate biological response of cells to 
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different regulatory cues requires a precise temporal and spatial organisation of 
nucleic acids and proteins. This indicates how complex is the structure and 
organisation of the mammalian cell nucleus. The non-random organisation of the 
genome and their interacting factors, by compartmentalising different processes 
within the nucleus, create new mechanisms that regulate the output and functional 
status of the genome (Misteli, 2007; Zaidi et al., 2005). 
 
1.3. DNA methylation 
1.3.1. Role and inheritance 
DNA methylation is the only known epigenetic modification of DNA in vertebrates 
and involves the addition of a methyl group at the carbon-5 position of a cytosine 
residue (5mC), by a family of DNA (cytosine-5)-methyltransferases (Dnmts; (Bestor, 
2000). In mammals, this modification occurs in the context of a cytosine-guanine 
(CpG) dinucleotide. DNA methylation is the most stable of all epigenetic 
modifications described to date and was first discovered in 1948 (Hotchkiss, 1948). 
The symmetrical distribution of DNA methylation ensures that DNA methylation 
patterns are faithfully maintained following DNA replication on the two DNA 
daughter strands, in the manner already suggested by two independent laboratories 
in 1975 (Holliday and Pugh, 1975; Riggs, 1975). Numerous studies showed that DNA 
methylation plays an essential role in epigenetic gene regulation and silencing, in 
particular in genomic imprinting and X-chromosome inactivation in mammals, 
silencing of both genes and repetitive sequences in plants and mammals, and in 
mammalian cell differentiation (Bird, 2002; Reik and Dean, 2001). Moreover, 
abnormal patterns of DNA methylation have been implicated in several diseases and 
particularly in cancer (Jones and Baylin, 2002).  
 
In mammals, between 60 and 90% of CpG are methylated (Ehrlich et al., 1982) and 
most are found in heterochromatin and at repetitive sequences, including 
transposable elements. It was then postulated that the primary function of 
methylation is to repress transposon activity (Yoder et al., 1997) which then evolved 
to repress gene expression, or vice-versa (Bird, 2002). Exceptions to this global 
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methylation are CpG islands (Bird et al., 1985). CpG islands are sequences that are 
frequently associated with promoters and enriched in CpG dinucleotides compared 
to the genome average. Most CpG islands in mammalian systems lack DNA 
methylation; but long term gene silencing of a gene can be achieved through 
methylation of the CpG island region, as it was shown in X-chromosome inactivation, 
imprinting and genes aberrantly silenced in cancer (Bird, 2002).  
 
1.3.2. Maintenance of DNA methylation and Dnmt1 
The methylation patterns of DNA are maintained throughout mitotic cell division. 
This is accomplished during DNA replication by the maintenance DNA 
methyltransferase Dnmt1 (Bestor et al., 1988; Li et al., 1992). Dnmt1 is the most 
abundant DNA methyltransferase present in mammalian cells and has strong affinity 
for hemi-methylated CpG dinucleotides. It is usually found associated with the 
replication foci in the S-phase of dividing cells (Chuang et al., 1997; Leonhardt et al., 
1992).  
 
1.3.3. De novo methylation and the Dnmt3 family 
During mammalian development, DNA methylation goes through cycles of genome 
wide reprogramming (Reik and Dean, 2001). In the developing embryo and during 
germ line specification, de novo DNA methylation patterns are introduced. This is 
accomplished by the family of de novo DNA methyltransferases Dnmt3, which 
includes Dnmt3a and Dnmt3b (Bestor, 2000). Inactivation of both genes leads to a 
complete failure to establish de novo methylation profiles at imprinted genes and 
repeats (Okano et al., 1999). Studies have shown that Dnmt3a and Dnmt3b have 
similar and overlapping roles, but also appear to have distinct targets (Okano et al., 
1999). The important role of these proteins during development is further enforced 
by the fact that both Dnmt3a and Dnmt3b are developmentally regulated and that 
expression of both enzymes is regulated by splice variants (Chen et al., 2002; 
Watanabe et al., 2002).  
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1.3.4. Impact of DNA methylation on chromatin properties 
The functional impact of DNA methylation in gene expression regulation is thought 
to be achieved by at least two independent mechanisms (Bird and Wolffe, 1999). 
Firstly, the methylation of promoter CpG islands can directly prevent the recruitment 
of transcription factors to their recognition target sites on the DNA (Jaenisch and 
Bird, 2003). Secondly, a wide family of proteins containing methyl CpG-binding 
domain (MBD) can specifically recognize and bind to methyl CpGs across the 
genome. MBD proteins can induce silencing by promoting recruitment of co-
repressor complexes to methylated DNA (Boyes and Bird, 1991), including histone 
deacetylases (HDACs) or histone methyltransferases (HMTs) (Bird, 2002). It is 
important to note that a link between DNA methylation and histone modifications is 
thought to exist and be important for propagating chromatin states throughout the 
cell cycle. An example of this link is seen in ES cells deficient for the histone 
methyltransferase (HMT) Suv39h, in which DNA methylation of pericentric major 
satellite repeats is impaired by a failure to recruit Dnmt3b to pericentric chromatin 
(Lehnertz et al., 2003).  
 
1.3.5. Distribution of CpG methylation genome wide 
To understand the biological significance of DNA methylation, particular attention 
has recently been given to genome wide profiling of this modification (Suzuki and 
Bird, 2008). Established techniques such as methyl-binding domain (MBD) affinity 
purification and bisulfite sequencing have been combined with the use of genomic 
microarrays or high throughput sequencing to profile DNA methylation on a 
genome-wide scale. Analyses on mammalian genomes (Eckhardt et al., 2006; 
Illingworth et al., 2008) have shown that unmethylated domains account only for    
1-2% of the total DNA and that unexpectedly methylation can also be found in the 
body of the genes, which is associated with gene activity. Moreover, some studies 
reinforced the idea that CpG methylation is a dynamic epigenetic mark that 
undergoes extensive changes during cellular differentiation, particularly in regulatory 
regions outside of core promoters (Meissner et al., 2008). Finally, a few pluripotency 
genes (like Nanog) are associated with DNA methylation in sperm and undergo 
26 
 
reprogramming and demethylation after fertilisation, crucial for their expression in 
ES cells (Farthing et al., 2008).  
 
1.4. RNA mediated epigenetic regulation 
Over the past years, RNA has become one of the most remarkable partners of 
chromatin in epigenetic gene silencing, alongside with more classical epigenetic 
phenomenon such as DNA methylation and histone modifications. This process was 
shown to involve many different forms and types of RNA, ranging from large non-
coding RNAs involved in X inactivation and imprinting to small non coding RNAs, 
present in organisms as diverse as the fission yeast S. pombe, plants, Drosophila and 
mammals. Initially, small RNAs were described as mediators of gene silencing at the 
post-transcriptional level by targeting degradation of RNA. Recently, it became 
apparent that they can also induce silencing at the transcriptional level by guiding 
epigenetic machinery to chromatin (Zaratiegui et al., 2007). More precisely, small 
interfering RNAs (siRNA) have been shown to be required for pericentric 
heterochromatin assembly and spreading in S. pombe (Irvine et al., 2006; Volpe et 
al., 2002). These siRNAs arise from centromeric transcripts and are immediately 
processed by the enzyme Dicer, a component of the RNAi machinery. The siRNAs are 
then incorporated into the RNA induced transcriptional silencing (RITS) complex 
(Verdel et al., 2004; Volpe et al., 2002). This complex is thought to target nascent 
transcripts for degradation and to recruit the RNA dependent RNA polymerase 
(RDRC) complex and the Rik1 complex (Kloc and Martienssen, 2008). The RDRC is 
necessary for amplification of the RNAi response and Rik1, which contains the 
histone methyltransferase Clr4 and the heterochromatin protein-1 homologue Swi6, 
is crucial for establishment and maintenance of a heterochromatic state (Kloc and 
Martienssen, 2008). RNAi has also been shown to be implicated in silencing of 
endogenous and heterochromatic sequence in C.elegans, in plants or in Drosophila 
(Girard and Hannon, 2008; Kloc and Martienssen, 2008). In Arabidopsis, transposable 
elements are methylated and associated with the histone modification H3K9me2 
and small RNAs, indicating that the RNAi pathway, alongside with DNA and histone 
methylation, is responsible for silencing transposons (Lippman et al., 2003). Similarly 
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to what is observed in S. pombe, repeats and transposons found at centromeres in 
Arabidopsis can also be transcribed. These centromeric transcripts are quickly 
processed into siRNA with the participation of various silencing factors (May et al., 
2005). 
 
Recently, a new class of small RNA has been discovered in various organisms and 
shown to play important regulatory roles (Klattenhoff et al., 2007). Piwi-bound siRNA 
(piRNA) are crucial for germline development and unlike siRNA, their biogenesis is 
not dependent on the enzyme Dicer (Vagin et al., 2006). piRNAs associate with Piwi 
proteins, which are related to Argonaute factors, component of the RNAi machinery. 
Those proteins have been shown to have a significant role in transposon silencing in 
the germline (Aravin et al., 2007). Sequencing of piRNA from C. elegans, Drosophila 
and mammals revealed that they match multiple transposon sequences, providing a 
new link between RNAi and silencing (Aravin et al., 2007).  
 
As opposed to the small RNA regulatory species described above, long non-coding 
RNAs (ncRNA) have also been shown to play important role in epigenetic regulation 
with several key examples in the mouse. Xist RNA, one of the earliest and best-
characterised ncRNA, is crucial for silencing of one of the two X chromosomes in 
female mammals (Wutz, 2007). The non-coding and anti-parallel transcript Air 
mediates the imprinting of the Igf2R locus (Braidotti et al., 2004). Both those ncRNAs 
act in cis. It appears that ncRNA can also regulate expression in trans. The 2.2kb 
ncRNA HOTAIR arises from the HOXC locus in human and has been shown to repress 
transcription across 40kb of the HOXD locus, located on another chromosome (Rinn 
et al., 2007).  
 
Non coding RNAs have been shown to participate in processes as diverse as 
heterochromatin assembly, genome surveillance and transposon silencing and in the 
regulation of expression of developmentally related genes. The prevalence of these 
RNA in all genomes appears to be higher than initially thought (Timmons and Good, 
2006). Understanding of the mechanisms affected by these RNAs will certainly shed 
light in how they contribute to the epigenetic landscape.  
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1.5. Histone modifications and their impact on chromatin states 
1.5.1. Regulation in different flavours - histone modifications 
Epigenetic modifications also occur, as already mentioned, on the protein 
counterpart of the chromatin, the histone proteins. The surface of chromatin is 
decorated with a variety of post-translational modifications of histones. The last 10 
years have revealed how these modifications are important in the regulation of 
many DNA-templated processes. Histone post-translational modifications can be 
divided into two major groups. First, a group of small chemical modifications, 
acetylation, phosphorylation and methylation. Secondly, a group of larger peptides 
that include ubiquitylation and sumoylation (reviewed in (Kouzarides, 2007)) (Figure 
1.3). The way these modifications regulate genomic functions can be separated into 
three broad mechanisms. A large body of evidence suggests that one of these 
mechanisms acts in cis by directly affecting the structure of chromatin, preventing or 
promoting crucial contacts that promote certain chromatin conformations or higher-
order structures. Two other mechanisms can be considered which operate in trans; 
either by disrupting the binding of proteins that associate with chromatin or, 
alternatively, by providing docking sites that recruit certain effector proteins. These 
mechanisms are responsible for contributing with different functional responses to 
chromatin based processes. Some of the histone modifications most relevant to this 
study will be described briefly, with a particular emphasis on the impact of these 
modifications on transcriptional regulation, effector proteins and chromatin 
dynamics. 
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Figure 1.3. Post-translational modifications of human histones. Different covalent post-translational 
modifications of the four core histone (H2A, H2B, H3 and H4) have been identified and are here 
represented above the corresponding amino acid residue. These include acetylation (ac), methylation 
(me), phosphorylation (ph) and ubiquitylation (ub1). The majority of the modifications identified 
occur at the NH2-terminal tails of histones. Different modifications have been implicated in the 
regulation of various DNA templated processes. Adapted from (Bhaumik et al., 2007). 
 
 
1.5.1.1. Histone acetylation and deacetylation 
Lysine residues of all core histones can be acetylated. Acetylation of histones was 
one of the first modifications studied and characterised. Transcriptionally active 
chromatin was initially shown to be enriched in acetylated histones (Pogo et al., 
1966), whereas heterochromatic regions of the genome were consistently shown to 
be underacetylated (Jeppesen and Turner, 1993; Maison et al., 2002). The 
association of histone acetylation with broader chromatin domains was further 
explored and confirmed by different large-scale studies mapping histone 
modifications across the genome (Birney et al., 2007; Koch et al., 2007). 
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All core histones are rich in lysine residues and these can be acetylated in vivo. The 
acetylation of lysine residues on the N-terminal tail of histones promotes the 
neutralization of the positive charge of these residues. As a consequence, the 
strength of binding of the strongly basic histones or histone tails to the negatively 
charged DNA is reduced (Hong et al., 1993). This leads to extensive rearrangements 
of the chromatin structure by relaxing the interaction between the DNA and histones 
and promoting an increased accessibility of different transcriptional regulatory 
proteins to DNA-binding sites (Vettese-Dadey et al., 1996). Besides this structural 
role, histone acetylation also creates binding sites for various chromatin-associated 
proteins containing specialised domains, such as the bromodomain. This domain was 
shown to specifically bind to acetylated lysines (Dhalluin et al., 1999; Jacobson et al., 
2000; Mutskov et al., 1998) and to be found in different proteins that regulate DNA-
templated processes. 
 
Given its nature and impact in genomic functions, histone acetylation has to be kept 
under a precise equilibrium. Acetylation is reversible in vivo and the enzymes that 
mediate the addition or removal of acetyl groups from lysine residues are known as 
histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively (de 
Ruijter et al., 2003; Marmorstein, 2001). In fact, this modification is highly dynamic 
and the patterns of lysine acetylation can change rapidly in response to external cues 
(Spotswood and Turner, 2002). It is interesting to note that many positive regulators 
of transcription were shown to possess HAT activity and associate with 
transcriptional activator complexes. Examples of such HATs are Gcn5, the first HAT 
identified (and in fact, the first histone modifying enzyme described) which was 
shown to be a transcription co-activator required for the full activity of a subset of 
transcriptional activators (Brownell et al., 1996). Subsequently, a variety of other 
transcriptional co-activators such as CBP/p300, TAF130/25 and P/CAF were shown to 
possess intrinsic HAT activity (Lee and Workman, 2007; Peterson and Laniel, 2004). 
Conversely, several proteins involved in transcriptional repression, such as Rpd3, 
were shown to have HDAC activity (Kadosh and Struhl, 1998; Taunton et al., 1996). 
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1.5.1.2. Histone methylation and demethylation  
Histones are methylated on arginine and/or lysine residues (Shilatifard, 2006; Sims et 
al., 2003). The methylation of histones is catalyzed by a group of enzymes called 
histone methyltransferases (HMTs) that can target specific lysine or arginine 
residues. Unlike other small chemical modification of histones, methylation of 
arginine and lysine residues can have a negative or positive influence over 
transcription depending on the position of the residue within the histone 
(Kouzarides, 2007). To add to this level of complexity, multiple methylated states can 
be observed on each residue. The ε-amino group of lysines can be mono- (me1), di- 
(me2), or tri- (me3) methylated, whereas the guanidine-ε-amino groups of arginines 
can be found on a me1 or me2 methylated state (Kouzarides, 2002). 
 
The importance of histone arginine methylation in transcriptional regulation became 
evident with the identification of CARM1, an enzyme that was shown to methylate 
arginines within H3 in vitro (Chen et al., 1999). Since then, arginine methylation has 
been more thoroughly studied and implicated in both the negative and positive 
regulation of transcription. Two protein arginine methyltransferase (PRMT), PRMT1 
and PRMT4/CARM1, were shown to be associated with transcriptional activation by 
methylating H4R3 (Strahl et al., 2001; Wang et al., 2001a) or H3R2, H3R17 and 
H3R26 (Bauer et al., 2002; Schurter et al., 2001), respectively. Contrasting with this, 
PRMT5, that can methylate H3R8 and H4R3, was shown to act as a transcriptional 
repressor (Fabbrizio et al., 2002; Pal et al., 2003).  
 
Methylation of lysine residues within histones has been known for many decades but 
only with the discovery of the first lysine methyltransferases did the biological 
significance of lysine methylation gain shape. The enzymes that methylate lysines, 
with the exception of Dot 1, all share a conserved 130-amino acid SET-domain 
(Jenuwein and Allis, 2001). Several lysine methyltransferases have been identified. 
They are normally very specific, targeting and modifying one single lysine on a single 
histone (Bannister and Kouzarides, 2005). Lysine HMTs were shown to methylate 
histone H3 at lysines 4, 9, 27, 36 and 79 and histone H4 at lysine 20 (Kouzarides, 
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2007). Methylation of H3K4, H3K36 and H3K79 are correlated with transcriptional 
activity, and found in euchromatic regions, whereas methylation of H3K9, H3K27 and 
H4K20 are linked to transcriptional repression. H3K9 and H4K20 were shown to be 
found predominantly, but not exclusively, at constitutive heterochromatin (Martin 
and Zhang, 2005; Peters et al., 2003). H3K27 was shown to be enriched at facultative 
heterochromatin, including the inactive X-chromosome (Rougeulle et al., 2004).  In 
addition to their role in transcription, H4K20 and H3K79 have been implicated in the 
process of DNA repair (Botuyan et al., 2006; Huyen et al., 2004; Sanders et al., 2004). 
 
Unlike histone acetylation, methylation of histones does not alter their charge. This 
implies that the outcome of histone methylation is unlikely to be the consequence of 
an electrostatic remodelling of nucleosomes and higher order chromatin structures. 
In fact, similar to acetylated residues providing binding sites for bromodomain 
proteins, it was shown that the presence of methyl marks in histones creates binding 
sites for a variety of chromatin associated proteins. Methylation is recognized by 
proteins containing the chromo-like domains of the royal family (chromo, tudor, 
MBT) and the non related PHD domain (Martin and Zhang, 2005). Depending on the 
histone marks recognized and the specific proteins binding to these sites, the 
functional outcome of lysine methylation is very diverse. Generally, proteins that 
associate with methylated H3K4 are involved in transcriptional activity (Pray-Grant et 
al., 2005; Wysocka et al., 2005), whereas those that recognize and bind methylated 
H3K9 or H3K27 have been implicated in transcriptional repression (Fischle et al., 
2003; Min et al., 2003).  
 
Until recently, it was unclear whether histone demethylation could take place in 
cells. Historically, histone methylation was considered to be a relatively stable and 
irreversible modification, in part because the turnover rates of methylated histone 
residues were found to be slower than those of histones themselves (Spotswood and 
Turner, 2002). However, recent studies demonstrated that both lysine and arginine 
methylation can be reversed. In the case of arginine methylation this is achieved by 
enzymatic deimination of arginine residues of histone H3 and H4 tails to citrulline by 
PAD14 – a member of the peptidyl arginine deiminase protein family (Cuthbert et al., 
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2004; Wang et al., 2004e). In the case of lysine methylation, several lysine histone 
demethylases have been described, the first being the Lysine-Specific Demethylase 1 
(LSD1), a protein previously identified as a component of several HDAC complexes, 
shown to possess the ability to catalyse mono- or di-methylated (but not 
trimethylated) H3K4 demethylation (Shi et al., 2004). The specificity of LSD1 is 
modulated by interacting proteins such as the androgen receptor. While in complex 
with the androgen receptor, LSD1 demethylates H3K9 instead of H3K4. Interestingly, 
under these conditions, LSD1 acts as a transcriptional activator rather than a 
repressor (Metzger et al., 2005).  
 
More recently, a vast family of enzymes containing a common catalytic structure 
called the Jumonji C (JmjC) domain have been found to be capable of removing 
lysine me1, me2 and me3 methylation marks from several different substrates 
(Trewick et al., 2005; Tsukada et al., 2006). These include JHDM1A that specifically 
catalyses demethylation of H3K36me2 and me1 (Tsukada et al., 2006) and JHDM2A 
that demethylates H3K9me2 (Yamane et al., 2006). Of particular interest is the 
discovery of the H3K27 demethylases JMJD3 and UTX (Agger et al., 2007; De Santa et 
al., 2007; Lan et al., 2007; Lee et al., 2007). These demethylases were found to 
interact with protein complexes that are involved in methylating H3K4 and thus, 
promoting transcription. This combines activity of a demethylation complex that 
eliminates a repressive mark and a methylation complex that introduces an active 
mark at homeotic (Hox) loci during developmental activation (Agger et al., 2007; Lan 
et al., 2007). 
 
1.5.1.3. Histone ubiquitylation 
Ubiquitin is a large polypeptide of 76-amino acid and histone ubiquitylation is 
therefore distinct from histone modifications introducing only a small chemical 
group, acetyl-, methyl- or phosphoryl-. Ubiquitin was first discovered in 1975 by 
Goldknopf. Addition of this small peptide to substrate proteins has, since then, been 
implicated in a variety of cellular processes including stress response, cell-cycle 
regulation, protein trafficking, endocytosis, signalling and transcriptional regulation 
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(Pickart, 2001). Substrates are often polyubiquitylated and this targets the proteins 
for proteosomal degradation, a process that has been extensively characterised 
(Pickart, 2001). Other substrates however are monoubiquitylated and this 
modification is not recognised by the proteosome. Examples of monoubiquitylated 
substrates are the histones H2A and H2B. In fact, the first proteins shown to be 
ubiquitylated were the histones (Goldknopf and Busch, 1975). H2A is ubiquitylated 
on lysine 119 and this modification has recently been shown to be associated with 
repressive chromatin (Wang et al., 2004a). H2B is ubiquitylated on lysine 123 and 
this modification is associated with gene activation (Sun and Allis, 2002). 
 
Ubiquitylation of proteins requires the concerted action of three enzymes. These are 
the E1 ubiquitin-activating enzyme, the E2 ubiquitin-conjugating enzyme and the E3 
ubiquitin ligase. Most organisms only possess one E1 enzyme, which is shared by 
several E2 proteins which, in turn, serve different E3 enzymes. The E3 enzymes 
define the specificity of the ubiquitylation reaction, targeting E2 activity to different 
substrates (Pickart, 2001). Briefly, the E1 enzyme hydrolyses ATP and adenylates the 
C-terminus of the ubiquitin, and then forms a thioester bond between the C-
terminus of ubiquitin and the active site cysteine of E1. The activated ubiquitin can 
then be transferred to the E2, ubiquitin-conjugating enzyme in an ATP dependent 
reaction. The final step in the process involves the E3 ubiquitin ligase-targeted 
transfer of the ubiquitin to the final protein.  
 
H2B monoubiquitylation is mediated by RNF20/RNF40 and UbcH6 and activates 
transcription (Zhu et al., 2005) by promoting H3K4 and H3K79 methylation (Briggs et 
al., 2002; Ng et al., 2002; Sun and Allis, 2002) and by increasing the efficiency of RNA 
polymerase II passage through the nucleosome (Pavri et al., 2006). H2Aub1, on the 
other hand, is repressive to transcription in mammals and catalysed by the Ring1/2 
E3 ligases found in PcG complexes and other repressor complexes (Wang et al., 
2004a). The molecular mechanism by which H2Aub1 causes transcriptional 
repression is not yet fully understood. 
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1.5.2. Function and heritability of histone modifications 
The above described modifications are only a small representation of the possible 
post-translational modifications that histones can be subjected to. Histones are 
modified at many sites and to date, over 60 different histone residues were shown 
to be modified by using specific antibodies or by mass spectrometry. This creates a 
vast number of possible combinations of tail modifications. This complexity led to 
the proposal that specific histone tail modifications and/or their combinations 
constitute a code, the histone code, that determines diverse downstream functions 
(Jenuwein and Allis, 2001; Spotswood and Turner, 2002; Strahl and Allis, 2000). This 
code can operate by affecting higher-order chromatin structures, by influencing the 
contact between different histones in adjacent nucleosomes or the interaction of 
histones with the DNA. It can also promote or else prevent the recruitment of 
different chromatin-associated proteins that bind to the modifications via specific 
protein domains. Besides the vast combinatorial potential that these modifications 
provide, there is also crosstalk between different modifications. This crosstalk can 
operate at different levels and can either be antagonistic or synergistic. Specific 
modifications can negatively influence the functional impact of other modifications 
or stimulate them. This crosstalk is not restricted to the same histone tails, which can 
be exemplified by the influence of ubiquitylation of H2B on the methylation of 
H3K4me3 (Sun and Allis, 2002). 
 
The classical definition of epigenetics implies heritability. Whether histone 
modifications are responsible for heritability or passing on a cellular memory or 
whether they are only responsible for implementing this memory is a question that 
remains to be clarified (Kouzarides, 2007). If histone modifications are truly 
“bearers” of a cellular memory, different mechanisms of transmission of these 
modifications onto the chromatin of replicating DNA should exist but this is still 
debated. Dodd and colleagues have proposed a conceptual model showing that 
clusters of nucleosomes are able to maintain themselves stably in a particular 
modification state (Dodd et al., 2007). These states are inherited during DNA 
replication, when nucleosomes of the parental chromosomes are distributed to both 
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daughter strands and recruit enzymes that propagate this state to newly formed 
nucleosomes (Annunziato, 2005). Dodd and colleagues developed a simple 
stochastic model for dynamic nucleosome modifications based on the silent mating-
type region of the yeast Schizosaccharomyces pombe and showed that a similar 
biological mechanism could provide bistability and heritability (Dodd et al., 2007). 
Nevertheless, the maintenance of a cellular memory will certainly require the 
integration of several other participants that might include non coding RNAs, 
amongst others. 
  
1.5.3. Genome wide mapping of histone modifications 
With the complete sequencing of genomes, mapping and understanding the 
epigenome, or the complete description of epigenetic modifications across the 
genome, is the next challenge. Numerous technologies to study genome-scale 
epigenetic modifications have emerged with the explosion of high-throughput 
sequencing platforms.  
 
The chromatin immunoprecipitation (ChIP) technique was introduced twenty years 
ago (Solomon et al., 1988) and has gradually imposed itself as a necessity in 
chromatin studies. This technique involves cross-linking of DNA-protein interactions 
and pull down of these complexes using specific antibodies, allowing the 
determination of the localisation of a particular protein of interest or histone 
modification across the genome. Analysis of a ChIP assay can be done by real time 
PCR, microarray hybridization (ChIP-chip) or high-throughput sequencing (ChIP-seq). 
PCR is limited as it can only be used for a small subset of known targets. Therefore, 
tilling genomic microarrays greatly improved the amount of data that can be 
gathered and used for a fine mapping across portions and entire chromosome or 
even the whole genome (Mockler et al., 2005), although the latter is costly. 
Additionally, the need to amplify the immunopurified DNA before hybridization is an 
additional experimental step that could be problematic and/or introduce some bias. 
More recently, new generation sequencing platforms have been employed to 
analyse ChIP DNA (Barski et al., 2007; Mikkelsen et al., 2007). High throughput 
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sequencing methods are very powerful as they can provide a full coverage of the 
genome, at better resolution and do not require any amplification step, unlike 
microarray hybridization. Moreover, data can be recovered from very small 
quantities of starting material. 
  
These techniques have very recently been applied to histone modifications and DNA 
methylation and corresponding genome-wide maps are now available for human 
and mouse embryonic stem (ES) cells, neural progenitor cells, fibroblasts, 
hepatocytes and T cells (Barski et al., 2007; Farthing et al., 2008; Guenther et al., 
2007; Meissner et al., 2008; Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al., 
2007). Overall, these studies, which display good concordance, have identified 
chromatin signatures of particular cell types with for example large domains of 
chromosomes showing the same modification (Bernstein et al., 2005; Guenther et 
al., 2005) or sequences displaying overlapping active and inactive marks (Bernstein 
et al., 2006). These studies have also helped identify sequence elements that can act 
as boundary elements defining chromatin domains (Noma et al., 2001). Finally, these 
maps will definitely be useful to define new functional elements of the genome, like 
enhancers, redefining promoters or control regions of epigenetic regulation 
(Mikkelsen et al., 2007).  
 
Altogether, the data obtained thanks to these new technologies will provide a 
comprehensive picture of epigenetic modifications across the genome and how 
these relate with each other and influence genome function.  
 
1.6. Polycomb and trithorax group proteins  
During mammalian development, 200-300 structurally and functionally distinct cell 
types specialise. In order to help shape an organism and maintain specialised states, 
specific patterns of temporal and spatial gene expression have to be precisely 
established and, most importantly, maintained. It was only in the 1960-1970s that 
Ernst Hadorn and colleagues demonstrated the existence of an inherent “cellular 
memory” that allows cells to maintain a specific developmental program that is 
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determined during early embryogenesis and followed for the rest of the 
development (Hadorn, 1978). This identity, at the molecular level, is intrinsically 
associated with patterns of gene expression, of which the homeotic (Hox) genes, a 
highly conserved class of regulators that define the positions of structures and 
appendages along the anterior-posterior axis, are a good example. The transcription 
of Hox genes is initially determined by the activity of maternally and zygotically 
produced transcription factors that define precise patterns of Hox gene expression 
for each embryonic segment. Interestingly, the segment-specific patterns of Hox 
gene expression are maintained throughout development, long after the early 
transcriptional regulators have disappeared.  
 
Genetic studies in Drosophila resulted in the identification of two classes of genes 
whose mutants had very similar phenotypes to Hox genes mutants. Detailed genetic 
and molecular studies demonstrated that these genes, which could be divided into 
two antagonizing groups, Polycomb (PcG) and trithorax (trxG), were essential for the 
maintenance of gene expression patterns of important developmental regulators, 
like Hox genes. This led several investigators to suggest that PcG and trxG proteins 
provide the molecular basis for molecular memory (Francis and Kingston, 2001; 
Ringrose and Paro, 2004). Generally, PcG proteins are implicated in gene repression, 
whereas trxG proteins seem to oppose PcG function by promoting transcription 
activation (Orlando and Paro, 1995; Pirrotta, 1998). Both these group of proteins 
were shown to form multimeric protein complexes that regulate chromatin structure 
in diverse ways (Mahmoudi and Verrijzer, 2001) (Figure 1.4). 
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Figure 1.4. Polycomb and trithorax group proteins form multimeric protein complexes. PcG proteins 
are found in two main complexes, PRC1 and PRC2, which were shown to mediate ubiquitylation of 
H2AK119 and methylation of H3K27, respectively. trxG proteins associate in one main complex that is 
involved in methylation of H3K4. PcG and trxG complexes act antagonistically to repress and promote 
gene expression, respectively. Adapted from (Pietersen and van Lohuizen, 2008). 
 
 
Presently it is recognized that PcG and trxG are involved in the regulation of many 
target genes in addition to Hox genes. PcG and trxG proteins have been implicated in 
regulating cell proliferation (Martinez and Cavalli, 2006; Martinez et al., 2006), stem 
cell identity, cancer (Jones and Baylin, 2007; Sparmann and van Lohuizen, 2006), 
genomic imprinting in plants and mammals (Delaval and Feil, 2004; Guitton and 
Berger, 2005; Kohler et al., 2005) and X-inactivation (Heard, 2005; Mak et al., 2004; 
Wang et al., 2001b).  
 
1.6.1. Polycomb group proteins 
To date, three distinct Drosophila PcG protein complexes have been biochemically 
purified and characterised. These are the Polycomb repressor complexes 1 and 2 
(PRC1 and PRC2) and the Pleiohomeotic repressive complex (PhoRC) (Figure 1.5). The 
Drosophila PRC1 complex contains a core of four proteins, the chromodomain 
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protein Polycomb (PC), Posterior Sex Combs (PSC), Polyhomeotic (PH) and dRING 
(Francis et al., 2001). The PRC2 complex is about 600 kDa in size and includes the 
core components enhancer of zeste [E(z)], extra sex combs (ESC), supressor of zeste 
12 (SUZ12) and Nurf55 (Czermin et al., 2002; Muller et al., 2002). The PhoRC complex 
contains the DNA-binding protein Pleiohomeotic (PHO) and is thought to be involved 
in sequence-specific recruitment of PcG proteins to target regions of the Drosophila 
genome (Ringrose and Paro, 2007). Each of these components has one or more 
mammalian homologs which have been extensively characterised and are shown on 
Table 1.1. Interestingly, homologues of PRC1 core proteins are not found in C. 
elegans and Arabidopsis.  
 
 
 
Figure 1.5. The different Polycomb group complexes identified in Drosophila. For each complex 
described, the core proteins are represented as solid coloured spheres. Accessory proteins are 
represented as light coloured spheres with dashed borders. (a) The PRC1 complex comprises four core 
components, RING, PSC (posterior sex combs), PC (polycomb) and PH (polyhomeotic). (b) The PhoRC1 
complex was shown to contain the PHO/PHOL (pleiohomeotic/pleiohomeotic-like) and the SFMBT 
(Scm-related gene containing four MBT domains) proteins. This complex is the only PcG complex 
known to bind DNA at PREs. (c) The PRC2 core components are ESC (extra sex comb), E(Z) (enhancer 
of zeste), SU(Z)12 (suppressor of zeste 12) and P55 (Nurf55). Two distinct PRC2 complexes have been 
described in Drosophila embryos: a 600 kDa complex containing the histone deacetylase RPD3 in 
addition to the core components and a 1 MDa complex, including both RPD3 and PCL (Polycomblike). 
The relationship between these two complexes is unclear and it is possible that they are found in a 
dynamic equilibrium. Adapted from (Schwartz and Pirrotta, 2008). 
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Table 1.1. Main Components of the Polycomb group in Drosophila and their respective mouse 
homologues. ASX, Additional sex combs; CBX, chromobox homologue; EED, embryonic ectoderm 
development; E(PC), Enhancer of Polycomb; ESC, extra sex combs; ESCL, extra sex combs like; E(Z), 
Enhancer of zeste; MTF, metal response element-binding transcription factor; MXC, multi sex combs; 
NPCD, neuronal pentraxin with chromodomain; PC, Polycomb; PCL, Polycomb-like; PH, polyhomeotic; 
PHC, polyhomeotic-like; PHF19, PHD-finger protein 19; PHO, pleiohomeotic; PHOL, pleiohomeotic-
like; SCE, Sex combs extra; SCM, Sex comb on midleg; SFMBT, Scm-related gene containing four MBT 
domains; SU(Z), Supressor of zeste ; SXC, super sex combs; YY, Yin-Yang transcription factor. Adapted 
from (Schwartz and Pirrotta, 2008). 
 
 
1.6.1.1. Polycomb Repressive Complex 2 (PRC2) 
Classically, PRC2 is seen as being important for the initiation of gene silencing, 
whereas PRC1 is implicated in the stable maintenance of gene repression 
(Hernandez-Munoz et al., 2005). The PRC2 complex was shown to possess histone-
modifying activity and methylate H3K27 and/or H3K9 (Cao et al., 2002; Kuzmichev et 
al., 2002; Plath et al., 2003). This activity is confered by the E(Z) protein (or its 
mammalian homologue, Ezh2), shown to be a histone methyltransferase which 
contains the typical SET domain that characterises most lysine HMTs. Both ESC (or 
the mammalian homologue Eed) and SU(Z)12 (or the mammalian homologue Suz12) 
were shown to be essential for the in vitro methylation of H3K27 as, in the absence 
of these components, E(Z) cannot efficiently methylate histones (Czermin et al., 
2002). SU(Z)12 and Nurf55 are essential for nucleosome binding by PRC2, whereas 
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ESC is crucial for enhancing the enzymatic activity of E(Z) in the complex (Ketel et al., 
2005; Nekrasov et al., 2005).  
 
In mammals, the roles of PRC2 components are similar but seem to have some 
different adaptations. For example, the loss of the E(Z) homologue Ezh2 only 
eliminates H3K27me2 and –me3, suggesting that monomethylation of this lysine 
residue is carried out by a different complex. Some data suggests that this might be 
accomplished by a complex containing Ezh1 and Eed (Montgomery et al., 2005). 
Additionally, Suz12 was shown to be essential for the HMTase activity of PRC2 (Cao 
and Zhang, 2004; Pasini et al., 2004). It was also suggested that in vertebrates, the 
inclusion of different isoforms of Eed has a dramatic effect on the enzymatic 
specificity of the PRC2 complex where it is incorporated, allowing for an Ezh2-Eed 
containing complex to methylate H1K26 instead of H3K27 (Kuzmichev et al., 2004). 
However, a second group tried to recapitulate these results with reconstituted 
recombinant PRC2 complexes containing different Eed isoforms and failed to do so 
(Martin et al., 2006). 
 
In addition to the core PRC2 complex, some variants of this complex have been 
identified as containing the HDAC RPD3 or the Polycomb-like (PCL) proteins (Tie et 
al., 2003). These variant PRC2 complexes are likely to reflect dynamic changes during 
development or tissue-specific variants and will be further explored in this work. 
 
1.6.1.2. Polycomb Repressive Complex 1 (PRC1) 
The core PRC1 complex functions on one level by counteracting the remodelling 
activity of the SWI/SNF complex and thus, preventing transcriptional activation 
(Francis et al., 2001). PRC1 was also shown to directly inhibit transcription by RNA-
Polymerase II (RNAPII) on naked DNA and on the context of recombinant 
nucleosomal arrays (King et al., 2002). More recent studies have shown that core 
PRC1 proteins Ring1/2  function as an E3 ligase that catalyses the 
monoubiquitylation of lysine 119 on histone H2A (H2Aub1) (Cao et al., 2005; de 
Napoles et al., 2004). The homologues of the PRC1 core protein Psc, Bmi1 and 
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Mel18, were shown to enhance E3 ligase activity (Cao et al., 2005; Elderkin et al., 
2007).  
 
It is interesting to note that mammals possess a multitude of homologues of the 
PRC1 PcG proteins which are expressed differently in different tissues and 
developmental stages. There are three Pc homologues (MPc1, MPc2 and MPc3), 
three Ph homologues (MPh1, MPh2 and MPh3), two Psc homologues (Bmi1 and 
Mel18) and two dRing homologues (Ring1a and Ring1b). The different homologues 
seem to be somehow redundant and PRC1 null mutant mice normally show milder 
phenotypes than PRC2 mutant mice which do not have so many homologues for 
each core component.  
 
Even though PRC1 and PRC2 do not physically interact, there is evidence that they 
function synergistically. Specifically the chromodomain of Pc, can bind to methylated 
lysine 27 of histone H3 (H3K27) (Fischle et al., 2003; Min et al., 2003) and the 
recruitment of Bmi1 to specific loci in the genome depends on members of the PRC2 
complex (Hernandez-Munoz et al., 2005). It should be mentioned that PRC2-
independent recruitment of PRC1 was also reported to occur in X-chromosome 
inactivation (Schoeftner et al., 2006). Nevertheless, these data suggests that PRC1 
and PRC2 interact cooperatively for the targeting and silencing of particular regions 
of the genome. 
 
1.6.1.3. Pleiohomeotic Repressive Complex (PhoRC) 
Given the close relationship between PcG proteins and the regulation of different 
DNA-templated processes, it was surprising to observe that the vast majority of PcG 
proteins described are not DNA binding factors. This was initially explained by the 
fact that PcG proteins essentially recognize chromatin features and that those were 
the determining factor for PcG targeting. However, the study of Drosophila Hox gene 
regulation revealed that PcG proteins associate to cis-regulatory sequences that are 
important for PcG mediated repression. These sequences were termed Polycomb 
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response elements (PREs). The discovery of these sequences was followed by the 
identification of the DNA binding protein Pleiohomeotic (Pho).  
 
Drosophila Pho and its closely related homologue, PhoL, are the only known PcG 
proteins that bind directly to DNA (Brown et al., 2003; Brown et al., 1998; Fritsch et 
al., 1999). Pho and PhoL are the Drosophila homologues of the mammalian protein 
Yin-Yang 1 (YY1), a protein shown to have both activating and repressive functions. 
Pho can be found in different complexes, but it seems to have a major role as part of 
the PhoRC complex. In Drosophila, PhoRC was shown to be involved in Hox gene 
silencing and to include both Pho and the Polycomb malignant brain tumour (MBT) 
domain protein, dSfmbt (Klymenko et al., 2006). dSfmbt was shown to selectively 
bind to the tails of histones H3 and H4, mono- or dimethylated at H3K9 or H4K20 
(Klymenko et al., 2006). The recruitment of PhoRC to PREs seems to be strictly 
dependent on the presence of Pho DNA binding sites, suggesting that the binding of 
the Sfmbt protein to methylated histones is not required for targeting of the PhoRC 
complex but rather for repression (Klymenko et al., 2006). Given that Pho was 
identified as an interactor of either PRC1 or PRC2 complexes (Mohd-Sarip et al., 
2005; Mohd-Sarip et al., 2002; Poux et al., 2001; Wang et al., 2004b), PhoRC was 
suggested to be an important component for the mechanism of recruitment of PRC 
complexes to their respective targets (Schuettengruber et al., 2007). 
 
To date, no PREs have been identified in mammals, but the genome-wide analysis of 
PcG proteins distribution will likely give us some clues on the mechanisms of PcG 
recruitment. It has been suggested that the mechanism of PcG recruitment in 
mammals will differ from the one in Drosophila quantitatively rather than 
qualitatively (Schwartz and Pirrotta, 2008). The identification of a mammalian PRE 
(or a PRE like DNA element) remains one of the objectives in the understanding of 
crucial regulatory decisions mediated by PcG. In summary, the data obtained in the 
Drosophila system suggests that PcG recruitment involves combinatorial signals from 
multiple sources that include different DNA motifs, chromatin structures and non 
coding RNAs. The later is exemplified by the role of Xist RNA in PcG recruitment in X-
inactivation (Silva et al., 2003). Additionally a non-coding RNA designated HOTAIR 
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was recently shown to have a role in targeting PcG proteins to HOX loci in trans (Rinn 
et al., 2007). 
 
1.6.2. Trithorax group proteins 
When considering mechanisms of epigenetic regulation, these are commonly binary-
switches and not “all-or-nothing” events. In concordance, most of the PcG target 
genes are also positively regulated by Trithorax (trxG) proteins, which seem to work 
antagonistically to the PcG proteins (Klymenko and Muller, 2004; Poux et al., 2002). 
TrxG protein complexes were found to be involved in the methylation of histone H3 
on lysine 4 (Milne et al., 2002), a modification that has been extensively studied and 
shown to be related to active transcription (Ruthenburg et al., 2007). H3K4me3 has 
been found associated with the upstream regions of virtually all actively transcribed 
genes from budding yeast to humans, whereas H3K4me1 was shown to selectively 
localise to putative enhancer regions in human cells, but not in yeast (Heintzman et 
al., 2007).  
 
The exact way in which PcG and trxG proteins interact and regulate the function of 
each other is not clear. It seems that trxG proteins function essentially as anti-
repressors rather than as typical activators, as in the absence of both PcG and trxG, 
the expression of target genes is unaltered (Klymenko and Muller, 2004). This inter-
dependence of PcG and trxG complexes might be explained by the fact that in 
Drosophila, both PcG and trxG proteins can be found occupying the same PREs, 
independently of the transcriptional state of the target gene (Chinwalla et al., 1995; 
Kahn et al., 2006; Papp and Muller, 2006). How the function of trxG is affected at 
PREs is unclear but it seems to be crucial in determining the switch between the 
transcriptionally repressed and active states or the balance between repression and 
transcription (Schwartz and Pirrotta, 2008). 
 
Whereas in Drosophila, trxG as well as PcG are targeted to the DNA by the 
Polycomb/Trithorax response elements (PRE/TRE) which are necessary and sufficient 
for the recruitment and function of either trxG or PcG proteins (Schwartz and 
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Pirrotta, 2007), these sequences have not yet been identified in mammals. The 
recruitment of these complexes might be more complex that in Drosophila. In fact, it 
was shown that recruitment of mammalian trxG protein MLL is facilitated by the 
basal transcription machinery (Ruthenburg et al., 2007). Another H3K4 HMT, Ash1, 
was shown to be targeted and regulated by non coding-RNAs (Sanchez-Elsner et al., 
2006).  
 
1.7. Early mammalian development and pluripotency 
In the previous sections of this introduction, I have explored mechanisms of 
epigenetic regulation that include layers of regulation acting at the level of DNA, 
histones and nuclear organisation. The combination of these processes is essential in 
part for the establishment and, most importantly, maintenance of a given cellular 
identity throughout development. In this second part of the introduction, special 
relevance will be given to early development of the mouse embryo, with a particular 
emphasis on embryonic stem (ES) cells, which are now widely used as an in vitro 
model to study early embryo development and the mechanisms involved in 
maintaining these cells in their pluripotent state and in their differentiation into 
defined cell types. 
 
1.7.1. Early embryo development and pluripotency 
In 1651, William Harvey was the first to recognize that an egg or oocyte is the only 
cell in the body capable of developing into a new organism. His affirmation, “Ex Ovo 
Omni” (“everything comes from an egg”), recognized that the egg leads to the 
progressive development into an organism. In fact, the diverse cell types that are 
found in a mammalian adult are all derived from a single fertilised egg that results 
from the fusion of two haploid cells, the sperm and the oocyte. Progressively, 
throughout development, specialised programmes of gene expression are 
established, resulting in differentiation of cells into specific pathways. This is 
accomplished by an expansion of early progenitor cells that gradually become 
restricted in their potential to give rise to any cell type and become more and more 
specialised while they commit to different cellular lineages (Morgan et al., 2005). 
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Following fertilization, the mouse embryo undergoes a series of sequential cleavage 
divisions during the first two days of development to lead to the production of an 8-
cell embryo. These 8 cells (or blastomeres) give rise to a compacted morula (Figure 
1.6). The cells of the morula are subjected to further divisions, eventually giving rise 
to a structure that possesses an epithelial monolayer of cells, the trophectoderm 
(TE), which is involved in uterine implantation and initiation of placenta formation 
and defines a spherical structure that is largely hollow and delimits an apolar mass of 
cells that forms the inner cell mass (ICM), which contains the founder cells of the 
embryo proper. This embryonic structure is the early blastocyst that corresponds to 
embryonic day 3.5 of development. Around the time of implantation of the embryo, 
the ICM further segregates into two lineages: the epiblast (EPI) and the hypoblast or 
primitive endoderm (PrE), which can be found at the blastocoelic surface of the ICM 
(Rossant, 2001).  
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Figure 1.6. Schematic representation of the early stages of the mouse development. Following 
fertilization the mouse embryo undergoes a series of cell divisions that lead to the production of an 8-
cell embryo, the morula. In the morula, cells compact against each other so that cell boundaries are 
no longer visible. Subsequent divisions lead to the generation of distinct internal and external cell 
populations and formation of an internal cavity, the blastocoele. This structure corresponds to the 
early blastocyst embryo. Two distinct lineages are apparent at this stage, the trophectoderm and the 
inner cell mass (ICM). The trophectoderm is still present in the late blastocyst stage, but the ICM has 
segregated into two lineages: the epiblast and the primitive endoderm. The trophectoderm and 
primitive endoderm lineages will give rise to extraembryonic tissues that support the embryo, while 
the epiblast will give rise to the germ cell lineage and the somatic lineages of the embryo. Figure 
adapted from (Niwa, 2007a). 
 
 
As already mentioned, with each cell division during embryonic development, cells 
increase their degree of differentiation and, inevitably, become more and more 
restricted to specific cell lineages. This commitment is thought to commence early, 
between the 2-cell and 4-cell stage when some blastomeres already indicate a 
preference for contributing to either cells of the ICM or of the TE (Fujimori et al., 
2003). In a recent study, Torres-Padilla and colleagues suggested that there are 
global epigenetic differences between different blastomeres in early-stage embryos, 
which can influence cell fate decisions as early as the 4-cell stage (Torres-Padilla et 
al., 2007). This is proposed to be achieved by different degrees of histone H3 
methylation at specific arginine residues. Blastomeres showing the highest 
methylation levels have an increased probability of contributing to the cells of the 
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ICM, indicating that global epigenetic modifications can influence cell fate 
determination. 
 
The fertilised egg and cells of the 2- and the 4-cell embryo are totipotent and can 
give rise to every cell type of the organism (including specialised extra-embryonic 
cells of the embryo). By the time the blastocyst stage is reached, the cells of the EPI 
are still able to give rise to all somatic lineages but have lost the ability to generate 
cells of the extra-embryonic tissues (placenta and extra-embryonic membranes). 
These cells are thus called pluripotent and have the ability to differentiate into all 
somatic cell types, giving rise to all tissues of the foetus, including the ectoderm, 
mesoderm, endoderm and primordial germ cells. The cells from the TE and PrE are 
called multipotent as they are able to exclusively differentiate respectively into the 
trophoblast lineages and the visceral and parietal endoderm layers that will line the 
yolk sac (Bielinska et al., 1999; Rossant, 2001). 
 
1.7.2. The embryonic stem (ES) cell and other stem cell types 
Pluripotency is an interesting phenomenon. In vivo this cellular property is only 
transiently found in the ICM of the blastocysts and is retained at later stages by 
specialised cells of the primordial germ layer. Pluripotency can be “isolated” ex vivo 
with embryonic stem (ES) cells that can be derived from the cells of the ICM under 
defined growing conditions that promote proliferation in the absence of 
differentiation (Boyer et al., 2006a; Niwa, 2007a). Mouse ES cells were derived for 
the first time in 1981 (Evans and Kaufman, 1981; Martin, 1981) and are characterised 
by a set of properties that define their pluripotent state. ES cells have the ability to 
self-renew in the presence of certain growth factors and, most importantly, can be 
maintained in culture in an undifferentiated state. These cells can be reintroduced 
into developing blastocysts to create chimeric animals and contribute to all foetal 
tissues that arise throughout development. Therefore, pluripotent ES cells have the 
property to give rise to all cells of an embryo and adult (Solter, 2006). The self-
renewal and multi-lineage differentiation that characterises stem cells make them 
uniquely suited for regenerative medicine, tissue repair and gene therapy 
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applications, reasons for which stem cells have become the focus of many current 
studies. 
 
 1.7.2.1. Stem cells from the early mouse embryo 
Apart from ES cells, other stem cell lines can be derived from the early mouse 
embryo and were successfully obtained from the TE (trophoblast stem (TS) cells; 
(Tanaka et al., 1998)) and the PrE (extra-embryonic endoderm stem (XEN) cells; 
(Kunath et al., 2005)). Together with ES cells, these cells all share a similar 
characteristic: they can self-renew without differentiating in culture and be induced 
to differentiate into lineage-specific cell types. Even though they share this property, 
all these stem cells are remarkably different. They all display different morphology, 
gene expression patterns and growth factor requirements that typify the lineage 
from where they are derived. These stem cells can be maintained in culture while 
keeping their lineage identity, as illustrated by the fact that their injection into early 
embryos leads to contribution to the appropriate differentiated lineages. Pluripotent 
ES cells contribute as already mentioned, to all tissues of the foetus, but poorly to 
PrE and rarely to TE lineages (Beddington and Robertson, 1989), while TS cells only 
contribute to the trophoblast lineages of the placenta (Tanaka et al., 1998) and XEN 
cells contribute exclusively to the parietal endoderm and visceral endoderm lineages 
(Kunath et al., 2005). Key lineage-specific transcription factors, such as Oct4/Sox2, 
Cdx2 and Gata6/Sox7 have been shown to determine the fate of ES, TS and XEN cells 
respectively (Ralston and Rossant, 2005). Moreover, recent studies have shown that 
altered expression of these factors can reprogram ES cells to TS or XEN cells (Niwa, 
2007a). 
 
1.7.2.2. Progenitor Stem cells 
Throughout development, pluripotent stem cells from the ICM become increasingly 
restricted in their lineage potential and give rise to tissue-specific, multipotent adult 
stem cells. These multipotent stem cells give rise to multiple cell types of one specific 
lineage. Adult stem cells have been identified in many tissues where they are 
responsible for generating and regenerating more differentiated cells either as part 
51 
 
of a normal physiological process or as a response to some injury. Amongst the 
different adult stem cells characterised are haematopoietic, neural and epidermal 
stem cells (Eckfeldt et al., 2005). One of the most obvious examples of adult stem 
cells can be found in the bone marrow and is the population of haematopoietic stem 
cells (HSCs), which are capable of forming all the types of blood cells in the body 
(Fisher, 2002). A second population of adult stem cells can be found in the bone 
marrow and are called bone marrow stromal cells which are responsible for 
generating the bone, cartilage, fat and fibrous connective tissue (Grove et al., 2004). 
Adult stem cells carry true potential for several therapeutic applications, most 
importantly in transplantation. In fact, adult blood stem cells derived from the bone 
marrow have been used for transplants for 30 years. The understanding of the 
mechanisms that govern the maintenance of these cells and their controlled 
differentiation into different pathways will establish the basis for therapies of many 
common diseases. 
 
1.7.2.3. Embryonic cancer (EC) and Carcinoma stem (CS) cells 
Ironically, the need for cellular proliferation, especially proliferation of adult stem 
cells, increases the risk of neoplastic transformations. Adult stem cells must have 
developed mechanisms to prevent the uncontrollable growth of their populations. 
Nevertheless, there is increasing evidence suggesting that some solid tumours or 
haematological cancers may contain a sub-population of cancer cells, the cancer 
stem cells (CSCs) that possess characteristics normally attributed to stem cells. 
Therefore, CSCs constitute the tumorigenic and replicating population of the tumour 
that gives rise to progeny with limited replication potential and lacking tumorigenic 
capabilities (Al-Hajj et al., 2003; Lapidot et al., 1994; Singh et al., 2004). According to 
this theory, CSCs persist in tumours as a distinct population and can cause relapse 
and metastasis by giving rise to new tumours. However, it is debated whether CSCs 
represent a minority of the cells in a tumour or if most of the cells share these “stem 
cell-like” properties. Similarly, it is also debated whether CSCs originate from adult 
stem cells that have lost their ability to regulate proliferation or if they originate 
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from more differentiated cells that acquired abilities of a stem cell (Clarke and Fuller, 
2006).  
 
The first evidence for cancer stem cells was published in 1997 by Bonnet and Dick 
(Bonnet and Dick, 1997). In this study, a sub-population of leukaemic cells was 
isolated and shown to be able to initiate tumours in mice that are histologically 
similar to the donor. This was followed by the identification of CSCs in several solid 
tumours, including breast cancer, brain cancer, colon cancer, amongst others (Al-Hajj 
et al., 2003) (O'Brien et al., 2007; Singh et al., 2003). Independently of what is the 
exact nature and origin of these CSCs, the understanding of the processes that 
regulate the expansion of these cells and where they originate from is of the 
uttermost importance to devise efficient strategies for cancer treatment. 
 
1.7.2.4. Embryonic germ (EG) cells 
The germline is absolutely essential for the continuity of species by assuring the 
transmission of genetic information across generations. Primordial germ cells (PGCs), 
the founder cells of the germ cell lineage, are usually specified early during 
embryonic development. This specification is one of the earliest events at the onset 
of gastrulation (Surani et al., 2004). Germ cells are maintained by mechanisms that 
prevent them from differentiating into somatic cells and are the only lineage of cells 
that maintain pluripotency after gastrulation. PGCs are the precursors of embryonic 
germ (EG) cells, which can be derived from PGCs between E8.5 and E11.5 (Matsui et 
al., 1992; Resnick et al., 1992). More recently, pluripotent stem cells were also 
derived from spermatogonial stem cells (Kanatsu-Shinohara et al., 2004), suggesting 
that pluripotency can be maintained during germ cell development. Derived EG cells 
have the ability to contribute to all the three germ layers of the embryo and adult 
tissues, thus defining these cells as pluripotent (Matsui et al., 1992). 
 
1.7.3. Molecular signature of ES cells 
The pluripotency observed in ES cells is a remarkable characteristic and has been the 
subject of widespread interest. Pluripotent stem cells have the ability to dominantly 
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reprogramme somatic cells to re-express markers of earlier embryonic stages (Tada 
et al., 1997; Tada et al., 2001), suggesting that specific factors present in pluripotent 
cells are capable of inducing dedifferentiation or transdifferentiation of somatic cells 
to an ES-like configuration. This implies that a particular “molecular stem-cell 
signature” exist to ensure the proper maintenance of pluripotency. Early attempts to 
define a set of molecular properties that define pluripotency first took place several 
years ago in a series of microarray expression studies (Conti et al., 2006; Ivanova et 
al., 2002; Ramalho-Santos et al., 2002). These reports attempted to compare gene 
expression profiles between ES cells, neural and haematopoietic stem cells and 
identified the transcription factors Oct4 and Nanog as ES-specific genes. 
Interestingly, expression patterns of the different stem cell types showed a very 
restricted overlap and the profiles identified in these different studies were 
significantly different (Evsikov and Solter, 2003; Fortunel et al., 2003).  
 
1.7.3.1. Genetic control of pluripotency 
Even if the characterisation of a stem cell at the expression level seems to be rather 
restricted, different key transcription factors were identified as being important for 
determining ES cell pluripotency. Amongst these are the POU-family transcription 
factor Oct4, the homeodomain DNA-binding protein Nanog and the SOX-family 
transcription factor Sox2 (Avilion et al., 2003; Mitsui et al., 2003; Nichols et al., 1998) 
(Chambers and Smith, 2004). Oct4 and Nanog have been identified as being 
expressed predominantly in pluripotent cell types. Loss of Oct4 results in the 
inappropriate differentiation of the inner cell mass with the embryo consisting 
exclusively of trophectoderm tissues (Nichols et al., 1998). In vitro, mouse ES cells 
lacking Oct4 promptly differentiate into trophectoderm, whereas over-expression of 
Oct4 leads to the differentiation of ES cells into primitive endoderm and mesoderm 
(Niwa et al., 2000). This clearly suggests that the precise regulation of the levels of 
Oct4 is essential for pluripotency. Mouse ES cells lacking Nanog are still able to 
proliferate undifferentiated but show a greater tendency to differentiate 
spontaneously towards extra-embryonic endoderm and cannot give rise to mature 
germ cells (Chambers et al., 2003; Chambers and Smith, 2004; Mitsui et al., 2003). 
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Conversely, over-expression of Nanog promotes self-renewal independently of the 
cytokine leukemia inhibitory factor (LIF), which is essential for promoting the 
maintenance of pluripotency by activating the transcription factor Stat3 (Matsuda et 
al., 1999).  
 
Oct4 regulates gene expression by interacting with other factors within the nucleus, 
including the high mobility group (HMG)-box transcription factor Sox2 (Boiani and 
Scholer, 2005; Chew et al., 2005). Contrasting with Oct4 and Nanog, Sox2 expression 
is not restricted to pluripotent cells and can also be found in early neural lineages 
(Avilion et al., 2003). Similarly to what is observed for Oct4, Sox2 deletion in ES cells 
also results in their conversion to trophectoderm (Masui et al., 2007). Sox2 and Oct4 
were shown to heterodimerise, constituting a synergistic complex that targets 
different enhancers and regulates the expression of stem cell-associated genes 
(Chew et al., 2005; Okumura-Nakanishi et al., 2005; Tomioka et al., 2002). Later 
studies have implicated Sox2 in the regulation of a series of transcription factors that 
affect Oct4 expression. Consequently, the forced expression of Oct4 in Sox2-null cells 
is able to rescue self-renewal and pluripotency (Masui et al., 2007). This seems to 
indicate that Sox2 is important for pluripotency by maintaining the appropriate 
levels of Oct4 expression. 
 
In order to gain further insight into how this transcriptional regulatory network 
operates in ES cells, different studies in human and mouse ES cells have used ChIP to 
map in a genome-wide approach the binding sites for Oct4, Nanog and Sox2 (Boyer 
et al., 2005; Loh et al., 2006; Mathur et al., 2008). Although mouse and human ES 
cell models are different from each other and show very specific targets, these 
reports determined that these core transcription factors bind the promoters of a 
large number of developmental genes that are either transcriptionally active or 
inactive in ES cells. Interestingly, they seem to co-localise at their target sites and 
positively influence the transcription of Oct4, Nanog and Sox2 genes themselves. In 
addition, several other transcription factors, chromatin remodelling factors and 
components of signalling pathways known to be important for pluripotency exhibit 
binding of these transcription factors at their promoters. Contrasting with this, 
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several genes are repressed by this network of transcription factors, including genes 
involved in cell fate decisions, such as the determination of the different germ layers 
and extra-embryonic lineages. These findings have redefined our perception of 
pluripotency. Ultimately, this resulted in the creation of the concept of “master 
regulators” of pluripotency, in which Oct4, Sox2 and Nanog seem to play an 
extremely important role in the definition of stem cell identity (Spivakov and Fisher, 
2007). 
 
Lately it has become evident that the network which controls pluripotency is more 
complex and involves other players that still need to be identified (Dejosez et al., 
2008; Kim et al., 2008). A good example of this is given by embryonic carcinoma (EC) 
cells. EC cells can be derived from naturally occurring or experimentally induced 
teratocarcinomas (Andrews et al., 2005). In these stem cells, all three transcription 
factors described are appreciably expressed, nevertheless EC cells do not have the 
same potential as pluripotent ES cells (Chambers and Smith, 2004). This strongly 
suggests that other transcription factors and regulators are required to either 
establish or retain pluripotency. This is supported by the reprogramming of mouse 
embryonic fibroblasts to ES-like pluripotent stem cells by the ectopic expression of 
Oct4, Sox2, Klf4 and c-Myc (Takahashi and Yamanaka, 2006). The extent of the 
pluripotency transcriptional network will continue expanding as our understanding 
of ES cells and the introduction of different tools to study them increase.  
 
1.7.3.2. Chromatin signature of ES cells 
Chromatin reorganisation is an essential step for the establishment of new heritable 
states that accompany lineage specification. In fact, the chromatin found in ES cells 
displays characteristics of a more transcriptionally permissive state and a more 
“open” conformation (Meshorer et al., 2006). It is enriched in acetylated histones 
and more accessible to nucleases (Boyer et al., 2006a). As differentiation progresses, 
cells start accumulating more inactive heterochromatic regions, accompanied by a 
drastic reduction of the acetylation levels of histones H3 and H4 and an increase in 
the global levels of the heterochromatic mark H3K9me3 (Lee et al., 2004). Consistent 
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with this view, a recent work demonstrated that chromatin proteins, namely 
histones H2B, H3 and heterochromatin protein 1 (HP1) are more dynamic in 
pluripotent cells than in differentiated cells (Meshorer et al., 2006). The more 
“relaxed” chromatin structure of ES cells can also be observed by the presence of 
fewer electron dense regions (originally classified as heterochromatin) in ES cells 
when compared with differentiated cell types (Niwa, 2007b). Finally and consistent 
with all these observations, several ATP-dependent remodelling factors are highly 
expressed in ES cells (Kurisaki et al., 2005) and the destabilisation of these molecular 
complexes results in reduced transcription and developmental errors (Bultman et al., 
2006). Collectively, these observations led to the paradigm that ES cells possess a 
very permissive chromatin conformation that is highly plastic or, in other words, 
capable of responding in a very flexible way to different differentiation signals. 
 
1.7.3.3. The role of PcG proteins in ES cell biology 
In addition to their recognized role in Hox gene regulation and definition of body 
segment identity, important roles for PcG proteins in early stages of development 
were suggested by studies on X-chromosome inactivation (Mak et al., 2002; Plath et 
al., 2003; Silva et al., 2003). In these studies it became apparent that PRC2 
components are highly abundant in cells of the ICM and show a decline at later 
embryonic stages. In 2006, several groups used genome wide ChIP analysis to map 
the binding sites of PcG proteins in mice (Boyer et al., 2006b), humans (Bracken et 
al., 2006; Lee et al., 2006) and Drosophila (Negre et al., 2006; Schwartz et al., 2006; 
Tolhuis et al., 2006). These studies revealed that PcG proteins bind to developmental 
regulator genes. In mouse and human ES cells, the identified PcG targets are mostly 
represented by key lineage determining genes and PcG proteins were shown to be 
important in maintaining these genes in a repressed state, suggesting a direct 
functional link between PRC2, gene silencing and the maintenance of a pluripotent 
state (Boyer et al., 2006b). 
 
Other studies revealed that in mouse ES cells, the promoters of many PcG target 
genes are marked by both repressive and active histone modifications, specifically 
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histone H3K27me3 co-localising with H3K4me3  and H3/H4 acetylation (Azuara et al., 
2006; Bernstein et al., 2006). These domains of both active and repressive histone 
marks were termed “bivalent domains”. These domains are intrinsically associated 
with developmentally regulated genes that are silent in ES cells and activated upon 
differentiation (Figure 1.7). These studies thus suggest that lineage specific genes are 
in a primed or poised state, ready for rapid activation or repression in response to 
signals during differentiation. A comparison of the binding sites of Oct4, Nanog and 
Sox2 with bivalent domains present in ES cells showed a significant overlap. This 
establishes a strong link between the epigenetic control of developmental regulators 
and stem cell pluripotency. 
 
 
 
 
 
Figure 1.7. Bivalent chromatin profiles in ES cells. In ES cells the promoters of developmental 
regulator genes can be found in different chromatin conformations. Expressed genes, such as Oct4, 
display active histone modifications associated with their promoters, such as acetylation of H3K9 
(H3K9ac) and methylation of H3K4 (H3K4me). The promoters of a range of non-transcribed 
developmental genes, such as Ikaros and Math1, display a combination of antagonist histone 
modifications, H3K9ac and H3K4me as well as methylation of H3K27 (H3K27me), associated with 
inactive chromatin states. This bivalent chromatin conformation indicates that these genes are 
“poised” for expression in response to appropriate differentiation cues. Through differentiation, these 
bivalent domains are generally resolved to promote either transcriptional activation or silencing of 
loci associated with distinct developmental lineages. Adapted from (Spivakov and Fisher, 2007). 
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1.7.3.4. Further studies on bivalent chromatin states 
What is the real importance of bivalent domains and what impact do they have on 
the biology of pluripotent cells? Bivalent chromatin domains were suggested to 
maintain tissue-specific regulator genes in a silenced or non-productively transcribed 
state in pluripotent cells, primed for a rapid activation upon appropriate 
developmental stimulus (Giadrossi et al., 2007; Spivakov and Fisher, 2007). Evidence 
suggests that during differentiation, bivalent domains are resolved to exclusively 
repressive or active modifications (Bernstein et al., 2006). To have a better 
perception of the “bivalent” chromatin structure, three groups have now analysed 
the co-occupancy of opposing histone marks on a genome-wide scale in mouse and 
human ES cells by analysing H3K4 and H3K27 methylation patterns by ChIP on 
different platforms (Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al., 2007). These 
different approaches converged on a more unifying view of the chromatin in 
pluripotent cells and allowed the assignation of genes to three different classes; 
those marked by H3K4me3 solely, by H3K27me3 and H3K4me3 simultaneously 
(bivalent) or by none of the modifications (Pan et al., 2007; Pietersen and van 
Lohuizen, 2008; Zhao et al., 2007). Remarkably, the genes from these different 
classes correspond to functionally distinct groups. Those associated with H3K4me3 
are highly expressed and encompass mainly genes involved in general metabolism. 
Genes that lack either mark are generally not expressed and are normally tissue-
specific genes. Finally, genes displaying both epigenetic marks are associated with 
very low expression (or non-productive expression) and characterise developmental 
regulators, similarly to what was already described for PcG targets mentioned above. 
 
Although bivalency has been initially characterised in ES cells, the understanding of 
how these bivalent domains respond as cells differentiate is essential. Mikkelsen and 
colleagues started to address this issue by studying what happens to bivalent 
domains during differentiation (Mikkelsen et al., 2007). These authors have analysed 
the distribution of H3K27me3 and H3K4me3 in mouse ES cells, mouse neural 
precursor cells (NPCs) and mouse embryonic fibroblasts (MEFs). The data obtained 
show that approximately half of the bivalent domains present in ES cells become 
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marked by H3K4me3 solely and highly expressed in NPC cells. The other half of the 
genes retain low level of expression. Of these, a very small fraction retains their 
bivalency whereas the majority of the domains get resolved by eliminating both 
marks or keeping H3K27me3 only. In MEFs, more regions remain bivalent which is 
not entirely surprising as MEFs are a less committed cell lineage than NPCs. This 
observation brings our view of bivalency one step forward. Bivalency not only poises 
genes for expression, it also predisposes genes for inactivation throughout ES cell 
differentiation. The results also show that bivalency is not exclusive to ES cells and 
bivalent domains can, in fact, be found in differentiated cell lineages. This extended 
view on bivalency redefines the more classical understanding of this unusual 
chromatin conformation. Bivalency can be better understood as a mechanism that 
allows the postponement of the decision for a gene to become either activated or 
repressed (Pietersen and van Lohuizen, 2008). Therefore, bivalency acts as a on/off 
switch that delays transcriptional state decisions of several genes in different cellular 
models and, most remarkably, in pluripotent ES cells. 
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1.8. Aims of this study 
The importance of PcG proteins in pluripotency is undeniable and the increasing 
amount of information we possess strongly suggest that PcG proteins play a key role 
in developmental decisions. The molecular mechanisms involved in regulation of PcG 
proteins, their function and how they act to promote gene silencing of 
developmentally regulated genes remain poorly understood. The aim of this work is 
to investigate the molecular mechanisms by which PcG proteins contribute in 
defining and maintaining pluripotency of ES cells. 
 
For this, I will initially focus on the study of mechanisms that are implicated on the 
regulation of PcG gene expression in ES cells and throughout differentiation, 
exploring the link with pluripotency transcription factors. I will then present a 
collaborative study in which I was involved that aimed to explore one of the 
molecular mechanisms employed by PcG proteins to retain bivalent genes in a 
poised state. Finally, I will describe the characterisation of a PRC2 sub-complex in 
mouse ES cells and its role in epigenetic control and bivalent domains regulation.  
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Chapter 2. Materials and Methods 
 
2.1. Tissue culture techniques 
2.1.1. Cell lines 
All cell lines used in this study are of murine origin with the exception of human 
HEK293T cells. 
 
2.1.1.1. Stem cell lines 
The XX embryonic stem (ES) cell line PGK12.1 and the XX trophoblast stem (TS) cell 
line B1 used in this study were derived in the laboratory and have been previously 
described (Mak et al., 2002; Penny et al., 1996). 
 
The extraembryonic endoderm (XEN) cell line, IM8A1 (Kunath et al., 2005), was 
kindly provided by Janet Rossant (Hospital for Sick Children, Toronto). 
 
The ZHBTc4 mouse ES cell line is a genetically engineered mouse ES cell line carrying 
a tetracycline-inducible Oct4 transgene replacing endogenous Oct4 alleles (Niwa et 
al., 2000). The ES cell line 2TS22c is a genetically engineered mouse ES cell line 
carrying a tetracycline-inducible Sox2 transgene replacing endogenous Sox2 alleles 
(Masui et al., 2007). These cell lines were kindly provided by Dr. H. Niwa (RIKEN 
Center for Developmental Biology, Japan).  
 
The ES cell line ES-ERT2 (Ring1A-/-, Ring1Bflx/flx), gift from Dr. H. Koseki (RIKEN 
Yokahama institute, Japan), is an ES cell line homozygote mutant for the Ring1A 
gene and which carries floxed alleles of the Ring1B gene. This cell line expresses Cre-
ERT2 recombinase. Activation by tamoxifen causes deletion of the floxed alleles 
(Endoh et al., 2008; Stock et al., 2007).  
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The ES cell line Suz12KO (Suz12-/-), gift from Dr. H. Koseki (RIKEN Yokahama institute, 
Japan), is deficient for the PcG protein Suz12 (Lee et al., 2006). Suz12WT is the wild 
type ES cell line, control for Suz12 -/- ES cells and was also provided by Dr. H. Koseki.  
 
The Es cell line Ezh2-1.3 carries floxed alleles of the Ezh2 gene (Ezh2flx/flx) and 
expresses Cre-ERT2 recombinase tamoxifen-inducible. This cell line was kindly 
provided by Dr. S. Sauer (MRC Clinical Sciences Centre, London, UK).  
 
2.1.1.2. Other cell lines 
The Oct4-GFP B cell line (OGB) is an Abelson transformed mouse pre-B cell line 
derived from bone marrow of the transgenic mice GOF18-∆PE (Palmieri et al., 1994), 
constitutively expressing Oct4 in fusion with GFP. This cell line was kindly provided 
by Filipe Pereira (MRC Clinical Sciences Centre, London, UK). 
 
The MP fibroblast cell line was derived in the laboratory by Dr. Tatyana Nesterova 
from a PGK strain male adult mouse. The fibroblast cell line NMLF stands for “Nanog 
Myc Lung Fibroblasts” and has been also derived in the laboratory by Claire Senner. 
This fibroblast cell line was derived from lungs of a mouse line carrying a Nanog-myc 
inducible transgene randomly inserted in the genome.  
 
Mouse embryonic fibroblasts (MEF), used as feeders for ES cell culture, were derived 
from 13.5dpc F1 wild type embryos and cultured for 2-3 passages before mitomycin-
inactivation (see section 2.1.3).  
 
HEK293T cells are a transformed human embryonic kidney cell line. 
 
2.1.2. Cell maintenance and passaging 
Fibroblast cell lines were cultured in EC10 medium, comprising of Dulbelcco’s 
Modified Eagle Medium (DMEM; Gibco BRL) supplemented with 10% fetal calf serum 
(FCS; GlobePharm), 1x Dulbelcco’s non-essential amino acids (NEAA), 100U/ml 
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penicillin and 100µg/ml streptomycin, 2mM L-glutamine, 0.1mM β-mercaptoethanol 
(all from Gibco BRL). 
 
ES cell lines were maintained in an undifferentiated state on a layer of inactivated 
mouse embryonic fibroblats (MEF) or directly on 0.1% gelatin coated flasks (Falcon, 
BD), depending of their specific needs. All ES cells were grown in ES medium, 
comprising DMEM supplemented with 15-20% FCS, 1x non-essential amino acids, 
100U/ml penicillin and 100µg/ml streptomycin, 2mM L-glutamine, 0.1mM β-
mercaptoethanol and leukemia inhibitory factor (LIF) conditioned medium 
(1000U/ml) to maintain cells in an undifferentiated state.  
 
All ES cell lines used in this study were grown on mitomycin-inactivated MEF (see 
section 2.1.3), except for PGK12.1, ZHBTc4, 2TS22c and Ezh2-1.3 cell lines which do 
not require feeders. For the Ring1B conditional deletion in ES-ERT2 Ring1A-/- cells, 
cells were plated without feeders on gelatin-coated plates 12h before 
supplementing the medium with 800nM of 4-hydroxytamoxifen (Sigma).  
 
TS cells were cultured in the presence of 70% inactivated MEF-conditioned media 
and 30% TS medium. TS medium comprises RPMI 1640 (Gibco) supplemented with 
20% FCS, 2mM L-glutamine, 1mM sodium pyruvate, 100U/ml penicillin and 
100µg/ml streptomycin, 0.1mM β-mercaptoethanol. Human recombinant fibroblast 
growth factor (FGF4, 25ng/ml) (Sigma) and Heparin (1µg/ml) (Sigma) were added to 
TS medium just before use. 
 
XEN cells were maintained on 0.1% gelatin-coated flasks in RPMI 1640 supplemented 
with 20% FCS, 2mM L-glutamine, 1mM sodium pyruvate, 100U/ml penicillin and 
100µg/ml streptomycin, 0.1mM β-mercaptoethanol. 
 
All cells were grown in a humidified 37°C incubator containing 5% CO2. ES cell 
cultures were fed every day. Fibroblasts and MEF cultures were fed every 2-3 days. 
All cell lines were grown to 80-90% confluence, then split and plated at a lower 
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density. To split cells, medium was aspirated, cells were washed briefly with 1xPBS 
and treated with 0.05% trypsin/EDTA, supplemented with 2% chicken serum (Gibco 
BRL) at 37°C for 5min. Trypsinisation was stopped by addition of medium and cells 
were plated at a lower density. Most ES cell lines were split 1:5 and re-plated on 
gelatinized plates with or without feeders (according to the cell line characteristics or 
experimental design).  
 
2.1.3. Preparation of feeders 
To prepare feeders for ES cell culture, MEF cells were grown to confluence in EC10 
medium and inactivated by treating cells with EC10 containing 10µg/ml of 
mitomycin C (Sigma) for 2h. When required, the feeders were thawed and plated on 
gelatinized plates, at a density of 4.2x104 cells/cm2, prior to plating ES cells. 
 
2.1.4. ES cell differentiation 
ES cell differentiation was achieved by promoting embryoid body (EB) formation. 
Briefly, ES cells were plated at a low density (1x106 cells) in a 9cm non-gelatinised 
tissue culture dish, in EC10 medium in the absence of LIF. Medium was changed 
every day. After three days of differentiation, the colonies were flushed from the 
plate with a pipette, collected and transferred to 9cm bacterial petri dishes, where 
they were kept until day 7 (medium was changed every day). Most of the cells will 
not adhere to these plates and will lead to the formation of spherical aggregates, the 
embryoid bodies, which contain differentiating cells. On day 7, EBs were transferred 
back to tissue culture plates, which allow the cells to adhere and further 
differentiate into different cell lineages in an uncontrollable manner.  
 
2.1.5. Establishing transgenic ES cell lines 
PGK12.1 XX ES cells were used to generate all transgenic cell lines used in this study. 
Briefly, cells were plated at a density of 1x106 cells per well in a 6-well plate and 
grown in antibiotic-free ES medium. The following day, when cells had grown to 
around 80% confluence, they were transfected using Lipofectamine 2000 reagent 
(Invitrogen). 4µg of DNA construct of interest was diluted in DMEM to a final volume 
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of 250µl while lipofectamine was also diluted 1:25 in DMEM to a final volume of 
250µl. Both solutions were gently mixed together after 5min incubation at room 
temperature. This mix was left at room temperature for 20min to allow formation of 
DNA-lipid complexes and then added drop-wise on top of the cells and incubated at 
37°C for 24h. The following day cells were passaged 1:5 in normal ES medium. 
Positive integrants were selected 48h post-transfection by incubating cells with 
medium containing geneticin (G418, Gibco, 400µg/ml) or blasticidin (Invitrogen, 
10µg/ml), depending on the selection marker present in the construct used. To 
enrich for positive integrants and where it applies, cells were sorted by Fluorescence 
activated cell sorting (FACS) based on their GFP expression. Individual ES colonies 
were isolated on day 8-10 of selection or after 2-3 rounds of FACS sorting and grown 
in regular ES medium thereafter. 
 
2.2. Mouse work and ES cell derivation 
All licensed animal procedures were carried out by Ruth Appanah and Sara Norton at 
the MRC Clinical Sciences Centre. MEF were derived using F1 mouse embryos 
coming from C57B16 x CBA strain crosses. Eed17Rn5-3354SB mutant mice were obtained 
from the Oak Ridge National Laboratory (USA) and maintained as heterozygote 
(homozygote mutant mice are embryonic lethal). Adult animals were genotyped by 
PCR on genomic DNA extracted from mouse tails using primers Eed_MC1 
(CTTGGCTAACTGGTACCATTTTCCT) and Eed_MC2 (CTTACTGACAGGAGAAGGTTTG 
GGT) (annealed at 60ºC). Amplified DNA fragments were digested with AluI 
restriction enzyme (New England Biolabs). Mutant and wild type alleles were 
resolved on a 2.5% agarose gel stained with ethidium bromide. Blastocysts for ES cell 
derivation were obtained from crosses between Eed17Rn5-3354SB heterozygous males 
and females, after super-ovulation of females. ES cells were derived according to a 
protocol from Prof. Haruhiko Koseki’s laboratory (personal communication). Cells 
were derived and maintained in undifferentiated conditions for the first passages in 
DMEM supplemented with 5% FCS, 15% Knock-Out Serum Replacement (KSR; Gibco 
BRL), 2mM L-glutamine, 1x NEAA, 0.1mM β-mercaptoethanol and LIF-conditioned 
medium (2000U/ml). Once established, all cell lines were genotyped as described 
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above and then sexed by PCR using primers Ube1xa 
(TGGTCTGGACCCAAACGCTGTCCACA) and Ube1xb (GGCAGCAGCCATCACATAAT 
CCAGATG) that give bands of distinct sizes for the UBE1X and UBE1Y genes 
respectively on the X and Y chromosome (Chuma and Nakatsuji, 2001). 
 
2.3. Genomic DNA extraction 
Cells were harvested, spun down, briefly washed with PBS and the cell pellet was 
resuspended and lysed in 500µl of lysis buffer (200mM NaCl, 100mM Tris-HCl pH7.4, 
5mM EDTA, 0.2% SDS, 250µg Proteinase K) overnight at 55ºC. Genomic DNA was 
then extracted once with phenol:chloroform:isoamylalcohol (25:24:1) and once with 
chloroform. DNA was precipitated using 0.7 volumes of isopropanol and 1/10th 
NaOAc pH5.2, followed by a 70% ethanol wash. The DNA pellet was air-dried and 
resuspended in TE. DNA concentration was determined using a Nanodrop 
spectrophotometer (Nanodrop Technologies).  
 
2.4. RNA techniques and gene expression analysis 
2.4.1. RNA extraction and reverse-transcription 
Total RNA was extracted from cells using Trizol reagent (Invitrogen) according to the 
manufacturer’s instructions. Cells were harvested, spun down, briefly washed with 
PBS and the cell pellet was resuspended and lysed in 1ml Trizol reagent. 0.2ml of 
chloroform was added to the lysate. Samples were shaken vigorously and 
centrifuged for 15min at 12,000g at 4°C. The upper phase, containing RNA, was 
transferred to a new tube and precipitated by addition of 0.5ml of isopropanol. RNAs 
were centrifuged at 12,000g for 10min at 4°C. RNA pellets were washed with 70% 
ethanol, air-dried and finally resuspended in 43µl Rnase-free H2O. To remove 
contaminating genomic DNA, RNA samples were treated with DNAseI (Turbo DNA 
free Kit, Ambion). 5µl of DNAse 10x buffer and 2µl of Turbo DNAseI were added to 
each sample. The mix was then left at 37°C for 1h. To remove the DNAse, 10µl of 
DNAse removal agent was added to each sample and incubated at room 
temperature for 5min. The samples were then centrifuged at 12,000g for 2min and 
the supernatant was transferred to a new tube. Concentration of the extracted RNA 
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was measured using a Nanodrop spectrophotometer and integrity of RNAs was 
checked by running 1µl on an agarose gel. First strand cDNA was synthesized using 
Superscript III reverse transcriptase (Invitrogen) in a 20µl reaction. 2µg of RNA 
template were denatured for 5min at 65°C for denaturation with 1µl of oligo(dT)12-18 
(Invitrogen) and 1µl 10mM dNTP mix (Promega), and then incubated  on ice for 
5min. 4µl of 5x first strand buffer, 2µl of 0.1M DTT, 1µl of RNaseOUT (Invitrogen) 
and 1µl of 200U/µl Superscript III were then added. A reaction without Superscript III 
was also set up as a control (designated “-RT”). Both reactions were incubated at 
50°C for 1h and 70°C for 15min for inactivation of the enzyme. 80µl RNase-free 
water was added to each cDNA sample. Gene expression analysis was achieved by 
semi-quantitative PCR or real-time PCR.  
 
2.4.2. Semi-quantitative PCR analysis 
Semi-quantitative PCR was used to assess gene expression of the following set of 
genes: Oct4, Nanog, Fgf4, Cdx2, Hand1, Errβ, Gata6, FoxA, Sox7, Afp, T and GAPDH. 
PCR reactions were performed for 34 cycles in a total volume of 25µl, using Taq DNA 
polymerase (Invitrogen), according to the manufacturer’s instructions. Expression 
analysis of a specific gene was resolved by visualising the PCR products after 
separation by electrophoresis on 1.5% agarose gel, stained with ethidium bromide 
and visualised under UV light using a Molecular Imager Gel Doc system (Bio-Rad). 
Primer sequences and respective annealing temperatures are shown in Table A1, in 
appendix. 
 
2.4.3. Real-time quantitative PCR analysis 
Real-time PCR reactions were prepared with 1x iQ™ Sybr Green supermix (Bio-Rad), 
300nm of each primer and 2µl of diluted cDNA template in a 25µl reaction volume. A 
reaction with H2O instead of DNA was included to control for the formation of 
primer dimers. Each specific reaction was performed in duplicate. Real-time PCR 
analysis was performed on an OpticonTM Chromo4 DNA engine using Opticon 
Monitor 3 software (MJ Research Inc. Waltham, MA). The following cycling 
conditions were used: an initial denaturating step at 95ºC for 10 min followed by 40 
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cycles of denaturation at 95ºC for 30 sec, annealing at 60ºC for 15 sec, elongation at 
72ºC for 15 sec. After each cycle, a fluorescence read of the plate was performed. 
After 40 cycles, the melting temperature of each amplified product was determined 
from 55ºC to 95ºC at 0.5ºC intervals. Analysis of data was performed with the 
Opticon Monitor 3 software. 
 
2.4.3.1. Quantitative PCR data analysis 
The relative expression of a gene was calculated using the ∆C(T) method (Pfaffl, 
2001). When the amplification efficiency is close to 2, the relative amount of PCR 
products between reaction 1 and 2 can be calculated as 2-∆C(T)1/2-∆C(T)2, where C(T) 
corresponds to the threshold cycle at which fluorescence due to a specific PCR 
product becomes detectable above background. Gapdh, Hmbs, Idh, B-actin and/or 
B2M were generally used for gene expression data normalisation. Primer sequences 
can be found in Table A2, in appendix. 
 
2.4.3.2. Primer design and testing for quantitative PCR 
Primers were designed with the Vector NTI Advance 10 program (Invitrogen) using 
sequences from the mouse genome build found on Ensembl website. The primers 
designed fall within the following characteristics: amplicon size of 100-200bp, GC 
content of 40-60%, melting temperature 55-65°C. All primer pairs were tested for 
predicted products within the mouse genome using in silico PCR tools. Primers 
yielding single predicted PCR product of the correct size were ordered from Sigma 
Genosys. The efficiency of amplification for each primer pair was determined by 
quantitative PCR with sequential 2-fold dilutions of cDNA or genomic DNA (Pfaffl, 
2001). Primers yielding poor linear fits of the C(T) versus logarithm of concentration 
(R2<0.99) or efficiencies lower than 1.8 or greater than 2.2 were discarded.  
 
2.4.4. mRNA half-life stability assay 
PGK12.1 and MP cells were seeded in multiple 100mm dishes at a density of 2.5 x 
106 per plate and cultured overnight. At time zero, medium was removed and 
replaced with identical medium containing 5μg/μl Actinomycin D (Sigma). At 
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appropriate time points, cells were harvested with trypsin/EDTA, washed in PBS and 
snap frozen in liquid nitrogen. Pellets were processed for RNA isolation as described 
in 2.4.1. RNA levels were quantified relative to amount of total RNA. 
 
2.5. Chromatin immunoprecipitation (ChIP) assays 
2.5.1. Crosslinked ChIP 
Approximately 1-2X108 cells were fixed in suspension in 1% formaldehyde (Fluka) 
solution (supplemented with 10mM NaCl, 5μM EGTA, 10μM EDTA, 500μM Hepes 
pH8.1) for 10min at room temperature. After quenching with 0.125M glycine for 
5min at room temperature, cells were washed in 1xPBS and lysed in 1ml lysis buffer 
(1% SDS, 10mM EDTA pH8.0, 50mM Tris-HCl pH8.1, Protease Inhibitors tablet 
(Roche)) for 5min on ice. Chromatin was fragmented to 300-500bp by sonicating at 
4°C 10-20min with 30sec on/off cycle on a Bioruptor sonicator (Diagenode) set to 
high output. The sonicated material was then analysed on a 2% agarose gel. If the 
chromatin was not at the desired size of 300-500 bp, the chromatin was further 
sonicated. DNA concentration was determined by spectrophotometric analysis at 
260nm. For each ChIP reaction, 150μg of chromatin was used, diluted 1:10 in 
dilution buffer (1% Triton X-100, 2mM EDTA pH8.0, 150mM NaCl, 20mM Tris-HCl 
pH8.1, Protease Inhibitors) and incubated for 90min at 4°C on a rotating wheel with 
30μl of protein A or G agarose beads/salmon sperm DNA (Millipore), depending on 
the antibody used for immunoprecipitation (IP). After centrifugation at 4,000g for 
5min, supernatant was subjected to IP overnight at 4°C, using a variety of antibodies. 
List of antibodies used for ChIP as well as quantity and suppliers is shown in Table A4 
in appendix. For all experiments performed, a mouse IgG antibody was used as a 
negative control and an anti-histone H3 antibody served as an input control. After 
12h at 4°C rotating, 30μl of IgG or IgA agarose beads were added for another 90min. 
Beads were washed 4 times in a low salt wash buffer (0.1% SDS, 1% Triton X-100, 
2mM EDTA, 150mM NaCl, 20mM Tris-HCl pH8.1 and Protease Inhibitors) and once in 
a high salt wash buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 500mM NaCl, 20mM 
Tris-HCl pH8.1 and Protease Inhibitors). Immunoprecipitated DNA was eluted from 
the beads by incubation in 450μl elution buffer (1% SDS, 0.1M NaHCO3), with 150μg 
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proteinase K and 50μg RNaseA for 2H at 37°C and overnight at 65°C. DNA was 
extracted twice with phenol:chloroform:isoamylalcohol (25:24:1, Sigma), and 
precipitated with isopropanol and 75μM NaOAc pH5.2. 30μg of Glycogen was added 
as a carrier. After precipitation, DNA was resuspended in 100μl H2O and 2μl were 
used per quantitative PCR reaction. Quantitative PCR reaction were set up and 
analysed in the same way as for gene expression, as described in section 2.4.3.  
 
2.5.2. Flag crosslinked ChIP 
Cells were grown in 3 to 4 14cm petri dishes. When confluent, cells were washed 
briefly in PBS and fixed with 1% formaldehyde for 20min at RT with very gentle 
agitation. Fixation was quenched by the addition of Glycine to a final concentration 
of 0.125M. Cells were then washed 3 times with cold PBS and scraped off the plates 
in wash buffer 1 (10mM Hepes pH7.5, 10mM EDTA, 0.5mM EGTA, 0.75% Triton X-
100, protease inhibitors). Cells were resuspended in 10ml of wash Buffer 1 and 
incubated for 10min rotating at 4ºC. The suspension was then spun for 5min at 
5,000rpm at 4ºC and the supernatant was discarded. The pellet was then 
resuspended in wash buffer 2 (10mM Hepes pH7.5, 200mM NaCl, 1mM EDTA, 
0.5mM EGTA, protease inhibitors) and incubated again for 10min at 4ºC on a 
rotating wheel. The suspension was then spun again at 5,000 rpm for 5min at 4ºC 
and the supernatant was discarded. The pellet (consisting of cleared nuclei) was 
finally resuspended in 500µl of lysis/sonication buffer 3 (150mM NaCl, 25mM Tris 
pH7.5, 5mM EDTA, 1% Triton, 0.1% SDS, 0.5% deoxycholate, protease inhibitors) and 
sonicated for 15-30min at 4°C with 30sec on/off cycle on a Bioruptor sonicator 
(Diagenode) set to high output, in order to produce fragments of 300-1000bp. DNA 
content was determined by spectrophotometric analysis at 260nm and 150μg of 
chromatin were used per IP. The chromatin preparations were diluted to 500μl in 
lysis/sonication buffer 3 and pre-cleared with protein A or G agarose beads (30μl per 
IP) for 2h rotating at 4ºC. After a short spin to remove the beads, primary antibodies 
(see Table A4 in appendix) were added to the chromatin and incubated overnight at 
4ºC rotating. The following day, 30μl of protein A or G agarose beads were added to 
the chromatin and incubated at 4ºC for approximately 2h rotating. The beads were 
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then washed sequentially in wash buffer 1 (50mM Tris pH8.0, 150mM NaCl, 0.1% 
SDS, 0.5% deoxycholate, 1% NP40, 1mM EDTA), wash buffer 2 (50mM Tris pH8.0, 
500mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP40, 1mM EDTA) and wash buffer 
3 (50mM Tris pH8.0, 250mM LiCl, 0.5% deoxycholate, 1% NP40, 1mM EDTA) for 
10min rotating at 4ºC. Reverse-crosslinking, DNA purification and PCR analysis were 
performed identically to the ChIP protocol described in section 2.5.1. 
 
2.5.3. ChIP for RNAP and H2Aub1 
A modified protocol of cross-linked ChIP was used for RNAP, Ring1B and the histone 
modification H2Aub1. This protocol has been described in detail in (Stock et al., 
2007). 
 
The list of all primers used in ChIP analyses can be found in Table A3 in the appendix. 
 
2.6. FISH and immunofluorescence techniques 
2.6.1. Immunofluorescence 
ES cells were harvested by trypsinization, re-plated onto gelatinized Superfrost Plus 
glass slides (BDH) placed in square petri dishes and allowed to adhere at 37°C in a 
5% CO2 incubator for approximately 6h. Slides were then washed briefly in PBS and 
fixed in 2% formaldehyde (Fluka) in PBS for 15min at RT. The slides were washed 
three times for 3min each in PBS and permeabilised in 0.4% Triton X-100 at RT for 
5min. Alternatively, when using Pcl2 antibody, cells were pre-extracted by 
treatment, prior fixation in 2% formaldehyde, with 0.4% Triton X-100 on ice for 1min. 
Unspecific hybridization was blocked by incubation of the slides in 0.2% fish gelatin 
(Sigma) in PBS for 30min. Slides were then incubated in primary antibody diluted in 
5% normal goat serum (Vector Laboratories) in 0.2% fish gelatin or, for Pcl2 
antibody, in CanGetSignalTM Solution (Toyobo, Japan) for 2h at RT in a moist 
chamber. Slides were then washed three times for 3min in 0.2% fish gelatin and 
incubated with the appropriate secondary antibody diluted either in 0.2% fish gelatin 
or CanGetSignalTM Solution for 1h at RT in a moist chamber. Slides were finally 
washed in PBS 3 times for 3min each and mounted in Vectashield antifade medium 
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(Vector Laboratories) containing DAPI counterstain (1.5µg/ml). See Tables A4 and A5 
in appendix for primary and secondary antibodies and dilutions used. 
 
2.6.2. RNA Fluorescence in-situ hybridization (FISH) 
Probes for RNA FISH were labeled with either digoxigenin-11-dUTP (DIG) or biotin-
16-dUTP nick translation kit (Roche) according to manufacturer’s instructions. Probes 
were purified in MicroSpin S-300 HR columns (Pharmacia). The probe used to detect 
Xist RNA was generated using the GPT16 plasmid DNA, containing Xist exon 1, 
[Duthie, 1999 #116] and labelled with biotin. The probe used to detect Tsix RNA was 
generated using a plasmid comprising the promoter and 5’ region of Tsix, labelled 
with DIG.  
 
For RNA FISH, cells were allowed to adhere on gelatinized slides for 6h, as for 
immunofluorescence. The slides were briefly rinsed in PBS and then transferred to 
ice-cold Cytoskeletal (CSK) buffer (100mM NaCl, 300mM Sucrose, 3mM MgCl2, 
10mM PIPES, 0.5% Triton X-100, 1mM EGTA and 2mM Vanadyl Ribonucleoside 
complexes (New England Biolabs)) for 5min on ice to permeabilise the cells. Slides 
were then fixed in ice-cold 4% formaldehyde in PBS on ice for 10min and then 
washed twice in 70% ethanol (EtOH) for 3min at RT. At this point, slides could be 
stored in 70% ethanol at 4ºC. Before hybridization, slides were dehydrated 
sequentially in 80%, 90% and 100% EtOH for 3min each at RT and dried in a vacuum 
dessicator. For each slide, 50ng of biotin-labeled and DIG-labeled DNA probe was 
mixed with 10µg of salmon sperm DNA (Invitrogen) and 10µg of yeast tRNA 
(Invitrogen). 2 volumes of 100% EtOH were added and the mix was dried using speed 
vacuum. The dried probes were resuspended in 5µl of formamide (Sigma) for 10min 
at 37ºC. The probes were then denatured for 7min at 74ºC after which 5µl of 2x 
hybridization buffer (20% dextran sulphate (GE Healthcare), 4xSSC, 2mg/ml BSA, 10% 
vanadyl ribonucleoside complexes) was added. Probes were kept on ice and then 
added to slides under an 18mm x 18mm coverslip (treated with a weak hydrochloric 
acid in 70% EtOH solution to eliminate traces of grease) and sealed with rubber 
cement. The slides were incubated in a box placed in a water bath at 37ºC overnight. 
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The next day, all wash solutions and coplin jars were pre-warmed to 42ºC. Slides 
were washed 3 times for 5min in 50% formamide in 2xSSC, followed by three 5min 
washes in 2xSSC and one final wash at RT in 4xSSC/0.1% Tween-20). Slides were 
blocked in blocking buffer (4xSSC, 4mg/ml BSA, 0.1% Tween-20) for 30min in a moist 
chamber at 37ºC. Probes were detected by incubating slides for 30min at 37ºC 
sequentially with anti-dig FITC, avidin-texas red and FITC anti-sheep, biotinylated 
avidin and finally avidin-texas red. All antibodies (see Table A5 in appendix for a list) 
were diluted in detection buffer (4xSSC, 1mg/ml BSA, 0.1% Tween-20). Between 
each and after the last incubation, slides were washed 3 times for 2min in 
4xSSC/0.1% Tween-20 at 37ºC. Slides were then briefly rinsed in PBS, before 
mounting in Vectashield antifade medium containing DAPI counterstain.  
 
2.6.3. Microscopy 
Scoring and image collection of RNA FISH and immunofluoresence was carried out 
using a TCS SP5 Leica laser-scanning confocal microscope using a 63x oil immersion 
objective. Images were processed using Leica Confocal software and Adobe 
Photoshop CS3. Microscope settings and laser power were kept constant between 
controls and samples. 
 
2.6.4. Analysis of alkaline phosphatase activity 
This assay was used for ES-ERT2 cells. Cells were cultured for 0, 24 and 48h in the 
presence of Tamoxifen. After fixation, alkaline phosphatase activity was measured 
using a commercial kit, according to the manufacturer’s instructions (Sigma, 
procedure 86). The stained colonies were visualised using a Leica microscope with an 
8x objective. 
 
2.7. Fluorescence activated cell sorting (FACS) analysis  
For Oct4 staining, ES-ERT2 cells were harvested by trypsinisation, washed in PBS and 
fixed (10min, 37˚ C) in 0.1% paraformaldehyde in PBS. Cells were washed in PBS and 
permeabilised (30min, 4˚C) with cold 90% methanol. After washing twice in PBS with 
2% FCS and 0.1% Triton X-100, cells (1-5 x105) were incubated for 1h with anti-Oct4 
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antibody (Santa Cruz N-19; diluted to 1:100). Cells were washed twice in PBS with 2% 
FCS and 0.1% Triton X-100 before incubating for 30min with an AlexaFluor568-
conjugated anti-Goat IgG secondary antibody (Molecular Probes). The cells were 
then washed twice in PBS with 1% BSA and 0.1% Triton X-100, and analysed on a 
FACScalibur flow cytometer (BD Biosciences). The profile of stained cells was 
compared to unstained cells and cells stained with the secondary antibody only.  
 
For stage-specific embryonic antigen-1 (SSEA-1) staining, ES-ERT2 cells were 
harvested by trypsinisation and washed three times in PBS with 2% FCS. Cells (1-5 
x105) were incubated for 30-40min at 4˚C in 35 µl of APC-coupled anti-SSEA-1 (R&D 
Systems; 1:3.5). Cells were washed twice in PBS with 2% FCS and analysed on a 
FACScalibur. SSEA-1 stained cells were compared to cells stained with APC-coupled 
non-relevant antibody (anti-B220).  
 
All analyses were performed on a FACScalibur flow cytometer (BD Biosciences) using 
the CellQuest software. For FACS sorting of cells, harvested cells were resuspended 
in FACS buffer (PBS with 5% FCS) and GFP expressing cells were sorted using a 
FACSAria cell sorter (BD Biosciences).  
 
2.8. Protein extraction and analysis methods  
2.8.1. Acid extraction of histones 
To prepare histone extracts, cells were harvested and washed with ice-cold PBS 
containing protease inhibitors (Roche). The cells were pelleted at 235g for 5min at 
4ºC. The pellet was resuspended in 1ml 0.2M H2SO4 and incubated on ice for 30min. 
This suspension was spun at 20,200g for 2min at 4ºC. The supernatant containing the 
extracted histones was collected into a new eppendorf tube and precipitated by 
addition of trichloroacetic acid (TCA, Sigma) to a final concentration of 25%. The 
samples were incubated on ice for 30min and centrifuged at 20,200g for 10min at 
4ºC. The protein pellet was washed twice with ice-cold acetone, air-dried and finally 
resuspended in H2O or 100mM Tris pH7.6. The protein concentration was 
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determined using Bradford assay with the Protein Assay reagent (Bio-rad), according 
to the manufacturer’s instructions and the extracts were stored at -80ºC until used. 
 
2.8.2. High-salt nuclear extracts 
Nuclear extract was prepared as described previously [Dignam, 1983 #89; 
Kuzmichev, 2002 #3]. Briefly, the cell pellet was resuspended in 5 pellet volumes of 
ice-cold buffer A (10mM Hepes pH7.9, 5mM MgCl2, 0.25M sucrose, 0.1% NP40, 
protease inhibitors). The cell suspension was then passed through an 18G needle 
and spun at 8,000rpm at 4°C for 10min. The pellet, which contained the nuclei, was 
then resuspended in approximately 1ml of ice-cold buffer B (10mM Hepes pH7.9, 
25% glycerol, 1.5mM MgCl2, 0.1 mM EDTA, 1M NaCl, protease inhibitors). The 
suspension was then passed 4 times through an 18G needle and then incubated in 
this high salt concentration buffer for 30min on ice to extract the proteins. Next, 
DNA was sheared by sonicating the sample for 5min at 4ºC on a Diagenode Bioruptor 
set to high output level. The extract was then dialyzed against BC100 buffer (25mM 
Tris-HCl pH7.9, 20% Glycerol, 0.2mM EDTA, 100mM KCl, 10mM β-mercaptoethanol, 
0.2mM PMSF) for 4h, the BC100 exchanged with fresh buffer after 2h. The dialyzed 
nuclear extract was centrifuged for 10min at 12,000g and supernatant was collected. 
Protein concentration was determined by Bradford assay and protein extracts were 
stored at -80ºC until used. 
 
2.8.3. Whole cell extracts 
Whole cell extracts were prepared by direct lysis of harvested cells washed in PBS in 
1xLaemmli sample loading buffer (50mM Tris-HCL pH6.8, 2% SDS, 10% glycerol, 
0.001% Bromophenol Blue, 166mM β-mercaptoethanol (added fresh)). Suspension 
was boiled for 5min at 95ºC and thoroughly vortexed to shear DNA.  
 
2.8.4. Cell fractionation 
Cells were harvested as usual and washed in ice-cold PBS containing protease 
inhibitors. Cells were then resuspended in 5 pellet volumes of buffer A (50mM Tris-
HCl pH7.9, 30% glycerol, 1mM EDTA, 0.5mM DTT and protease inhibitors) and lysed 
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by freeze-thawing in liquid nitrogen. Suspension was then spun at 1,400g for 10min 
at 4ºC. The supernatant (S1 fraction) was collected, consisting essentially of 
cytoplasmic proteins. The pellet was washed once with cold PBS containing protease 
inhibitors, spun down and then resuspended in 5 pellet volumes of hypertonic buffer 
(10mM Tris-HCl pH7.9, 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 2mM DTT, protease 
inhibitors) and incubated on ice for 5min. This suspension was then passed through a 
0.5mm needle 4 times and centrifuged at 3,000 g for 8min at 4ºC. The supernatant 
(S2 fraction), which corresponds to soluble nuclear proteins, was collected. The 
pellet was resupended in 5 pellet volumes of high salt buffer (50mM Tris-HCl pH7.5, 
10% sucrose, 420mM KCl, 5mM MgCl2, 0.1mM EDTA, 20% glycerol, 2mM DTT, 
protease inhibitors) and spun at 10,000g for 60min at 4ºC. The supernatant (S3 
fraction), which corresponds to high salt nuclear fraction, was collected. The 
remaining pellet was resuspended in 5 pellet volumes of 2x Laemmli loading buffer 
and corresponds to insoluble proteins and the chromatin bound fraction (C). Fraction 
C was sonicated before loading on a SDS-PAA gel.  
 
2.8.5. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and gel 
staining 
Protein extracts were separated on SDS-Polyacrylamide (SDS-PAA) gel using the 
Mini-Protean system (Bio-Rad). Gels were prepared as described by Sambrook et al 
(Sambrook, 1989). Protein extracts were resuspended in Laemmli buffer (50mM Tris-
HCl pH6.8, 10% glycerol, 2% SDS, 1mg/ml bromophenol blue, 166mM B-
mercaptoethanol (added fresh)), boiled at 100ºC for 5min and spun down at 
maximum speed for 5min. Proteins were loaded together with pre-stained protein 
marker (Bio-Rad). Gels were run in SDS-Running Buffer [1.5%(w/v) Tris, 7.2% glycine, 
0.5%(w/v) SDS] at 80V until the dye front reached the stacking gel and at 120V 
thereafter. After the run was complete, gels were either transferred to a membrane 
(see section 2.8.6) or stained with Coomassie or silver. Gels were Coomassie-stained 
using the SimplyBlue SafeStain (Invitrogen) according to the manufacturer’s 
protocol. Silver staining was performed using the SilverQuest silver staining kit 
(Invitrogen) according to the manufacturer’s instructions.  
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2.8.6. Western blot 
Proteins separated by SDS-PAGE were transferred to a polyvinylidene fluoride (PVDF) 
membrane (Hybond-P, GE healthcare) using a transblot semi-dry transfer cell system 
(Bio-Rad). The membrane was incubated in methanol for 1min and rinsed thoroughly 
in water to remove methanol traces. Whatman filter papers, the gel and the 
membrane were then soaked in 1x transfer buffer (48mM Tris, 39mM glycine, 
0.037% (w/v) SDS and 20% (v/v) methanol). Proteins were then transferred onto the 
membrane for 1h at approximately 2mA/cm2 (or 20V maximum). After transfer, the 
membrane was blocked in TBS-T (100mM Tris pH7.5, 150mM NaCl, 0.5% Tween) 
with 5% skimmed powder milk (Marvel) for 1h at room temperature. The primary 
antibody, diluted in blocking solution, was incubated for either 2h at room 
temperature or at 4ºC overnight on a shaker. The blot was washed 3 times in 
blocking solution for 10min each and then incubated with an appropriate HRP-
Conjugated secondary antibody (diluted 1:2000 in blocking solution, GE healthcare) 
for 1h at RT on a shaker. The membrane was washed 3 times for 10min in TBS-T, 
once in TBS and the secondary antibody was detected using an enhanced 
chemiluminescence (ECL) kit (GE healthcare) following the manufacturer’s 
instructions. The membrane was exposed to X-Omat AR film (Kodak) for 
visualisation. When using the Pcl2 antibody, this was diluted in CanGetSignal solution 
(Toyobo, Japan) rather than blocking buffer, to improve detection, according to the 
manufacturer’s protocol.  
 
2.9. FLAG-tagged protein purification and analysis 
2.9.1. Nuclear extracts 
PGK PCL2-FLAG ES cell lines and PGK12.1 ES cells were expanded in 20 14cm dishes 
each. When confluent, cells were washed once with cold PBS, scraped off the plates, 
collected in 50 ml falcon tubes and washed with ice cold PBS containing protease 
inhibitors. The cell suspension was then spun for 5min at 1,500 rpm at 4ºC. PBS was 
pipetted off until 2 pellet volumes were left and the pellet was then transferred to a 
15ml falcon tube. Suspension was spun again for 5min at 1,500 rpm at 4ºC and the 
supernatant was carefully removed. The pellet was gently resuspended in 5 pellet 
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volumes of buffer A (10mM Hepes pH7.6, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT and 
protease inhibitors) and left incubating for 10min on ice. After this, the cell 
suspension was spun at 3,000rpm for 10min at 4ºC and the supernatant discarded. 
The pellet was resuspended in 2 pellet volumes of buffer A and the cell suspension 
was homogenized using an ice-cold Dounce homogenizer (Sigma) and 10 strokes 
with pestle A (loose) were applied. The suspension was transferred into a new 15ml 
falcon tube and spun at 3,000 rpm for 10min at 4ºC. Supernatant, containing 
cytoplasmic proteins, was collected. The pellet was resuspended in 1.5 pellet 
volumes of buffer C (20mM Hepes pH7.6, 25% glycerol, 420mM NaCl, 1.5mM MgCl2, 
0.2mM EDTA, 0.5mM DTT and protease inhibitors) and transferred back into a 
Dounce Homogenizer and 10 strokes with pestle B (tight) were applied. This 
suspension was transferred into a clean 15ml falcon and incubated on a rotating 
wheel for 30min at 4ºC. After this incubation, the suspension was transferred to 
eppendorf tubes and spun for 15min at 13,000rpm at 4ºC to remove insoluble 
material. The supernatant was collected carefully and dialysed in 2 x 2L of buffer D 
(20mM Hepes pH7.6, 20% glycerol, 100mM KCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM 
DTT, 0.2mM PMSF) for 4h at 0-4ºC. The dialysed extracts were transferred to 
eppendorf tubes and spin for 15min at 13,000rpm at 4ºC to eliminate any 
precipitates. At this point, nuclear extracts were snap-frozen in liquid nitrogen. 
 
2.9.2. Immunoprecipitation of FLAG-tagged proteins 
The entire purification procedure (including washes and elution) was carried out in a 
cold room. For each IP, 100µl of anti-FLAG M2 agarose beads (Sigma) were added to 
siliconized microtubes (Alphalaboratories). Beads were washed 4 times with C-100 
buffer (20mM Hepes pH7.6, 10% glycerol, 100mM KCl, 1.5mM MgCl2, 0.2mM EDTA, 
0.02% NP40, 0.5mM DTT and protease inhibitors (Roche)). Nuclear extracts were 
thawed quickly and spun for 10min at 13,000rpm to remove any remaining 
precipitates. The extract was then added to the washed beads, together with 
protease inhibitors and Benzonase (150U/ml, Novagen). Beads were incubated with 
the nuclear extracts for 3h on a rotating wheel, in order to pull down protein 
complexes. The suspension was then spun for 2min at 1,000rpm and the 
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supernatant collected. This constituted the flow-through fraction. The beads were 
washed with 1ml C-100 buffer 4 times for 5min and 10min for the final wash, 
followed by centrifugation at 3,000rpm for 1min. Proteins were eluted from the 
beads with a 0.2mg/ml FLAG tripeptide solution in C-100 buffer. 4 elutions were 
carried out by adding 60-90µl of FLAG tripeptide solution to the beads and 
incubating for 15min per elution. Finally, beads were resuspended in 2x Laemmli 
buffer to assess elution efficiency. For each sample, input nuclear extract, flow-
through fraction, the 4 elutions and bead fraction were loaded onto two 10% SDS-
PAA gels, for silver staining and western blotting. Elutions 1 and 2, containing the 
majority of the FLAG-tagged protein, were used for mass spectrometry analysis, 
chromatography and western blot to check for proteins interacting with the FLAG-
tagged protein.  
 
2.9.3. Mass spectrometry 
Elutions 1 and 2, containing the majority of the FLAG-tagged protein, were 
concentrated using 25% TCA supplemented with 0.1% deoxycholate (DOC), 
combined and loaded onto a 10% SDS-PAA gel. The gel was subsequently stained 
with Colloidal Coomassie (Invitrogen) according to the manufacturer’s instructions. 
Gel lanes were cut and subjected to in-gel digestion with trypsin (Promega), as 
described previously (van den Berg et al., 2008). Nanoflow liquid chromatography-
tandem mass spectrometry (Nano-LC-MS/MS) was performed on an 1100 series 
capillary LC system (Agilent Technologies) coupled to an LTQ-Orbitrap mass 
spectrometer (Thermo), as described previously (van den Berg et al., 2008). A 
database search to assign proteins to the found peptide fragmentation spectra was 
performed using MASCOT, as described previously (van den Berg et al., 2008).  
 
2.9.4. Size exclusion chromatography 
A Superose 6 SMART gel filtration column (GE healthcare) was pre-calibrated with 
gel filtration standards thyroglobin (669kDa), g-globulin (158kDa), ovalbumine 
(44kDa), myoglobulin (17kDa) and vitamin B12 (1.35kDa) (Bio-Rad Laboratories). 
Purified FLAG-tagged Pcl2 and associated proteins, obtained from a single elution of 
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the IP of 1.5ml of PGK PCL2-FLAG nuclear extract, were loaded onto the column pre-
equilibrated with C-100 buffer. Fractions (26µl) were collected at a flow rate of 40 
µl/min. 6µl of each fraction was separated on a 10% SDS-PAA gel and proteins of 
interest were detected by western-blot using the appropriate antibodies.  
 
2.10. Cloning and DNA Constructs 
2.10.1. Engineering of protein expression 
The mouse Pcl2 open reading frame (ORF) was amplified from ES cells by RT-PCR 
using the following primers 5’-GGATCCACCATGAGAGACTCTACAGGAGCA-3’ and 5’-
GGTACCacctccGGATGCAGTCGCTCCTTCCCA-3’, which introduce flanking restriction 
sites respectively for BamHI and KpnI (underlined) for cloning in pCBA-2xFLAG vector 
(a gift from Dr. Raymond Poot, Rotterdam, Netherlands). Alternatively, the 
subsequent primers were used, 5’-GGATCCACCATGAGAGACTCTACAGGAGCA-3’ and 
5’- CAATTG
2.10.2. Short hairpin RNA constructs 
GCacctccaccGGATGCAGTCGCTCCTTCCCA-3’ which introduce restriction 
sites for BamHI and MfeI, for cloning in the pGM-cTAP vector (a gift from Dr. Gordon 
Peters, Cancer Research UK, London, UK). The PCR products were digested, 
dephosphorylated and then ligated overnight at 4°C in the corresponding vector, 
using T4 DNA ligase (Promega). Ligations were transformed in competent XL2-blue 
cells (Stratagene) according to the manufacturer’s instructions. Transformed cells 
were plated onto Luria Broth (LB) agar supplemented with 50µg/µl of ampicillin and 
incubated overnight at 37°C. Individual colonies were picked and grown overnight at 
37°C with agitation into LB broth with 50µg/µl of ampicillin. DNA was extracted from 
the cultures using the Qiaprep Spin Miniprep kit (Qiagen) according to 
manufacturer’s instructions. All constructs were verified by sequencing (MRC Clinical 
Sciences Centre sequencing facility). 
        
2.10.2.1. Pcl2 knockdown 
To knockdown endogenous expression of the Pcl2 gene in ES cells, small interfering 
RNA (siRNA) sequences targeting the Pcl2 transcript were designed using the on-line 
software from the Whitehead Institute (http://jura.wi.mit.edu/bioc/ 
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siRNAext/home.php). The oligonucleotide sequences obtained and selected were as 
follows: 
TP4- GAGCACTCCAGACTCAGAA 
TP8- GTCATGAAGCAGACATTAC 
MC1- GAATCCTACGTTGGATTTA 
MC2- GAGGGTCAAGATGTCTTAG 
MC3- GGACCAAATGCCAAAGCAT 
MC4- GGTCGCCTTCCACGAAGAG 
 
A control siRNA, with no transcript target, was included (GCGCGCTTTGTAGGATTCG) 
in the study.  
 
ShRNA constructs TP4, TP8 and control were obtained from Tanja Preissner. For the 
remaining four siRNAs, four sets of oligonucleotides (see Table A6 in appendix) were 
designed in order to be cloned in a vector for stable production of short hairpin RNA 
after integration of the construct in the genome. Oligonucleotides were designed in 
antisense direction and containing the desired restriction sites used for cloning as 
overhangs. The synthetic oligonucleotides were resuspended in H2O to a final 
concentration of 300 µM. Phosphorylation and annealing was achieved by treating 
2.5µl of the sense with the matching antisense oligonucleotide with T4 
polynucleotide kinase (PNK, Promega) for 30min at 37ºC. The reaction was then 
diluted with 180µl of Buffer A (10mM Tris pH7.5/50mM NaCl), incubated at 90ºC for 
5min and allowed to cool slowly to room temperature for primer annealling. This 
produced two sets of annealed oligonucleotides per siRNA, that were ligated in a 
one-step ligation to each other and in the pSuper.neo/gfp vector (OligoEngine; 
previously digested with BglII/HindIII and dephosphorylated) overnight using T4 DNA 
ligase at 4ºC. Ligations were transformed in competent XL2-blue cells (Stratagene). 
Bacterial clones were then picked, grown and sequenced for analysis (MRC Clinical 
Sciences Centre sequencing facility). 
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2.10.2.2. Oct4 and Nanog knockdown 
ShRNA constructs for knockdown of Oct4 and Nanog transcription factors were 
kindly provided by Filipe Pereira, Lymphocyte Development group, MRC Clinical 
Sciences Centre, London. 
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Chapter 3. Regulation of PRC2 in pluripotent ES 
cells 
 
3.1. Introduction 
In the ICM of early blastocyst stage embryos, PRC2 proteins are expressed at a 
relatively high level when compared to differentiated cells of the trophectoderm 
lineage (Mak et al., 2004; Silva et al., 2003) (Figure 3.1). This observation led to the 
hypothesis that PRC2 has a role in determining pluripotency. Consistent with this 
idea, high levels of PRC2 and the associated epigenetic mark H3K27me3 are also 
seen in developing primordial germ cells which give rise to pluripotent mature germ 
cells (Erhardt et al., 2003). Further to this, in ES cells PRC2 levels and associated 
H3K27me3 are also found to be elevated when compared with their differentiated 
derivatives (Kuzmichev et al., 2005; Silva et al., 2003). Pluripotent cells are thought 
to have a relatively “open” chromatin organisation that would allow a specific gene 
expression program to be promptly switched on. Therefore it seemed paradoxical 
that PRC2 proteins, which are involved in establishing and maintaining repressed 
chromatin states, are expressed at high levels in pluripotent cells. 
 
 
 
Figure 3.1. ICM cells show high levels of Eed and H3K27me3. Immunostaining of a 4.5dpc blastocyst 
stage embryo, illustrating high expression of the PcG protein Eed and enrichment of H3K27me3 in 
cells of the ICM, relative to the primitive endoderm (PE) and the trophectoderm (TE) (from (Mak et 
al., 2004)). The images are a single optical section through an embryo.  
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3.1.1. Role of PcG in pluripotency 
Several studies have resulted in a more comprehensive understanding of the role of 
PcG proteins in pluripotency. In 2006, several genome-wide studies identified the 
binding sites of PcG components in human (Bracken et al., 2006; Lee et al., 2006), 
mouse (Boyer et al., 2006b) and Drosophila melanogaster (Negre et al., 2006; 
Schwartz et al., 2006; Tolhuis et al., 2006). Interestingly, collective analysis of the 
data revealed that PcG targets included not only Hox genes, the classical PcG targets, 
but also a large number of transcriptional regulators that are silenced in ES cells and 
become derepressed upon lineage commitment. ES cells lacking key PcG members 
showed mis-expression of a number of these target genes. The mis-expression of 
these target genes affected not only the stability of pluripotent cells but also certain 
aspects of ES cell differentiation. This can be illustrated by the observation that Eed 
deficient ES cells are more prone to spontaneous differentiation, possibly as a 
consequence of aberrant over-expression of several lineage specific transcription 
factors (Azuara et al., 2006; Boyer et al., 2005; Boyer et al., 2006b). Additionally, it 
was shown that ES cells deficient for Suz12 show a failure in efficiently silencing ES 
specific transcription factors upon induction of differentiation (Pasini et al., 2007).  
 
Based on these findings it has been suggested that PcG proteins function in 
pluripotency by restraining lineage specific regulator genes in a poised state 
(Jorgensen et al., 2006). Consistent with this, it has been found that PcG targets in ES 
cells are enriched for histone modifications associated with gene activity, such as 
H3K4me3, in addition to PcG mediated H3K27me3 (Azuara et al., 2006; Bernstein et 
al., 2006). These results are discussed in greater detail in Chapter 4. 
 
3.1.2. Regulation of PRC2 proteins in ES cells 
Given the role of PRC2 proteins in regulating pluripotency it is important to 
understand the basis for high levels of PRC2 activity in pluripotent cells. One can 
speculate that the regulation of the PcG components is closely associated with the 
transcriptional circuitry of ES cells, notably the transcription factors Oct4, Nanog and 
Sox2 (Boyer et al., 2005; Boyer et al., 2006a). A recent study using chromatin 
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immunoprecipitation paired-end ditags was able to map the binding sites of Oct4 
and Nanog (Loh et al., 2006). PRC2 genes Ezh2, Suz12, Eed and the non-canonical 
PcG member Pcl2 (see Chapter 5 and 6) were shown to be associated with Oct4 
and/or Nanog. The binding sites for these key pluripotency factors were found to be 
located upstream of the transcription start site for the core PRC2 genes and, in the 
case of Pcl2, both Oct4 and Nanog were found to bind the Pcl2 gene in an intronic 
region, downstream of the transcription start site. 
  
In this chapter, I will explore how PcG proteins which form the PRC2 complex are 
regulated in ES cells and will attempt to shed light on possible mechanisms involved 
in maintaining the high levels of PRC2 expression in ES cells by using different cellular 
systems. 
 
3.2. Results 
3.2.1. Steady state RNA levels of genes encoding PRC2 factors in mouse 
ES cells and fibroblasts 
Immunofluorescence analysis showed that PRC2 proteins are highly expressed in ES 
cells compared to differentiated cells (Silva et al., 2003). To determine if this is 
reflected at the transcript level, gene expression analyses were performed in 
fibroblasts (MP cell line) and ES cells (PGK12.1 cell line). The expression of several 
housekeeping genes [Glyceraldehyde-3-phosphate dehydrogenase (Gapdh), 
Hydroxymethylbilane synthase (Hmbs), Isocitrate dehydrogenase (Idh) and β-actin] 
and PRC2 genes (Suz12, Eed, Ezh2) were compared between the two cells lines. 
Additionally, the expression of Polycomblike 2 (Pcl2), a factor found in a sub-fraction 
of PRC2 complexes (see Chapter 5 and 6), was also assessed (Figure 3.2). The data 
confirm that genes encoding the PRC2 core components Eed and Suz12 are 
expressed at higher levels in ES cells compared to MP cells, as is the Pcl2 gene. 
However, the gene encoding the core PRC2 protein Ezh2 showed only a moderate 
elevation in expression in ES compared to MP cells (Figure 3.2).  
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Figure 3.2. PRC2 genes are more highly expressed in ES cells than in fibroblast cells. Expression 
levels of four housekeeping genes (Gapdh, Hmbs, Idh and B-actin) and the core PRC2 genes as well as 
Pcl2 were analysed by qRT-PCR in PGK12.1 ES cells and MP fibroblast cells. RT reactions were 
performed with the same quantity of total RNAs for both cell lines, determined by 
spectrophotometry. For each gene analysed, the expression level is set at 1 for the fibroblast cell line. 
Expression levels in ES cells are represented relative to MP cells. Graphs show the mean +/- standard 
deviation of the mean for each gene (n=3). 
 
 
3.2.2. PRC2 RNA levels decline during ES cell differentiation 
The regulation of PRC2 component expression was investigated at both the mRNA 
and the protein levels throughout ES cell differentiation. PGK12.1 ES cells were 
induced to differentiate by culture in medium without leukaemia inhibitory factor 
(LIF) and by transferring cells to non-adherent tissue culture plastic to promote the 
formation of embryoid bodies. Cells were collected every 24 hours and total RNA 
and protein were extracted. The analysis of gene expression shows that Oct4, one of 
the key pluripotency transcription factors, shows an increase of expression at around 
day 1-3 of differentiation. The level of Oct4 mRNA decreases steadily thereafter 
(Figure 3.3a). Similarly, mRNA for all of the PRC2 genes analysed shows a slight 
increase during the first 48-72 hours of differentiation, followed by a reduction at 
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later stages of differentiation (Figure 3.3a). Ezh2 shows a relatively small decrease 
throughout the differentiation process.  
 
The dynamics of PRC2 protein levels showed similar trends (note that Pcl2 was not 
included in this analysis). The proteins were detected at high levels in 
undifferentiated cells and their levels then reduced during differentiation (Figure 
3.3b). Overall the protein levels mirror the RNA levels, suggesting that translational 
control is unlikely to be a significant factor in PRC2 regulation.  
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Figure 3.3. PRC2 gene expression is down-regulated during ES cell differentiation. (a) Expression 
levels of Oct4 and PRC2 component genes were analysed by qRT-PCR from day 1 to day 10 of 
differentiation of the ES cell line PGK12.1 (1 to 10). 0 corresponds to undifferentiated ES cells. For 
each gene analysed, expression levels were normalised to the housekeeping gene Idh. Graphs show 
the mean +/- standard deviation of the mean for each gene at each day of differentiation (n=3). (b) 
Protein levels for Oct4, PRC2 core components and LaminB were analysed from day 1 to day 10 of 
PGK12.1 ES cell differentiation (1 to 10). ES corresponds to undifferentiated ES cells. Nuclear extracts 
were prepared, separated by SDS-PAGE and analysed by western-blotting using antibodies raised 
against Oct4, Suz12, Eed, Ezh2 and LaminB. LaminB is used as a loading control to show equal loading 
of proteins. Molecular weight markers are indicated (kDa). 
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3.2.3. PRC2 components are transcriptionally regulated 
The levels of mRNA for PRC2 proteins in ES cells could be regulated at the 
transcriptional level or by post-transcriptional regulation of mRNA stability. To test 
this hypothesis, the half-life of PRC2 mRNA was measured by treating cells with 5 
µg/ml actinomycin D for a period of 12 hours. Actinomycin D acts by blocking 
transcription, preventing formation of new mRNA. This allows discrimination 
between transcriptional regulation, in which differences observed are due only to a 
higher promoter activity and transcription rate, and post-transcriptional regulation in 
which the stability of mRNA might be affected. Analysis of the data acquired shows 
that for several house keeping genes the mRNA half-life is around 6 to 10 hours (the 
period needed for the initial amount of mRNA to be reduced to 50%) (Figure 3.4). 
This is consistent with previous studies (Leclerc et al., 2002; Raghavan et al., 2002; 
Ross, 1995). The analysis of PRC2 mRNA half-life reveals that PRC2 mRNAs have a 
relatively fast turn-over, with the half-life ranging from 2 to 4 hours (Figure 3.4). 
Importantly, the analysis shows that the stability of the different mRNA analysed is 
similar in ES cells and fibroblasts. These data strongly suggest that mRNA for PRC2 
proteins are regulated at the transcriptional and not the post-transcriptional level.  
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Figure 3.4. PRC2 genes are transcriptionally regulated. Expression levels of 4 housekeeping genes 
(Gapdh, Hmbs, Idh and B-actin), core PRC2 genes and Pcl2 were analysed by qRT-PCR at various time 
points (0, 1, 2, 4, 6, 8, 10 and 12h) during actinomycin D treatment of PGK12.1 ES cells and MP 
fibroblast cells. RT reactions were performed starting with the same quantity of total RNAs at each 
time point and for both cell lines, accurately measured by spectrophotometry. Expression levels are 
represented at each time point analysed relative to untreated cells. Graphs show the mean +/- 
standard deviation of the mean for each gene at each time point (n=4). 
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3.2.4. PRC2 regulation is linked to expression of key pluripotency 
transcription factors 
The transcription factors Oct4, Sox2 and Nanog have been widely described as being 
involved in maintenance of ES cell pluripotency (Smith, 2005), and are interesting 
candidates as factors regulating PRC2 proteins. To test this hypothesis, transgenic 
cell lines which allow the manipulation of the levels of these factors were used. Two 
types of systems were used: differentiated cell models that express, out of its 
cellular context, one of the transcription factors mentioned above and 
undifferentiated cell models where the down-regulation or complete depletion of 
one of these factors is inducible.  
 
3.2.4.1. Induced Oct4 and Nanog expression in differentiated cells 
Using mouse B lymphocytes expressing Oct4-GFP constitutively (OGB, (Palmieri et 
al., 1994)), the effect of Oct4 over-expression on levels of RNA for PRC2 proteins was 
analysed and compared to control B lymphocytes. In the OGB cells, although Oct4 is 
highly expressed, no obvious effect is seen on the expression of the different PRC2 
genes analysed when compared to the levels of the same genes in control B cells 
(Figure 3.5a). Similarly, in NMLF fibroblasts, where Nanog expression is induced by 
the addition of doxycycline (DOX) (Claire Senner, unpublished data), increased 
expression of Nanog did not result in an increase in the expression levels of any of 
the PRC2 genes (Figure 3.5b). These data suggest that the over-expression of 
individual transcription factors in a differentiated cell line is not sufficient to induce 
the over-expression of PRC2 genes. This could suggest that these specific factors are 
unable to function correctly outside of their normal cellular context. The 
transcription factors Oct4 and Nanog might not be able to act without the presence 
of other transcription factors, in a synergistic fashion. Alternatively, it could mean 
that these factors are not involved directly in regulating PRC2 genes.  
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Figure 3.5. Induced Oct4 and Nanog expression in differentiated cells does not result in up-
regulation of PRC2 genes. (a) Expression levels of Oct4, core PRC2 genes and Pcl2 were analysed by 
qRT-PCR in mouse B lymphocytes constitutively expressing Oct4-GFP (OGB cells) and in control B cells. 
Expression levels were normalised to the housekeeping gene Idh. Graphs show the mean +/- standard 
deviation of the mean for each gene (n=3). (b) Expression levels of Nanog and the PRC2 genes Suz12, 
Eed, Ezh2 and Pcl2 were analysed by qRT-PCR in NMLF fibroblast cells following induction of Nanog 
expression with doxycycline for 0, 6, 12, 24, 48, 72 and 96h. Expression levels were normalised at 
each time point to the housekeeping gene Idh. Graphs show the mean +/- standard deviation of the 
mean for each gene at each time point analysed (n=3).  
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3.2.4.2. Reduction of Oct4, Nanog and Sox2 levels in ES cells 
To study the effect of removing the candidate transcription factors from ES cells, 
various transgenic cell systems were used. The ZHBTc4 mouse ES cell line carries a 
tetracycline-regulated Oct4 transgene replacing endogenous Oct4 alleles (Niwa et 
al., 2000). Treating cells with DOX for a prolonged period of time leads to depletion 
of Oct4 mRNA levels within 6 hours of treatment (Figure 3.6). The control 
housekeeping gene Idh did not show any significant change until approximately 24 
hours post-induction, but showed an increase thereafter. All of the PRC2 genes 
analysed showed a slight increase in mRNA levels during the first 3 hours of 
induction while the levels of Oct4 mRNA were reduced. This was followed by a 
significant decrease thereafter (Figure 3.6). After 12 hours of DOX treatment, most 
of the PRC2 genes showed a clear reduction at the mRNA level compared to the 
levels of PRC2 mRNAs in untreated cells. Interestingly, Ezh2 did not seem to be 
largely affected by the reduction in levels of Oct4.  
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Figure 3.6. Reduced expression of Oct4 in ES cells results in a decrease of PRC2 gene expression. 
Expression levels of Oct4, the housekeeping gene Idh and PRC2 genes Suz12, Eed, Ezh2 and Pcl2 were 
analysed by qRT-PCR in ZHBTc4 cells following depletion of Oct4 expression by doxycycline treatment 
for 0, 1, 3, 6, 12, 24, 48, 72 and 96h. Expression levels were normalised at each time point to the 
housekeeping gene Gapdh. Graphs show the mean +/- standard deviation of the mean for each gene 
at each time point analysed (n=3).  
 
 
In order to confirm the results obtained, an independent system was used to 
knockdown expression of Oct4 in PGK12.1 ES cells, using short hairpin RNA 
constructs. PGK12.1 ES cells were transfected with a pSuper.gfp/neo vector 
containing a shRNA construct targeting Oct4 (a gift from Filipe Pereira). The effects 
of knocking down Nanog were also studied using two different shRNA constructs 
targeting Nanog mRNA (a gift from Filipe Pereira). A vector containing a shRNA with 
no known target was used as a control. 24 hours post-transfection, GFP positive cells 
(i.e. expressing the shRNA constructs) were sorted by fluorescence activated cell 
sorting (FACS) and kept in culture for a further 24 hours to increase the number of 
transfected cells. 48 hours post transfection, cells were collected and total RNA was 
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extracted for gene expression analysis. Both Oct4 and Nanog shRNAs reduced the 
expression levels of Oct4 and Nanog, respectively, indicating the efficient knockdown 
of these genes (Figure 3.7). Additionally, knockdown of either factor led to reduction 
in expression levels of the other. This is consistent with data showing that Nanog is 
regulated by Oct4 (Kuroda et al., 2005) and vice versa (Loh et al., 2006). The 
knockdown of Oct4 led to a dramatic reduction in the expression levels of the PRC2 
members, similar to what was seen in the DOX inducible ES cell line. Again, the levels 
of Ezh2 mRNA were not dramatically changed as a consequence of Oct4 depletion, 
confirming the previous results obtained. Contrasting with these results, Nanog 
knockdown did not have an impact on the expression of PRC2 genes, despite the fact 
that the global levels of Oct4 mRNA are reduced. One can speculate that the levels of 
Oct4 are still sufficient to maintain its normal function in ES cells and assure normal 
regulation of PRC2 genes.  
 
 
Figure 3.7. Knockdown of Oct4 using shRNA in ES cells induces down-regulation of PRC2 gene 
expression. PGK12.1 ES cells were transfected with constructs containing various shRNA (control, 
Oct4 and Nanog). Expression levels were analysed 48h post-transfection by qRT-PCR for two 
housekeeping genes (Hmbs and B2M), various stem cells markers (Oct4, Nanog, Gata6 and Cdx2) and 
the PRC2 genes Suz12, Eed, Ezh2 and Pcl2. Expression levels for each gene and shRNA were 
normalised to the housekeeping gene Idh and are represented as a relative measure of the expression 
in ES cells transfected with the control shRNA. For Nanog, expression is presented as the mean of the 
data obtained for the two shRNA used and standard deviation of the mean. 
 
 
As expected, the depletion of Oct4 led to a large increase in the mRNA levels of the 
trophectoderm marker Cdx2 and, to some extent, of the primitive endoderm marker 
Gata6. Knocking down Nanog led to an increase in the levels of Gata6 mRNA. These 
observations are consistent with previously published data showing that after 
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depletion of Oct4 or Nanog, ES cells promptly differentiate and acquire a TS or XEN 
cell identity, respectively (Mitsui et al., 2003; Niwa et al., 2000; Niwa et al., 2005).  
 
Sox2 is known to act synergistically with Oct4 in vitro to activate Oct-Sox enhancers, 
which are involved in regulating the expression of different pluripotent stem cell-
specific genes, including Nanog, Oct4 and Sox2 itself (Boiani and Scholer, 2005). Sox2 
is required to maintain cells in a pluripotent state by maintaining adequate levels of 
expression of Oct4 in ES cells (Masui et al., 2007). 2TS22c is a mouse ES cell line that 
carries a tetracycline-regulated Sox2 transgene replacing the endogenous Sox2 
alleles (Masui et al., 2007). Similarly to the ZHBTc4 ES cell line, culturing of the 
2TS22c cell line in the presence of DOX leads to the depletion of the mRNA levels of 
the Sox2 transgene (Figure 3.8). This facilitates analysis of the effects of Sox2 
reduction on the expression of PRC2 genes. In accordance with published results 
(Masui et al., 2007), a reduction in the levels of Sox2 resulted in a reduction in the 
mRNA levels of Oct4 over time (Figure 3.8). Analysis of PRC2 gene expression 
showed a reduction in the mRNA levels of all PRC2 genes analysed (Figure 3.8). The 
down-regulation of expression of PRC2 genes as a consequence of either Oct4 or 
Sox2 depletion (but not Nanog) suggests that Oct4-Sox2 transcription factors act in a 
positive way to regulate the expression levels of PRC2 genes in ES cells.  
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Figure 3.8. Reduced expression of Sox2 in ES cells results in a significant decrease of PRC2 genes 
expression. Expression levels of Sox2, Oct4, Cdx2 and PRC2 genes Suz12, Eed, Ezh2 and Pcl2 were 
analysed by qRT-PCR in 2TS22c cells following depletion of Sox2 expression by doxycycline treatment 
for 0, 6, 12, 24, 48, 72 and 96h. Expression levels were normalised at each time point to the 
housekeeping gene Hmbs. Graphs show the mean +/- standard deviation of the mean for each gene 
at each time point analysed (n=3). 
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3.3. Discussion 
In this chapter, I have explored the levels at which PRC2 activity may be regulated in 
ES cells. For this, the mRNA levels, mRNA stability and protein levels were 
determined for PRC2 components in ES cells, during ES cell differentiation and in 
fibroblasts. The data revealed that Eed, Suz12 and Pcl2 are all found to be regulated 
at the transcriptional level in ES cells. It is important to note that these results do not 
exclude the possible contribution of other post-transcriptional or post-translational 
regulation mechanisms. In fact, a series of studies highlight the fact that PRC2 
components can be targeted by different post-translational modifications. 
Specifically, Ezh2 and Eed were both shown to be phosphorylated and this influences 
either the efficiency of the Ezh2 HMTase activity or the ability of Eed to dimerise, 
respectively (Cha et al., 2005; Tie et al., 2005). Recently, it has become evident that 
Suz12 and Ezh2 are also sumoylated in vitro and in vivo which might constitute a new 
mechanism for PRC2 regulation (Riising et al., 2008). 
 
Ezh2 is generally not markedly up-regulated in undifferentiated cells when compared 
to their differentiated derivatives. A possible reason for this is that Ezh2 has been 
shown to have functions besides the methylation of H3K27. Ezh2 was shown to exist 
in a cytosolic form and is involved in the control of receptor-induced actin 
polymerization and proliferation in a methylation-dependant manner (Su et al., 
2005). 
 
A large set of pluripotency factors, such as Oct4, Nanog, Sox2, Klf4, Myc, have been 
described as being important for the maintenance of ES cell proliferation and self-
renewal. Co-expression of a group of these genes can reprogram terminally 
differentiated fibroblasts into pluripotent ES-like cells that contribute to the germline 
(Okita et al., 2007; Takahashi and Yamanaka, 2006; Wernig et al., 2007). Based on 
the analysis of ChIP data for Oct4 and Nanog (Loh et al., 2006), it was hypothesised 
that these factors may be involved in the regulation of PRC2 genes. To test this 
hypothesis, different transgenic cell systems that allow the regulation of several 
pluripotency key factors, namely Oct4, Nanog and Sox2, were used. The results 
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indicate that Oct4 and Sox2 have a role in the up-regulation of PRC2 genes in ES cells 
with the exception of Ezh2. The expression of Oct4 or Nanog in terminally 
differentiated cell lines has no visible effect on gene expression of PRC2 genes, 
suggesting that a combination of factors and/or a correct cellular context is essential 
for these effects to be seen.  
 
The down-regulation of PRC2 gene expression levels upon induced silencing of either 
Oct4 or Sox2 could have different explanations. One explanation would involve a 
direct effect of Oct4/Sox2 binding at regulatory elements present in PRC2 genes. 
Alternatively, it could be an indirect effect, a secondary consequence of 
differentiation, or the effect of factors which act downstream of Oct4/Sox2 down-
regulation. In the study by Loh et al., ChIP-PET data have shown that Oct4 and Nanog 
are associated with all PRC2 core genes and Pcl2 (Loh et al., 2006). Interestingly, the 
regions found to be bound by Oct4 and/or Nanog are not associated with a 
particular gene feature. For example, for Suz12, Ezh2 and Eed, these key factors are 
found upstream of the genes at a distance which ranges from 12 Kb to 80 Kb. In 
contrast, Oct4 and Nanog are found on the Pcl2 gene in an intronic region located 
around 11 Kb downstream of the transcription start site. To distinguish between 
direct or indirect regulation of PRC2 by key pluripotency factors, key regulatory 
elements need to be mapped and cloned and their activity should be tested in 
reporter gene assays.  
 
Two recent papers have provided evidence for a direct effect of the regulatory 
transcriptional network present in pluripotent cells on the regulation of PRC2 genes. 
These papers confirmed that key pluripotency transcription factors are located close 
to different PcG genes and that manipulating the expression of Oct4 and Sox2 has a 
direct effect on the transcriptional control of different PcG genes (Sharov et al., 
2008; Ura et al., 2008). Additionally, Ura and colleagues have shown that Oct4 and 
Stat3, a transcription factor essential for self-renewal of mouse ES cells activated as a 
consequence of LIF stimulation of ES cells, directly bind the promoter of Eed. The 
binding of both these key pluripotency factors is a determinant for the high levels of 
Eed expression observed in mouse ES cells (Ura et al., 2008).  
100 
 
Interestingly, Lee and colleagues showed that the Jun amino-terminal kinase (JNK) 
pathway is directly involved in the down-regulation of PcG genes during 
regeneration of Drosophila imaginal discs, which can result in progenitor cells 
switching identities in a process known as trans-determination (Lee et al., 2005). In 
the imaginal discs, PcG proteins maintain cellular fates by controlling the expression 
patterns of homeotic genes and other developmental regulators. The absence of PcG 
proteins or their down-regulation by JNK might result in changes in cellular fate. This 
mechanism is evolutionarily conserved, and may be involved in regulating the 
plasticity of ES cells (Lee et al., 2005). This would certainly be an elegant mechanism 
to regulate PcG genes, by opposing the effect of transcription factors like Oct4 and 
Sox2, with transcription factors from the JNK pathway. 
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Chapter 4. Function of Polycomb repressive 
complexes in pluripotency and early embryo 
development 
 
4.1. Introduction 
Several recent reports have implicated PcG proteins as major determinants of 
pluripotency and lineage commitment in ES cells (Azuara et al., 2006; Boyer et al., 
2006b; Lee et al., 2006). These reports all share a similar view regarding the mode of 
action of PcG proteins, suggesting they function as a buffering mechanism, keeping 
ES cells in a poised state while, at the same time, preventing differentiation without 
the appropriate stimulus. Not surprisingly, PcG proteins have been shown to be 
associated with the regulatory region of several linage specific and developmental 
regulators and this is essential for regulating expression levels in ES cells (reviewed in 
(Spivakov and Fisher, 2007)). The PcG proteins, Eed and Suz12 were shown to be 
important for the maintenance of pluripotent ES cells (Faust et al., 1995; Pasini et al., 
2007) and, in the absence of these PcG components ES cells show a greater tendency 
to differentiate, which is linked to the deregulation of gene expression (Azuara et al., 
2006; Boyer et al., 2006b). 
 
4.1.1. A unique chromatin signature of PcG target genes in ES cells 
Genome-wide studies have defined the genomic regions bound by PcG proteins in 
mouse and human ES cells (Boyer et al., 2006b; Lee et al., 2006). These reports 
revealed that the repressive modification H3K27me3 and PRC2 components are 
present at a number of key developmental regulators. More recent studies have 
revealed that many of the PcG target genes unexpectedly show promoter 
enrichment for histone modifications associated with gene activity, specifically, 
H3K4me3 and H3 and H4 acetylation, in addition to PRC2 mediated H3K27me3 
(Azuara et al., 2006; Bernstein et al., 2006). The simultaneous presence of these 
opposing marks at particular regions within the genome has been termed bivalent 
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chromatin (Bernstein et al., 2006) and was initially suggested to be a signature mark 
of ES cell chromatin (Bernstein et al., 2007). Recent studies have shown that bivalent 
domains found in ES cells are resolved upon ES cell differentiation by selecting 
exclusively active or repressive histone marks and thus, promoting transcriptional 
activation or repression of the associated genes, respectively (Mikkelsen et al., 
2007). Interestingly, some of the bivalent domains found in ES cells were shown to 
be maintained in differentiated derivatives of ES cells, although at a lower level 
(Mikkelsen et al., 2007), contradicting the initial idea that bivalency would be a 
defining ES cell characteristic. Bivalent domains provide a mechanism to postpone 
either the activation or the repression of a different subset of genes of which 
developmental regulators are the major representatives (reviewed in (Pietersen and 
van Lohuizen, 2008).  
 
4.1.2. Mechanisms of regulation of gene expression by PcG complexes 
The importance of PcG proteins in regulating gene expression is well established, but 
the exact mechanisms by which this is accomplished are still largely unknown. PcG 
proteins could potentially create a scaffold of non-permissive chromatin which 
prevents transcriptional activity occurring at target loci. A second possible 
mechanism involves PcG proteins directly preventing the binding of particular 
transcription factors which are required for the expression of a specific gene. Given 
our recent understanding of histone modification activities of PRC1 and PRC2, the 
most likely mechanism is that PcG factors modify chromatin, directly or indirectly 
influencing RNA polymerase II transcriptional activity. 
  
Eukaryotic transcription is a highly coordinated cycle of events that includes the 
assembly of a pre-initiation complex and recruitment of RNA polymerase II (RNAPII) 
to the promoter, followed by initiation, elongation and termination. The regulation 
of transcription occurs at multiple levels, the most common being RNAPII 
recruitment to the promoters of target genes. Additionally, the regulation of RNAPII 
could involve mechanisms which occur after initiation and involve transcription 
elongation and RNA stability. In fact, RNAPII can initiate transcription but then 
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pauses after transcribing 25-50 bases of DNA (Saunders et al., 2006). Recent studies 
have shown that RNAPII is associated with the promoters of many transcriptionally 
silent genes, suggesting that mechanisms of pausing elongation or RNA stability 
might play a crucial role in regulation of gene expression (Guenther et al., 2007; 
Muse et al., 2007; Zeitlinger et al., 2007). Interestingly, paused RNA polymerases are 
often present at inducible genes which have specialized roles in development. 
 
In this chapter I will discuss two different studies I was involved in that relate to the 
mechanisms of PcG protein action. In the first study, ES cell lines lacking the core 
PRC2 component Eed were derived and characterised. The results confirmed 
previous data that PRC2 function is important for repression of bivalent genes and 
maintenance of pluripotency. The second study examines the role of PRC1 and H2A 
ubiquitinylation in ES cells, specifically in restraining poised RNA polymerase II at 
bivalent promoters.  
 
4.2. Results 
4.2.1. PRC2 is important for the maintenance of ES cell pluripotency 
In an effort to characterise the role of PRC2 in maintaining pluripotency and 
particularly to understand the role of PRC2 in early mouse development, cell lines 
deficient for PRC2 were derived. Three different types of stem/progenitor cells can 
be derived from the mouse blastocyst under defined conditions, embryonic stem 
(ES) cells, trophoblast stem (TS) cells and extraembryonic endoderm (XEN) cells 
(Ralston and Rossant, 2005) (Figure 4.1a). To study the role of PRC2 in the 
establishment of these lineages and in the maintenance of 
pluripotency/multipotency, cell lines were derived from blastocysts isolated from 
heterozygous crosses of mice carrying a null mutation in the Eed gene (eed3354SB), 
encoding the essential PRC2 protein Eed. The eed3354SB mutation is a point mutation 
that disrupts the structure of a WD40 domain, required for the interaction of Eed 
with Ezh2 (Denisenko et al., 1998). The phenotype of eed3354SB homozygotes, embryo 
lethality at around 8.5 dpc, is indistinguishable from complete deletion of the Eed 
locus (Faust et al., 1995; Shumacher et al., 1996). Loss of Eed function destabilises 
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the PRC2 complex and results in complete loss of H3K27me3 (Silva et al., 2003). 
Previous studies have demonstrated that Eed deficient ES cells can be derived 
(Morin-Kensicki et al., 2001; Williams et al., 2006), but these cells show reduced 
survival during long-term passaging.  
 
 
Figure 4.1. Eed -/- ES, XEN and TS cells derivation. (a) Schematic representation of an early blastocyst 
stage embryo (embryonic day 3.5dpc), illustrating the ICM (yellow), the trophectoderm (TE, blue) and 
the primitive endoderm (PE, green) lineages. TS, XEN and ES cells can be derived respectively from the 
TE, PE or ICM of a blastocyst, when cultured under defined conditions as indicated below the pictures. 
Characteristic images for each stem cell type after derivation are shown. (b) Sexing and Eed 
genotyping PCR were performed to determine the sex and genotype of the derived ES cell lines (ESL 1, 
3.2, 12, 21 and 26 are shown). DNA extracted from XY (129/1) and XX (PGK12.1) ES cells were used as 
controls. The sexing PCR assay, described in material and methods (section 2.2.), gives a single band 
for XX cell lines and a doublet for XY cells. The genotyping PCR, illustrated in Figure 4.1c, gives a 
doublet for heterozygote cell lines, solely the bottom band for wild type cells and the top band for 
homozygous mutant cell lines. Note that the shadow bottom band that can be observed for the Eed-/- 
cell lines comes from feeder cells. (c) Eed genomic sequence illustrating the genotyping strategy. 
EedMC1 and EedMC2 primers were designed around an AluI restriction site, abolished by the Eed 
lethal point mutation (CTG to CCG). PCR of the wild type (WT) allele gives a product of 295bp after 
AluI digest. PCR of the mutant (MUT) allele gives a product of 339bp, which can not be digested by 
AluI.  
 
 
Several rounds of derivation were undertaken to derive ES, TS and XEN cells. Using a 
PCR assay, the genotype of the derived cell lines was determined. A set of primers 
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amplifying a PCR fragment of 339bp comprising the region where the eed3354SB point 
mutation is found was used. This mutation abolishes an Alu1 restriction site, which 
can therefore be used to discriminate between the wild type and the mutant allele. 
This assay is an improvement on a previous assay designed for the detection of the 
mutation (Silva et al., 2003) as it allows for the identification of the alleles based 
solely on the size of the final bands obtained after digestion and not on the number 
of bands. A full summary of the cell lines obtained and their genotype is given in 
Table 4.1. Homozygous Eed-/- TS and XEN cell lines were not obtained, suggesting 
Eed may be required for establishment and/or maintenance of these cell types. 
However 3 independent Eed-/- ES lines were identified, as well as matched wild type 
and heterozygous control cell lines (Figure 4.1b). The newly derived ES cell lines were 
designated ESL. The Eed genotyping shows that ESL 1, 3.2 and 26 are mutant ES cells 
(Figure 4.1c), while ESL 12 is heterozygous (notice the approximate 1:1 ratio of both 
alleles) and ESL 21 is wild type. PCR analysis of the Ube1 gene which gives different 
sized products for the X and Y linked copies revealed that both ESL12 and 21 are XX 
ES cells, while the remaining cell lines including Eed mutant cell lines are XY. 
 
 
Table 4.1. List of stem cell lines derived and their respective genotypes. 
 
Although Eed mutant ES cells could be derived, they displayed unusual 
characteristics while maintained in culture. Specifically, Eed mutant cell lines had 
heterogeneous colony morphology. This was not observed with wild type or 
heterozygous cells. A small subset of colonies showed TS or XEN like morphology 
(Figure 4.2a). These observations suggest that Eed, although not needed during ES 
cell derivation, is in fact important for maintenance of ES cells in an undifferentiated 
state.  
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Figure 4.2. Eed -/- ES cells have a tendency to differentiate to extra-embryonic lineages and show 
inappropriate expression of some lineage specific markers. (a) Heterozygous and wild type cells 
show normal ES cell morphology, while ESL 1 (Eed-/-) shows heterogeneity, with some ES colonies 
resembling extra-embryonic lineages (pointed arrows). (b) RT-PCR analysis for a set of lineage specific 
markers (Oct4, Nanog, Fgf4, Cdx2, Hand1, EsrrB, Gata6, Foxa2, Sox7, Afp, T) and one housekeeping 
gene (Gapdh) was performed for ES, TS, XEN and fibroblast (Fib) cell lines and five derived ESL cell 
lines (ESL 1, 3.2, 12, 21 and 26). Outlined are Eed deficient ES cell lines ESL 1, 3.2 and 26. Positive (+) 
and negative (-) RT corresponds to reaction performed with or without reverse transcriptase. H2O, 
water control.  
 
 
The ability of Eed mutant ES cells to spontaneously differentiate has been described 
previously (Azuara et al., 2006; Boyer et al., 2006b) and recent work has reported 
that Eed mutant ES cells derepress a set of lineage specific and extraembryonic 
genes (Azuara et al., 2006; Boyer et al., 2006b; Jorgensen et al., 2006). In order to 
characterise the newly derived cell lines and to confirm these previous results, 
expression analysis was performed by reverse transcriptase PCR (RT-PCR) on RNA 
isolated from Eed deficient ES cells and various control cell lines. Several known 
markers of the epiblast lineage and the extra-embryonic trophectoderm and 
endoderm lineages, were used in this analysis.  
 
The ES cell markers Oct4, Nanog and Fgf4 were analysed. Oct4 and Nanog both 
encode transcription factors that are expressed in the inner cell mass/epiblast and 
are important for the establishment and maintenance of this lineage (Chambers et 
al., 2003; Mitsui et al., 2003; Palmieri et al., 1994). The signalling molecule Fgf4 is a 
known target of Oct4 and is essential for post implantation mouse development 
(Yuan et al., 1995). These 3 markers were all expressed in control ES cell lines as well 
as in all the ESL lines, confirming that these are bona fide ES cell lines (Figure 4.2b).  
 
The TS cell markers Cdx2, which encodes a transcription factor involved in the early 
stages of trophectoderm (TE) lineage specification (Niwa et al., 2005; Strumpf et al., 
2005), Hand1 and Esrrβ which are involved in later stages of TE cell differentiation 
(Luo et al., 1997; Scott et al., 2000) are expressed in the TS control cell line. Cdx2 
seems to be restricted to the TS control cell line as does Hand1, while Esrrβ was 
found to be expressed in both TS and ES cells. The recent analysis of Eed deficient ES 
cells by Azuara et al. and Jorgensen et al. revealed that both Cdx2 and Hand1 are 
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misexpressed (Azuara et al., 2006; Jorgensen et al., 2006). The ESL 1, 3.2 and 26 cell 
lines also show misexpression of Hand1, but not of Cdx2 (Figure 4.2b). The reasons 
for this are currently unknown.  
 
The XEN cell markers Gata6, a transcription factor involved in primitive endoderm 
(PE) commitment (Koutsourakis et al., 1999; Morrisey et al., 1998), Foxa2, a 
transcription factor that is expressed throughout all PE lineages (Dufort et al., 1998), 
Sox7, expressed in undifferentiated XEN cells (Kanai-Azuma et al., 2002; Kunath et 
al., 2005) and Afp, a marker of differentiated PE (Dziadek and Adamson, 1978; 
Kunath et al., 2005) were also analysed (Figure 4.2b). All of the markers tested were 
expressed in control XEN cell lines at their higher levels. In Eed deficient ES cell lines 
the levels of Gata6, Sox7, Foxa2 and Afp are similar to those observed in XEN control 
cell lines and significantly higher expression is detected when compared to wild type 
or heterozygous cells. This data is consistent with the results obtained for other Eed 
deficient cell lines (Jorgensen et al., 2006). Finally, a marker involved in epiblast 
differentiation, T/Brachyury, was tested (Wilson et al., 1995). We observed that 
none of the cell lines tested express this marker with the exception of the control ES 
cell line and one of the mutant ESL cell lines. This can be explained by the fact that in 
an ES cell population a proportion of cells spontaneously differentiate.  
 
These results confirm that PRC2 is indeed essential for the proper maintenance of ES 
cells and for early mouse development. Loss of Eed (and consequently all other PRC2 
components, as explained in Chapter 6), does not initially result in ES cell 
differentiation, but tips the balance of pluripotency into a disequilibrium. ES cells 
mutant for Eed have a greater tendency to differentiate and show a deregulation of 
gene expression of several extraembryonic genes. 
  
4.2.2. The role of PcG complexes in RNA polymerase II poising at 
bivalent genes 
This section presents work that formed part of a collaborative study involving the 
laboratories of Dr. Ana Pombo and Professor Amanda Fisher. Jointly these 
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laboratories found that poised RNA polymerase II (RNAPII) is present at the 
promoters of bivalent genes in ES cells, although these genes are not transcribed at a 
significant level (Stock et al., 2007). RNAPII is known to be subjected to extensive 
phosphorylation of the amino-acid residues composing the C-terminal domain (CTD) 
which is implicated in the regulation of different aspects of transcription 
(Buratowski, 2003; Phatnani and Greenleaf, 2006). RNAPII phosphorylated at Serine 
5 (Ser 5P) is normally associated with transcription initiation complexes and has 
been detected at the promoters of inducible genes prior to their activation whereas 
RNAPII phosphorylated at Serine 2 (Ser 2P) is associated with transcription 
elongation and recruitment of the RNA processing machinery (Phatnani and 
Greenleaf, 2006). In ES cells, Stock and colleagues found that RNAPII adopts an 
unusual conformation characterised by immunoreactivity with antibodies to RNAPII 
phosphorylated on serine 5 (Ser5) and non-immunoreactivity to antibodies detecting 
serine 2 (Ser2) phosphorylated RNAPII. Interestingly, poised RNAPII at bivalent genes 
in ES cells was also found to have non-immunoreactivity to antibodies detecting the 
non-phosphorylated CTD (8WG16), which is normally detectable at all promoters of 
RNAPII occupied and paused genes (O'Brien et al., 1994). An important question was 
whether histone modifications catalysed by PcG complexes had a role in maintaining 
this unusual RNAPII configuration. 
 
4.2.2.1. Conditional knockout model for PRC1 
To test the role of PcG proteins in RNAPII poising at bivalent genes, it was important 
to use a conditional knockout model that would allow assessment of bivalent genes 
rapidly following loss of PcG mediated histone modifications. For this purpose, 
Ring1A/B ES ERT2 cells, in which H2A ubiquitylation activity of PRC1 and related 
complexes can be rapidly switched off by tamoxifen (Tmx) inducible deletion of the 
Ring1B gene on a Ring1A-/- background (Endoh et al., 2008) was used. The double 
knockout Ring1A/B cell line was analysed as Ring1A and Ring1B function redundantly 
in H2A ubiquitylation in ES cells (Endoh et al., 2008). PRC1 and H2A ubiquitylation 
are believed to function downstream of PRC2 and H3K27me3 and therefore 
probably function as the effector in PcG silencing. 
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ES-ERT2 cell lines were cultured in the presence of 800nM Tmx for a 48 hour period. 
Under these conditions, the floxed Ring1B allele is efficiently deleted (Figure 4.3a). 
This was confirmed by genotyping with a set of 3 primers that are located upstream 
of the first loxP site (s3), downstream of the first loxP site and upstream of the first 
exon (as5) and finally, downstream of the PGK-neo cassette (4681). Using these 3 
primers in combination led to the amplification of a 200bp band on the untreated 
cell lines corresponding to the unfloxed, wild type (wt) allele (PCR product between 
s3 and as5). Upon 12h of treatment with Tmx, the 200bp product could no longer be 
detected (as the region containing the as5 annealing site has been excised) and 
instead a 500bp band was detected (Figure 4.3b). This band corresponds to the 
product of s3-4681 amplification which could not be detected in untreated 
conditions as the amplicon size is too big. After 12 hours of Tmx treatment, in most 
of the ES-ERT2 ES cells the wild type Ring1B allele was efficiently deleted (Figure 
4.3b). The efficient excision of the Ring1B wild type allele leads to a progressive 
depletion of the levels of Ring1B protein with no significant reduction in the levels of 
Suz12 and Ezh2 (PRC2 core proteins) (Figure 4.3c). In parallel with the reduction of 
Ring1B protein levels, cells treated with Tmx show depletion of global levels of 
histone H2A ubiquitylation whereas H3K27me3 levels are unaffected (Figure 4.3d). 
This is in concordance with the data showing PRC1 biochemical activity in 
ubiquitylation of the lysine 119 of histone H2A (de Napoles et al., 2004; Wang et al., 
2004a). These observations show that the ES-ERT2 ES cell line can be used to study 
the role of Polycomb complexes in the dynamic regulation of gene expression which 
occurs upon removal of PRC1 and H2A ubiquitylation from ES cells. 
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Figure 4.3. Conditional deletion of Ring1B alleles in ES-ERT2 Ring1A-/- cells leads to complete 
depletion of ubiquitylation of H2A after 48h of tamoxifen treatment. (a) Schematic representation 
of the Ring1B conditional allele. Tamoxifen treatment induces deletion of exon 1 and the PGKneo 
cassette. Position of primers s3, as5 and 4681 are indicated, and were used to check efficiency of 
Ring1B deletion by PCR. (b) ES-ERT2 cells were cultured in the presence of 800nM tamoxifen for 0, 12, 
24 and 48h. DNA was extracted from cells at each time point and analysed by PCR for the presence of 
the wild type (wt) and deleted (mut) Ring1B alleles. (c) Nuclear extracts were prepared from cells 
treated with tamoxifen for 0, 24 and 48h, separated by SDS-PAGE and analysed by western blotting 
using anti-Ring1B, anti-Suz12, anti-Ezh2 and anti-LaminB antibodies. LaminB was used as a loading 
control to show equal loading of proteins. (d) Acid-extracted histones were prepared from cells 
treated with tamoxifen for 0, 12, 24 and 48h, separated by SDS-PAGE and analysed by western 
blotting using anti-H2Aub1, anti-H3K27me3 and anti-H2A antibodies. H2A was used as a loading 
control to show equal loading of histones.  
 
 
Deletion of Ring1B in ES cells results in up-regulation of a number of PcG target 
genes but ES cells are maintained in an undifferentiated state (Endoh et al., 2008). 
This is similar to the outcome of deleting the core PRC2 protein Eed (as discussed in 
the previous section of this chapter). Double knockout of Ring1A and Ring1B 
however results in a more dramatic up-regulation of target genes and cells 
differentiate uncontrollably after approximately 72 hours (Endoh et al., 2008). In 
order to discriminate the direct effects of PRC1 loss on the regulation of PcG target 
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genes, it was important to analyse ES-ERT2 cells at early time points within the first 
48 hours following addition of Tmx. To confirm that ES-ERT2 cells remain overtly 
undifferentiated in this timeframe, expression of key ES cell regulators/markers 
Oct4, Nanog, Rex1, SSEA1 and alkaline phosphatase, were monitored. Expression of 
SSEA-1 and Oct4 (markers of mouse ES cells) was assessed by fluorescence-activated 
cell sorting (FACS) analysis. The data acquired shows that ES-ERT2 cells express 
normal levels of both markers 48 hours after Tmx induction (Figure 4.4a). After 4-7 
days in culture, expression of both markers was strongly reduced and the cell culture 
was morphologically differentiated (data not shown). Alkaline phosphatase activity 
was also analysed and found to be maintained 48 hours post Tmx treatment (Figure 
4.4b). Expression of Nanog was analysed by immunofluorescence in cells treated 
with Tmx and compared to untreated cells. The data shows that Nanog is detected in 
a similar proportion of cells (74% in untreated compared to 64% in 48h Tmx treated 
cells) (Figure 4.4c). Finally, the global protein levels of Nanog, Oct4 and Rex1 were 
analysed by Western blot at 0, 24 and 48 hours of Tmx treatment (Figure 4.4d). 
There is no detectable change in the global levels of these pluripotency markers. 
Collectively, these results show that ES-ERT2 cells remain undifferentiated 48 hours 
after Tmx induction (and Ring1B depletion) and retain several characteristics of 
pluripotent ES cells. This suggests that ES-ERT2 cells can be used during the first 48 
hours following deletion of Ring1B to analyse immediate consequences of the loss of 
H2A ubiquitylation on target gene regulation. 
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Figure 4.4. ES-ERT2 cells remain undifferentiated after 48h of tamoxifen treatment. (a) FACS 
analyses of SSEA-1 and Oct4 expression in ES-ERT2 cells before and 48h after tamoxifen (Tmx) 
induction. Percentage of positive cells, as measured by the fluorescence intensity, is indicated on each 
graph. (b) Alkaline phosphatase activity analysis in ES-ERT2 cells was measured before and after 48h 
of Tmx treatment. ES colonies positive for alkaline phosphatase gene activity show a pink staining. (c) 
Nanog protein expression and nuclear localisation was analysed by immunofluorescence using anti-
Nanog antibody (green) in untreated and 48h Tmx-treated ES-ERT2 cells (approximately 76% versus 
64% positive cells respectively). Nuclei were counterstained with DAPI (red). The levels of Nanog 
protein detected in individual cells were variable, consistent with previously published data (Singh et 
al., 2007). (d) Nuclear extracts were prepared from cells treated with tamoxifen for 0, 24 and 48h, 
separated by SDS-PAGE and analysed by western blotting using anti-Nanog, anti-Oct4, anti-Rex1 and 
anti-LaminB antibodies. LaminB was used as a loading control to show equal loading of proteins. 
Molecular weight (MW) markers are indicated (kDa). 
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4.2.2.2. Effect of Ring1A/B depletion on chromatin configuration of 
bivalent genes 
In order to determine early events triggered upon removal of Ring1A/B from ES cells, 
the distribution of different histone marks and PcG proteins at the promoters of 
bivalent genes was studied within the first 48 hours following Tmx treatment. For 
this, a panel of genes distributed amongst 3 classes was specifically studied. These 
classes comprise genes that are expressed in ES cells (the housekeeping gene β-actin 
and the pluripotency key factors Oct4 and Sox2), genes that were classified as 
bivalent and show very low levels or non-productive expression (like Nkx2.2, HoxA7 
and Mash1) and genes that are silenced in ES cells (like Myf5 and λ5 HS2). ChIP 
analysis revealed that Ring1B is enriched at the promoter and coding regions of most 
of the bivalent genes analysed, whereas no detectable association was found with 
genes highly expressed in ES cells or silenced genes. After treatment of ES cells with 
Tmx, the levels of Ring1B are promptly reduced at 24h and almost undetectable 
after 48 h (Figure 4.5a).  
 
During this same time window, the levels of Ezh2, H3K27me3 and H3K4me3 
occupancy at target promoters were analysed. A small decrease on both the levels of 
the PRC2 protein and the associated histone modification was observed at the 
promoters of the bivalent genes 48 h post-induction (Figure 4.5b and c). Conversely, 
the levels of H3K4me3 (a mark of actively transcribed chromatin) show a slight 
increase, although not statistically significant, at the promoters of bivalent genes and 
a slight decrease at the promoters of Oct4 and Sox2 (Figure 4.5d). This is in 
concordance with the fact that Nkx2.9 and Gata4 genes show rapid de-repression at 
48 hours post-Tmx treatment whilst Cdx2, Flk1, HoxA7, Math1, Nkx2.2, Mash1 and 
Msx1 genes are slightly de-repressed at 48 hours post-induction but show significant 
de-repression at 72h after Tmx induction (Stock et al., 2007). The removal of the 
PRC1 component Ring1B, leads to a steep reduction in the occupancy of this protein 
at target promoters. This event does not lead to an extensive and fast re-
organisation of PRC2 targeting and occupancy at their target promoters, suggesting 
an independent role for PRC2 and PRC1 in gene expression regulation.  
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Figure 4.5. Ring1B depletion in ES-ERT2 cells results in a small decrease in Ezh2 and H3K27me3 
levels and a slight increase of H3K4me3 at bivalent genes promoters. Ring1B occupancy of control 
(B-actin, Oct4, Sox2), bivalent (Math1, Nkx2.2, Msx1, Nkx2.9, Mash1, Cdx2, HoxA7, Flk1, Gata4) and 
silenced (Gata1, Myf5, λ5) gene promoters (blue bars) and coding regions (red bars) was assessed by 
ChIP before (-Tmx) and following tamoxifen treatment for 24 and 48h (a). Enrichments assessed by 
qPCR are presented as the mean of 3-4 independent ChIP experiments (+/- standard deviation) and 
are expressed relative to input DNA. Background levels (enrichment from control antibodies or beads 
alone) are shown as pale blue or white bars. Similarly, enrichments for H3K27me3 (b), Ezh2 (c) and 
H3K4me3 (d) at control, bivalent and silenced gene promoters were assessed by ChIP and qPCR. 
Differences in abundance of H3K27me3, Ezh2 and Ring1B at bivalent genes over time are statistically 
significant (p<0.0001, p=0.01 and p<0.0001 respectively; ANOVA), while variation in H3K4me3 is not 
(p=0.91; ANOVA).  
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4.2.3.3. PRC1 mediated H2A ubiquitylation restrains RNAPII at bivalent 
promoters 
In a final set of experiments the effect of Ring1A/B deletion on RNAPII conformation 
at bivalent genes was assessed. This experiment was carried out by myself 
(preparation of cells before and after Tmx treatment) and collaborators from Dr. Ana 
Pombo’s group, Julie Stock and Emily Brookes (ChIP analysis of RNAPII). As a 
consequence of the depletion of Ring1B from ES-ERT2 cells, the levels of H2Aub1 
detected at the promoter and coding regions of the bivalent genes analysed fell 
dramatically and were undetectable after 48h of culture in the presence of Tmx 
(Figure 4.6a). H2Aub1 was not detectable at the promoters of the two other classes 
of genes before or after Tmx treatment.  
 
During the first 48h after Ring1B depletion, the levels of the RNAPII Ser 5P remained 
high at bivalent promoters and RNAPII Ser2P levels also did not change noticeably at 
either promoter or coding regions of bivalent genes. Similarly, no changes in RNAPII 
conformation were detected for the other groups of genes at either promoter or 
coding regions (Figure 4.6b and c). However, the 8WG16 antibody, known to 
recognise hypophosphorylated and intermediately phosphorylated forms of RNAPII 
(Xie et al., 2006) detected a rapid increase of this form of RNAPII following Ring1B 
deletion. The levels of RNAPII detected by the 8WG16 antibody were initially very 
low at either promoter or coding regions of all genes analysed, with the exception of 
the genes being highly expressed in ES cells (β-actin, Oct4 and Sox2), where this form 
of RNAPII was present at high levels. The gene expression deregulation observed 
upon deletion of Ring1B (Stock et al., 2007) was accompanied by a significant 
increase on the levels of RNAPII detected by 8WG16 at the promoters of bivalent 
genes (and not at the body of these genes). The same trend was not observed at the 
promoters of silent, non-bivalent genes (like Myf5 and Gata1) (Figure 4.6d). These 
observations suggest that upon removal of Ring1B and H2Aub1, the RNAPII 
conformation dramatically changes at the promoters of bivalent genes in ES cells. 
The data suggests that an unusual RNAPII conformation present at bivalent genes in 
ES cells is restrained by the presence of H2Aub1 catalysed by Ring1A/B. 
117 
 
 
 
Figure 4.6. Loss of H2Aub1 results in changes in RNAP conformation at bivalent genes in ES-ERT2 
cells. The enrichment for H2Aub1 (a), RNAP phosphorylated at Ser5 (b), RNAP phosphorylated at Ser2 
(c) and the hypophosphorylated form (8WG16) of RNAP (d) was assessed by ChIP and qPCR at the 
promoter (blue bars) and coding regions (red bars) of control, bivalent and silenced genes before (-
Tmx) and following tamoxifen treatment for 24 and 48h. Enrichment for each modification is 
presented as the mean of 3-4 independent ChIP experiments (+/- standard deviation) and is 
expressed relative to input DNA. H2Aub1 is normalised to H2A levels. Background levels (enrichment 
from control antibodies or beads alone) are shown as pale blue or white bars. Differences in 
abundance of H2Aub1, Ser5P and 8WG16 RNAP at bivalent genes with time are statistically significant 
(P<0.0001, P=0.02 and P=0.002 respectively; ANOVA), whereas variation in Ser2P is not (p=0.14; 
ANOVA).  
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4.3. Discussion 
4.3.1. Role of Eed and PRC2 in stem cells of the early embryo 
In this work three new Eed mutant ES cell lines were derived. The success rate for 
the derivation of Eed mutant cells was low. From the total number of new cell lines 
(51), only three Eed mutant cell lines (corresponding to three ES cell lines) were 
derived. This may indicate that cells lacking Eed have an impaired survival and/or 
derivation efficiency. It also suggests that the derivation of TS and XEN cells deficient 
for Eed is further impaired than the derivation of ES cell lines deficient for Eed. A 
recent study reports the successful derivation of TS cells deficient for Eed but failed 
to derive XEN cells, reinforcing the idea that Eed is important in maintaining the 
stability of different stem cell types derived from the mouse blastocyst (Kalantry et 
al., 2006).  
 
The Eed mutant ES cells derived in this work possess ES like characteristics consistent 
with previous reports (Morin-Kensicki et al., 2001). Although Eed-/- cells are able to 
replicate and maintain an undifferentiated state in vitro, they are more sensitive to 
culture conditions than their heterozygous or wild type controls. The Eed deficient ES 
cells could easily differentiate into other cell types, some of which resembled 
extraembryonic cell lines. This observation implicates Eed (and consequently PRC2) 
in the ability of ES cells to maintain their characteristics of pluripotency under tight 
control. The importance of PRC2 complexes in ES cells has been widely studied. The 
lack of a functional PRC2 complex by depletion of Eed was shown to induce ES cells 
to deregulate a large number of genes involved in developmental processes, making 
mutant ES cells more prone to spontaneous differentiation (Azuara et al., 2006; 
Boyer et al., 2006b). These mutant cells remain in a pluripotent state as they 
maintain the ability to form the three germ layers and differentiate in vitro into 
various lineages (Morin-Kensicki et al., 2001). Suz12 deficient ES cell lines were 
recently derived and maintained in culture in an undifferentiated state while 
expressing different pluripotency markers such as Oct4 and Nanog. The Suz12 
mutant cells showed deregulation and misexpression of developmental regulators, 
similar to Eed deficient cells (Pasini et al., 2007). Distinct from Eed deficient ES cells, 
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Suz12 deficient ES cells cannot properly differentiate to form neurons in vitro. These 
results are intriguing and suggest that Suz12 might be involved in functions outside 
of the canonical PRC2 complex (similar to Ezh2). Nevertheless, these studies strongly 
suggest that PcG proteins have an important role in defining ES cell pluripotency. 
Contrasting with these reports, recent lines of evidence suggest that the presence of 
a functional PRC2 complex in ES cells is not essential for the maintenance of 
pluripotency. Chamberlain and colleagues characterised Eed deficient ES cells and 
reported that although developmental regulators are overexpressed as a 
consequence of Eed depletion, Eed deficient cells are functionally pluripotent and 
are able to be incorporated into all adult lineages (Chamberlain et al., 2008). These 
authors suggest a positive-only model for pluripotency, in which the positive 
regulation of pluripotency factors is sufficient to determine pluripotency 
(Chamberlain et al., 2008). These opposing views can be integrated by assuming that 
pluripotency transcription factors present in ES cells are adequate to maintain the 
undifferentiated state of ES cells (Chamberlain et al., 2008; Niwa, 2007a) whilst PcG 
proteins play an important role in helping ES cells to maintain an appropriate gene 
expression profile and by controlling differentiation of ES cells along different lineage 
pathways. 
 
The expression profile of the derived ESL cell lines showed several genes that are 
involved in the specification of extraembryonic tissues being up-regulated. This is in 
accordance with several analyses described in recent reports in which it was shown 
that genes required for the specification of alternative lineages including mesoderm 
(Flk-1), endoderm (Gata4 and Hnf4) and extraembryonic tissues (Gata6 and Cdx2) 
are up-regulated in Eed deficient ES cell lines (Azuara et al., 2006; Jorgensen et al., 
2006). A key question for the future is to determine whether this expression pattern 
originates from a small proportion of cells that have differentiated, or whether Eed 
deficient ES cells can co-express factors from ES and differentiated lineages. A 
related question is whether extraembryonic like colonies observed in Eed deficient 
ES cell cultures truly represent TS or XEN like cells. The differentiation to the TS 
lineage would be particularly interesting because normally ES cells are unable to 
differentiate along this lineage pathway (Niwa et al., 2000). The over-expression of 
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Cdx2 or Eomeso was shown to induce wild type mouse ES cells to differentiate along 
the trophectoderm lineage (Niwa et al., 2005). An understanding of the 
differentiation dynamics of Eed mutant ES cells will shed light on the role the PRC2 
complex plays in developmental processes. As described above, a recent report 
indicates that mouse ES cells mutant for Suz12 are maintained in an undifferentiated 
state and are unable to differentiate, implicating PRC2 in regulation of gene 
expression changes that operate during mouse ES cell differentiation (Pasini et al., 
2007). It will be important to determine whether Eed mutant ES cell lines can be 
induced to properly differentiate into specific lineages and how precise this 
differentiation process is.  
 
4.3.2. Ring1A/B mediated H2A ubiquitylation restrains RNAPII at 
bivalent gene promoters 
Several models have been proposed to explain how PcG proteins function in gene 
silencing. Both PRC1 and PRC2 act as transcriptional repressors which seem to 
operate at distinct levels in order to accomplish this. Analysis of ES-ERT2 cells 
suggests a new model for the regulation of gene expression in mouse ES cells by 
PRC1. Specifically, RNAPII seems to be held in a poised state by the 
monoubiquitylation of histone H2A lysine 119 which is, in turn, mediated by PRC1.  
 
The loss of Ring1A/B from ES cells does not lead to a dramatic change on the 
occupancy of PRC2 components and H3K27me3 at target promoters. This is 
consistent with the idea that the main function of H3K27me3 is to recruit PRC1 that 
then acts to repress genes by H2A ubiquitylation. However, the mechanism by which 
H2A ubiquitylation affects gene expression is poorly understood. Results presented 
here suggest that H2A ubiquitylation affects RNAPII conformation, maintaining 
promoters of bivalent genes in a poised state. In ES cells, poised RNAPII shows Ser5P 
CTD phosphorylation but is not detected by the 8WG16 antibody at the bivalent 
promoters. Once H2Aub1 is depleted from the promoters, a rapid increase of RNAPII 
detected by the 8WG16 antibody occurs. This correlates with an increase in gene 
expression. Previous studies analysing the promoter of poised or stalled genes 
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however generally detect hypophosphorylated CTD RNAPII using the 8WG16 
antibody (Boehm et al., 2003). The promoter of the heat shock gene Hsp70 was 
shown to possess a paused form of RNAPII characterised by high levels of both Ser5 
RNAPII and high levels of hypophosphorylated RNAPII (detected by the 8WG16 
antibody) (Boehm et al., 2003). This was suggested to be a characteristic of 
promoter-paused RNAPII (O'Brien et al., 1994). The fact that no hypophosphorylated 
RNAPII is detected at the promoters of bivalent genes suggests that pluripotent ES 
cells have a unique RNAP conformation. This unique conformation can either be due 
to a unique phosphorylation pattern of RNAPII CTD in ES cells or to the masking of 
the epitope recognized by 8WG16 by the binding of specific factors.  
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Chapter 5. Functional analysis of Pcl2-PRC2 in ES 
cells 
 
5.1. Introduction 
Recent reports provided evidence that the two major PcG complexes, PRC1 and 
PRC2, function by introducing post-translational modifications onto core histones. 
PRC2 was shown to methylate lysine 27 of histone H3 (Cao et al., 2002; Czermin et 
al., 2002; Kuzmichev et al., 2002), while PRC1 mediates monoubiquitylation of lysine 
119 of histone H2A (Wang et al., 2004a). The modifications introduced by PcG 
proteins on core histones have various consequences on the transcriptional activity 
of target genes, as described in the previous chapter. Mechanisms involved in the 
targeting of PcG proteins to specific loci however remain poorly understood. In 
Drosophila, the recruitment of PcG to appropriate loci of the genome is mediated by 
cis-acting regions essential for silencing, the Polycomb response elements (PREs) 
(Chan et al., 1994; Simon et al., 1993). In mammals, no PREs have been identified 
and it remains unclear whether these elements are more complex and harder to 
identify or whether other recruitment mechanisms exist. In mammals, the 
recruitment of PcG proteins can also be mediated by RNA related mechanisms. A 
classical example of this is the Xist-dependent recruitment of PcG proteins to the Xi, 
at the onset of X-chromosome inactivation (Kohlmaier et al., 2004; Plath et al., 2003; 
Plath et al., 2004; Silva et al., 2003). Independently of the recruitment mechanism 
considered, it is noteworthy that core PcG proteins do not have DNA or RNA binding 
domains, suggesting possible involvement of other factors. 
 
5.1.1. The Polycomblike protein 
One candidate accessory factor for PcG targeting is the Polycomblike (Pcl) protein. 
Pcl was first identified in a genetic screen in D. melanogaster as a PcG component 
involved in the regulation of HOX gene expression during development (Duncan, 
1982). Previous studies showed that in Drosophila, Pcl interacts with E(z) (O'Connell 
et al., 2001; Tie et al., 2003) and is part of a PRC2-like complex, found at PREs (Papp 
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and Muller, 2006; Tie et al., 2003). The Drosophila Pcl gene encodes for a 857 amino 
acid protein which is structurally characterised by the presence of a Tudor domain at 
the N-terminal region and two Plant Homeodomain fingers (PHD) in the middle part 
of the protein (Lonie et al., 1994; O'Connell et al., 2001; Wang et al., 2004d). Tudor 
domains are found in many organisms and together with plant Agenet, Chromo 
PWWP and MBT domains, they form the Tudor domain “Royal Family” (Maurer-
Stroh et al., 2003). Proteins containing a Tudor domain were shown to interact with 
other proteins and the efficiency of this interaction depends on the presence of 
methylated arginine and lysine residues on the target protein (Brahms et al., 2001; 
Cote and Richard, 2005; Huyen et al., 2004; Kim et al., 2006; Sprangers et al., 2003). 
Several Tudor domain proteins were shown to interact with modified histones. For 
example, the 53BP1 protein has a tandem Tudor domain that binds histone H3 on 
methylated lysine 79 which seems to be essential for the recognition of DNA double-
strand breaks during cell cycle checkpoint responses (Huyen et al., 2004). Recently, 
the Tudor domain of several other proteins was shown to bind to methylated 
residues of histones H3 and H4 (Huang et al., 2006; Kim et al., 2006) and also to RNA 
(Pryde et al., 2005).  
 
The PHD finger is a very common structural motif that can be found in all eukaryotic 
genomes. This motif was shown to be a Zn2+-binding domain and the closest 
structural relative to the RING domain (Bienz, 2006). PHD fingers comprise around 
60 amino acids that show a typical Cys4-His-Cys3 signature with a characteristic 
cysteine spacing and some additional conserved residues, like tryptophan or other 
aromatic amino acid preceding the final cysteine pair (Aasland et al., 1995). Proteins 
containing PHD fingers were shown to be essentially nuclear and to be involved in 
transcriptional regulation by modulating different aspects of chromatin (Aasland et 
al., 1995). PHD fingers were proposed to be protein-protein interaction domains and 
a number of recent studies indicate that PHD fingers can interact with specific lysine 
methylated histones (Mellor, 2006). PHD fingers may also mediate interaction with 
other proteins. In the case of Pcl, one of the PHD domains was shown to be essential 
for the interaction with Ezh2 (O'Connell et al., 2001). 
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5.1.2. Polycomblike mutants 
In contrast to Drosophila where only a single Pcl gene exists, three Pcl homologue 
genes have been identified in the genomes of frog, chicken and mammals and 
named Pcl1 (also Phf1 or Tctex3), Pcl2 (also Mtf2 or M96) and Pcl3 (also Phf19) 
(Coulson et al., 1998; Inouye et al., 1994; Kawakami et al., 1998; Kitaguchi et al., 
2001; Wang et al., 2004d; Yoshitake et al., 1999). All homologues share extensive 
sequence homology, particularly in the Tudor and PHD domains (Figure 5.1). 
Mammalian Pcl1 was shown to be expressed specifically in the testis (Kawakami et 
al., 1998). Pcl2 was initially cloned as a metal response transcription factor (Inouye et 
al., 1994). Pcl3 was recently identified in human and shown to be up-regulated in 
multiple cancers (Wang et al., 2004c). In Drosophila, the lack of Pcl in homozygous 
null mutants leads to embryonic lethality, while heterozygous exhibit an adult 
phenotype in which the second and third legs of males are transformed to resemble 
the first leg (Duncan, 1982). In Xenopus and chicken embryos, absence of Pcl1 
and/or Pcl2 leads to the deregulation of genes involved in the developing anterior 
central nervous system or the development of a left-right axis, respectively 
(Kitaguchi et al., 2001; Wang et al., 2004d; Yoshitake et al., 1999). Mice lacking the 
PHD domain of Pcl2 were shown to be viable and grow to adulthood but exhibit 
retarded growth defects and reduced fertility. Interestingly, these mice display 
posterior transformations of the axial skeleton, similar to those found in other PcG 
mutants (Wang et al., 2007). 
 
Based on the observation that the mammalian Pcl homologue Pcl2 localises to the 
inactive X chromosome, a previous PhD student in the laboratory, Tanja Preissner, 
began to study the function of Pcl2. Pcl2 was found to be expressed predominantly 
in ES cells and in early development. RNAi mediated knockdown of Pcl2 was shown 
to affect PRC2 recruitment to the inactive X and at other targets but the data 
obtained using different shRNAs were ambiguous. In this chapter I present further 
analysis of the role of Pcl2 in PRC2 function at target genes in ES cells and in X 
inactivation. 
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Figure 5.1. Phylogenetic tree of human, mouse and Drosophila Polycomblike homologues. The 
Polycomblike protein is structurally characterised by the presence of a Tudor domain and two PHD 
domains. In contrast to Drosophila, where only a single Pcl gene exists, three Pcl homologue genes 
have been identified in mammals. For each of the corresponding proteins, the relative positions of the 
Tudor and the two PHD domains are indicated as well as the number of amino acids. Adapted from 
(Cao et al., 2008). 
 
 
5.2. Results 
5.2.1. Design and selection of shRNAs for Pcl2 in ES cells 
To understand the role of Pcl2 in the function of the PRC2 complex in mouse ES cells, 
a set of functional studies were undertaken. Several small hairpin RNAs (shRNA) 
constructs were designed and cloned into the pSuper.gfp/neo vector (Materials and 
Methods, section 2.10.2.1). This vector allows the expression of shRNAs which 
trigger an RNAi response in mammalian cells and lead to knockdown expression of 
the RNA complementary to the shRNA. Additionally, this vector has the advantage of 
allowing selection of stable integrants either by GFP or drug selection (Figure 5.2a). 
Six shRNAs were designed, targeting different regions of the Pcl2 mRNA, including 
the Tudor domain, a region between the PHD fingers and the 3’ region of the mRNA 
(Figure 5.2b). Two of these shRNA, CL4TP and CL8TP were used in previous studies 
carried out by Tanja Preissner (Tanja Preissner and Neil Brockdorff, personal 
communication). The six Pcl2 shRNA constructs and a control shRNA with no target 
specificity to any mouse mRNA were transfected into PGK12.1 XX ES cells. Cells were 
selected by FACS sorting for GFP positive cells and by culture in the presence of 
geneticin (G418). Sorting cells based on their GFP expression is an advantage over 
antibiotic selection, because it allows selection of cells displaying high levels of GFP 
expression and thus the shRNA.  
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Figure 5.2. Pcl2 shRNA design and cloning. (a) Map of the pSUPER.gfp/neo vector used to clone small 
hairpin RNA (shRNA) oligonucleotides for Pcl2. shRNA are cloned downstream of the H1 promoter. 
Both the EGFP and the neomycin marker genes can be used to select positive transfectants. (b) 
Schematic representation of Pcl2 ORF. Positions of the Tudor, PHD1 and PHD2 domains and the 6 
small RNA (CL1.5MC, CL2.4MC, CL3.5MC, CL4.8MC, CL4TP and CL8TP) designed are indicated.  
 
 
To evaluate whether the shRNA transgenes were functional, the mRNA levels of Pcl2 
were analysed in 12 clonal ES cell lines for each construct tested. The different 
shRNA constructs knocked down Pcl2 with different efficiency, but from the six 
constructs initially used, four led to strong down-regulation of Pcl2 mRNA (Figure 
5.3).  
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Figure 5.3. Pcl2 shRNA ES clone selection. Each Pcl2 shRNA construct and one shRNA control were 
transfected in PGK12.1 ES cells. For each, 12 individual clones were analysed by qRT-PCR for Pcl2 
expression using two different primer pairs (Pcl2 F1/R1 and Pcl2 F2/R2). For each clone analysed, 
expression levels are normalised to the housekeeping gene Hmbs. Clones selected for further analysis 
are indicated with an asterisk.  
 
 
Several clones were selected (indicated in Figure 5.3) for further analysis. Both 
mRNA and protein levels of Pcl2 were compared between the Pcl2 shRNA selected 
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clones and two shRNA control cell lines. The ES Pcl2 shRNA clones selected show a 
very good knockdown efficiency for Pcl2 mRNA ranging from 60 to 88% relative to 
Pcl2 mRNA levels present in ES control shRNA cells (Figure 5.4a). Protein extracts 
from the control cell lines and Pcl2 knockdown cell lines were used for western blot 
analysis using an antibody raised against Pcl2. This antibody detects 3 bands in the 
control cell lines which correspond to three possible isoforms of Pcl2 (Haruhiko 
Koseki, personal communication). In all knockdown cell lines analysed, the protein 
levels of Pcl2 were reduced, affecting the 3 Pcl2 isoforms and with a strong 
correlation with the decrease seen at the mRNA level (Figure 5.4b). The two cell lines 
showing highest levels of Pcl2 knockdown, CL4TP4 and CL3.5MC10, were selected for 
use in further studies.  
 
As already mentioned, the different mouse Pcl homologues have distinct expression 
patterns. Pcl1 is expressed primarily in male germ cells (Kawakami et al., 1998). Pcl3 
expression patterns are not well characterised, but it has been shown to be highly 
expressed in several cancers (Wang et al., 2004c). Pcl2 seems to be expressed 
throughout development but show high expression levels during early stages of 
embryonic development and in ES cells (Tanja Preissner, personal communication). 
Given the similarity of the different Pcl homologues, it is likely that different Pcl 
proteins can compensate for one another and this could mask possible effects from 
the knockdown of Pcl2. To test this possibility, the expression of both Pcl1 and Pcl3 
was analysed in different Pcl2 knockdown ES cell lines. Neither Pcl1 nor Pcl3 were 
found to be up-regulated in the absence of Pcl2 (Figure 5.4c). 
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Figure 5.4. Efficient down-regulation of Pcl2 mRNA and protein levels using shRNA. (a) Clones 
selected in Figure 5.3 were further analysed for Pcl2 gene expression by qRT-PCR with the two primer 
pairs Pcl2 F1/R1 and Pcl2 F2/R2. Results obtained are normalised to the housekeeping gene Hmbs and 
values are expressed relative to control 6. Percentages showing levels of expression of Pcl2 in each 
clone analysed are indicated. (b) Nuclear extracts were prepared from each clone selected in Figure 
5.3 and Pcl2 protein levels were analysed by western blot using a monoclonal antibody raised against 
Pcl2 (a gift from Haruhiko Koseki). The antibody reproducibly detects strong signals at 52, 60 and 
68kDa in extracts of wild type ES cells. LaminB is used as a loading control to show equal loading of 
proteins. Molecular weight markers are indicated (kDa). (c) Pcl1 and Pcl3 expression levels were 
analysed by qRT-PCR for CL4TP and CL8TP constructs in pool of positively transfected cells. Data are 
normalised to the housekeeping gene Hmbs and values are expressed relative to shRNA control.  
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5.2.2. Effect of Pcl2 knockdown on global levels of histone 
modifications 
The effect of Pcl2 knockdown on the global levels of PRC2 mediated H3K27me3 and 
other histone modifications was analysed by western blot. No consistent changes in 
the levels of any of the methylated forms of H3K27 were detectable (Figure 5.5). One 
of the ES Pcl2 shRNA cells, CL3.5MC10, did show a slight reduction in the global 
levels of H3K27me3, but the same was not seen in the other knockdown ES cell line. 
No changes were observed in the methylation levels of H3K9 and H3K20, 
modifications that are normally related to gene repression. Additionally, no changes 
were observed for modifications related with gene activity, such as H3K4 
trimethylation or acetylation of H3K9.  
 
 
Figure 5.5. Pcl2 knockdown has no effect on global levels of histone modifications. Western blot 
analysis of acid-extracted histones from PGK12.1 ES cells, one control (control 10) and two 
knockdown cell lines (CL4TP4 and CL3.5MC10) using various histone and histone modification 
antibodies. Histone H3, H2A and H4 blots, in addition to the Coomassie stained gel are used as loading 
controls. Position of each core histone is indicated on the right of the Coomassie gel.  
 
 
5.2.3. Pcl2 is important for PRC2 recruitment to target genes 
In addition to assessing the global levels of trimethylated H3K27 following Pcl2 
depletion, the levels of H3K27me3 and PRC2 components at the promoters of target 
genes were determined using ChIP analysis. Recent reports have identified PcG 
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targets in mouse and human ES cells and revealed that the majority of the targets 
are developmentally regulated genes involved in certain steps of cell differentiation 
and lineage commitment. Many of these genes display a bivalent chromatin 
conformation at their promoters as described in the previous chapter. 
  
A panel of genes was chosen for analysis. PcG target genes included genes involved 
in extra-embryonic lineage differentiation (Cdx2, Hand1, Gata6, Hnf4 and Gata4) and 
in differentiation of various embryonic lineages (Sox1, HoxA7, Nkx2.2, Fgf5, Msx1, 
Math1, Flk1 and Ikaros). Control genes were markers expressed specifically in ES 
cells (Oct4, Sox2, Nanog and Rex1) and one housekeeping gene expressed in all 
lineages (Beta-2-microglobulin, B2M). ChIP analysis was performed using antibodies 
for H3K27me3, Ezh2, Suz12, H3K4me3, histone H3 and IgG as a negative control. The 
DNA recovered from the immunoprecipitation was analysed by quantitative real-
time PCR. As expected, the promoters of B2M and ES cell expressed genes had very 
low levels of PRC2 mediated trimethylated histone H3K27 both in control and Pcl2 
knockdown cells (Figure 5.6a). The promoters of extra-embryonic and embryonic 
PcG target genes showed high levels of enrichment for H3K27me3 and interestingly, 
H3K27me3 levels were slightly reduced in the Pcl2 knockdown cell lines when 
compared to the matched control. This effect was observed for the two shRNAs ES 
cell lines analysed. Contrasting with this result, the levels of H3K4me3 at the 
promoters of the genes analysed did not show any differences between control and 
Pcl2 knockdown ES cell lines (Figure 5.6b).  
 
When the occupancy of the PRC2 proteins, Ezh2 and Suz12, was analysed at the 
promoters of the panel of genes studied, a very obvious reduction in enrichments of 
these two proteins was observed in the Pcl2 knockdown ES cell lines compared to 
controls (Figure 5.6c and d). This decrease indicates that reduced levels of Pcl2 in ES 
cells severely impair the recruitment of PRC2 to target loci. However, whilst PRC2 
levels at target promoters are clearly reduced, the levels of H3K27me3 are only 
affected to a small degree (Figure 5.6a). Possible explanations are discussed below. 
No significant changes in nucleosome occupancy were observed (histone H3) at 
target promoters (Figure 5.6e). Background levels measured with the control 
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antibody IgG confirmed that the results obtained are specific to the antibodies used 
and are not an artefact of the method (Figure 5.6f).  
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Figure 5.6. Pcl2 knockdown leads to destabilisation of PRC2 at target genes. Levels of H3K27me3 (a) 
and H3K4me3 (b) modifications and recruitment of Ezh2 (c) and Suz12 (d) to promoters of various 
genes were analysed by ChIP in a control (control 10) and two knockdown ES cell lines (CL4TP4 and 
CL3.5MC10). Genes analysed are arranged in three groups: housekeeping and pluripotency (B2M, 
Oct4, Sox2, Nanog, Rex1), extra-embryonic (Cdx2, Hand1, Gata6, Hnf4, Gata4) and PcG target genes 
(Sox1, HoxA7, Nkx2.2, Fgf5, Msx1, Math1, Flk1, Ikaros). Enrichments for each modification assessed 
by qPCR are presented as the mean of 3 independent ChIP experiments (+/- standard deviation) and 
are expressed relative to 1/10th of input DNA. Histone H3 ChIP is shown as a control for nucleosome 
distribution (e). Background levels (enrichment from IgG control antibody) are shown (f). 
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5.2.4. Pcl2-FLAG is recruited to developmentally regulated genes 
Reduced localisation of PRC2 to PcG target genes in Pcl2 knockdown cells suggests 
that Pcl2 associated with PRC2 in a complex likely localises to these targets. The Pcl2 
antibody used in this study is unsuitable for ChIP analysis (Haruhiko Koseki, personal 
communication). Consequently, ChIP analysis was carried out on ES cells expressing a 
FLAG-tagged version of Pcl2. Detailed description of the development of these cell 
lines is provided in the following chapter. A modified protocol for crosslinked ChIP 
(Materials and Methods, section 2.5.2) was used to specifically pull down Pcl2 using 
a FLAG antibody. The parental cell line used to derive Pcl2-FLAG lines, PGK12.1, was 
used as a control. ChIP for H3K27me3 and H3K4me3 were carried out in parallel. An 
equal amount of IgG was used as a control for antibody specificity. The results shown 
in Figure 5.7 indicate that Pcl2-FLAG is found at promoters of most of PRC2 target 
genes analysed and correlates with high levels of H3K27me3. Interestingly, the over-
expression of Pcl2 in ES cells, similarly to what is observed when knocking down Pcl2, 
does not lead to any visible change on the levels of H3K27me3 or H3K4me3 at the 
promoters of the genes studied in this assay. These results suggest that Pcl2 localises 
together with PRC2 components at promoters of the PcG target genes analysed.  
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Figure 5.7. Pcl2 is recruited to the promoters of PcG target genes in ES cells. Pcl2 recruitment to the 
promoters of various genes was analysed by FLAG ChIP using the M2 Flag antibody in PGK12.1 cells 
(blue bars) and Pcl2-FLAG clone E1 (red bars). H3K27me3 and H3K4me3 enrichments were also 
measured using the same protocol. Enrichments for each modification analysed by qPCR are 
presented as the mean of 3 independent ChIP experiments (+/- standard deviation) and are expressed 
relative to 1/10th of input DNA. Background levels for the FLAG ChIP (enrichment from Protein G 
beads alone) are shown for each cell line as pale blue and pale red bars. Genes analysed are arranged 
in three groups as in Figure 5.6.  
136 
 
5.2.5. Expression analysis of PcG target genes in Pcl2 knockdown ES 
cells 
The previous experiments demonstrated that reduced levels of Pcl2 in ES cells result 
in a decrease in the recruitment of PRC2 to its target genes and that this is 
associated with a modest decrease in the levels of H3K27me3 at target promoters. 
Gene expression analysis was performed to determine if this can affect repression of 
PcG target genes as observed for example in Eed knockout ES cells (see section 
4.2.1.). As expected, the transcription levels of housekeeping genes (B2M, Idh1 and 
HPRT) remained similar in the Pcl2 knockdown cell lines relative to controls, while 
the levels of Pcl2 were efficiently reduced in both knockdown clones (Figure 5.8). 
The group of genes expressed in ES cells (Oct4, Nanog, Rex1, Eed, Ezh2 and Suz12) 
were, as expected, unaffected. Analysis of PcG target genes, both extraembryonic 
genes (Cdx2, Hand1, Gata6 and Eomes) and embryonic (HoxA7, Gata4, MyoD, Flk1, 
Nkx2.2, Sox1, Ikaros) indicated that their expression is also largely unaffected in Pcl2 
knockdown cell lines (Figure 5.8). These results are consistent with the observation 
that H3K27me3 levels are only marginally reduced in Pcl2 knockdown cells.  
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Figure 5.8. Pcl2 knockdown does not affect expression levels of PRC2 target genes. Expression 
analysis of housekeeping (B2M, Idh1, HPRT), pluripotency and extraembryonic (Oct4, Nanog, Rex1, 
Cdx2, Hand1, Gata6, Hnf4, Gata4, Eomes), PRC2 (Pcl2, Eed, Ezh2, Suz12) and known PcG target 
(HoxA7, MyoD, Flk1, Nkx2.2, Sox1, Ikaros) genes was assessed by qRT-PCR in two control (control 6 
and 10) and two knockdown cell lines (CL4TP4 and CL3.5MC10). Expression levels are normalised to 
the housekeeping gene Hmbs for each cell line and values are expressed relative to control 6. The 
graph shows the mean +/- standard deviation of the mean (n=3).  
 
 
5.2.6. Pcl2 co-localises with H3K27me3 to the inactive X and is 
important for efficient PRC2 recruitment 
PRC2 has been shown to play a role in X chromosome inactivation. During 
differentiation of mouse XX ES cells, PRC2 components are recruited to the inactive X 
(Xi) in an Xist-dependent manner (Kohlmaier et al., 2004; Plath et al., 2003; Silva et 
al., 2003). Resultant H3K27me3 functions as one of a number of epigenetic silencing 
levels of the inactive X chromosome (Heard, 2005). As mentioned before, previous 
work in the laboratory demonstrated that Pcl2 localises to the inactive X 
chromosome. To confirm this result PGK12.1 XX ES cells were differentiated in vitro 
for 3 days and then processed for immunofluorescence using antibodies raised 
against H3K27me3 and Pcl2 (Figure 5.9a). Pcl2 was found to co-localise with 
H3K27me3 at the inactive X (Xi). These results confirm that Pcl2 is indeed recruited 
to the Xi during the initial stages of X inactivation.  
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To further study the role of Pcl2 in X inactivation and more specifically in the 
recruitment of PRC2 to the Xi, PGK12.1 XX ES cells and Pcl2 shRNA ES cell lines were 
used. These cell lines were differentiated in vitro for 72 hours and 
immunofluorescence was performed using antibodies raised against Ezh2, Suz12, 
Eed and H3K27me3. In parallel to this, cells were also processed for RNA FISH using a 
specific probe set to detect Xist RNA expression. For each experiment, the number of 
foci corresponding to the Xi was counted and divided by the total number of cells 
analysed. The results show that the percentage of cells showing Xist up-regulation 
was similar in the three cell lines analysed, indicating that Xist expression is not 
affected by the knockdown of Pcl2 (Figure 5.9b). Immunofluorescence experiments 
revealed that, compared to the control cell line, the number of foci for all PRC2 
components and H3K27me3 at the Xi was significantly reduced in Pcl2 knockdown 
cells (Figure 5.9b), strongly suggesting that the recruitment of PRC2 to the Xi is 
impaired in the absence of Pcl2. Similarly to what was observed for PRC2 target 
genes, the reduction seen on the recruitment of PRC2 to the Xi is more obvious than 
the reduction observed for H3K27me3 Xi foci. Collectively, these experiments 
demonstrate that Pcl2 is important for the efficient recruitment of PRC2 to the Xi 
during differentiation of ES cells, similar to what was observed for PcG target genes 
in ES cells. 
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Figure 5.9. Pcl2 co-localises to the inactive X and Pcl2 knockdown impairs recruitment of PRC2 to 
the Xi. (a) Immunofluorescence detection of H3K27me3 (red) and Pcl2 (green) in PGK12.1 XX ES cells 
differentiated in vitro for 72h. Nuclei were counter-stained with DAPI (blue). Examples of four 
individual cells showing co-localisation of Pcl2 with the inactive X territory, marked by H3K27me3, are 
shown. Co-localisation was observed in 100% of cells where an H3K27me3 focus could be detected. 
(b) Xist RNA FISH and immunofluorescence detection of H3K27me3, Ezh2, Suz12 and Eed were 
performed in one control (blue bars) and two Pcl2 knockdown cell lines (green and red bars) 
differentiated in vitro for 72h. Graph indicates the mean +/- standard deviation (n=3) of the 
percentage of cells where Xi foci could be observed. On average 100 cells were scored per slide.  
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5.3. Discussion 
The results presented in this chapter demonstrate that in mouse ES cells the efficient 
recruitment of PRC2 components to PRC2 target genes requires Pcl2. Moreover, Pcl2 
is essential for recruitment of PRC2 to the Xi during ES cell differentiation. Although 
the knockdown of Pcl2 markedly influences the ability of PRC2 to be targeted to 
specific loci of the genome in ES cells, global levels of H3K27me3 remain unchanged. 
Additionally, Pcl2 knockdown has only mild effects on the local association of 
H3K27me3 at promoters of bivalent genes in ES cells. In contrast, during X-
chromosome inactivation, the effect of Pcl2 knockdown on the enrichment of 
H3K27me3 to the Xi is more obvious. The different amounts of PRC2 proteins 
present in ES cells and differentiating cells could account for these differences. In ES 
cells, high levels of PRC2 proteins could prevent the knockdown of Pcl2 having a 
major impact on local levels of H3K27me3. As cells differentiate and PRC2 protein 
levels go down, the inefficient recruitment of PRC2 in the absence of Pcl2 would be 
expected to have a bigger impact on H3K27me3 levels. 
 
It was recently suggested that in Drosophila, Pcl is part of a high molecular weight 
complex named Pcl-PRC2, distinct from PRC2, which has a critical role in H3K27 
trimethylation at PcG target genes (Nekrasov et al., 2007). In the absence of Pcl, 
PRC2 components are recruited less efficiently to PREs and levels of H3K27me3 are 
reduced, but not depleted. This leads to the derepression of PRC2 target genes. In 
vertebrates, the scenario seems to be similar and two recent reports suggest that 
Pcl1 (hPHF1) interacts with PRC2 and affects its HMTase activity (Cao et al., 2008; 
Sarma et al., 2008). The loss of Pcl1 leads to a reduction of the local and global levels 
of H3K27me3 and HOX gene derepression. Contrasting with the results obtained 
from Drosophila and my work, Sarma and colleagues suggest that the individual 
knockdown of Ezh2 or Pcl1 has no effect on their mutual recruitment to the 
promoters of the HOXA6, HOXA9 and HOXA11 genes (Sarma et al., 2008). Similarly, 
Cao and colleagues show that the effect of Pcl1 knockdown on recruitment of Suz12 
to the promoter of the HOXA10 gene is only very mild (Cao et al., 2008). Both these 
studies suggest that Pcl1 affects Ezh2 activity and Cao and colleagues show that Pcl1 
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stimulates the activity of the PRC2 complex by increasing the maximal velocity 
(Vmax) and the Michaelis-Menten constant (Km) of the methyltransferase reaction 
promoted by the Ezh2 containing complex (Cao et al., 2008).  
 
In mouse ES cells and early embryos, Pcl2 appears to be the key homologue of 
Drosophila Pcl. Unlike the reports described above, the knockdown of Pcl2 in mouse 
ES cells does not result in a global decrease of the HMTase activity of PRC2 or the 
deregulation of PcG target gene expression. This can have different explanations. 
Pcl2 might not play the exact same role as Pcl in Drosophila or hPHF1 in human cells. 
In mouse ES cells, Pcl2 could simply be involved in targeting a specific subset of PcG 
target genes and/or increasing the efficient recruitment of PRC2 to its targets. 
Another explanation comes from the observation that in vertebrates, Pcl 
homologues are expressed very dynamically throughout development and seem to 
have tissue/cell lineage specific roles. This observation suggests that PRC2 is not a 
single core complex and partner proteins could confer different functions and 
specificities to various PcG complexes. According to this idea, Pcl2 could be part of a 
PRC2 sub-complex and its depletion may be compensated by other PRC2 complexes. 
Finally, it is important to notice that the ES cell model used is not a knockout. These 
cells still express low levels of Pcl2 protein which may be able to maintain a basal 
level of function, implying that the HMTase activity of PRC2 may not be significantly 
affected. To clarify this, it will be important to derive and study ES cells null for Pcl2. 
Moreover, the combination of a Pcl2 knockout system with knockdown of the other 
Pcl homologues in ES cells will definitely exclude the possibility of functional 
redundancy by the Pcl homologues Pcl1 and Pcl3.  
 
The structural characteristics of the Pcl2 protein, containing PHD and Tudor domains, 
which are usually involved in protein binding and interaction with methylated 
histones and RNA, strongly suggests that Pcl2 may act as a component in targeting a 
particular chromatin conformation and thus recruiting PRC2 to specific locations of 
the genome. As PRC2 recruitment to the Xi is known to be Xist dependent 
(Kohlmaier et al., 2004), Pcl2 could theoretically act as an anchoring component for 
PRC2 by binding directly to Xist RNA or any other chromatin mark present on the Xi. 
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Functional studies of the PHD fingers and Tudor domains of Pcl2 will help to clarify 
the importance of these motifs in PRC2 recruitment and in localisation to the Xi.  
 
As a conclusion, Pcl2 plays an important function in ES cells. The data obtained 
suggest that Pcl2 forms a sub-complex with PRC2 which could undertake multiple 
functions distinct from the core PRC2 complex. These functions may involve the 
recruitment and stabilisation of the Pcl2-PRC2 sub-complex at a subset or all PRC2 
target genes. Further studies are needed to clarify the mechanism of action of Pcl2 
and to understand its importance in ES cells. Genome wide analyses of gene 
expression in Pcl2 knockdown ES cells and analyses of Pcl2-FLAG distribution in PGK 
Pcl2-FLAG ES cells will give a better idea on the identity of the genes targeted by 
Pcl2-PRC2 and on the differentiation pathways in which they are involved. These 
analyses will moreover help to determine if PRC2 recruitment is dependent upon 
Pcl2 at all its targets. Another important aspect to analyse is the effect of the lack of 
Pcl2 on the distribution of H3K27me3 and PRC2 components across some PcG target 
genes. Given the reduction, although modest, on the levels of H3K27me3 and the 
decrease of PRC2 recruitment at promoters of PcG target genes, it would be 
interesting to determine if this local reduction could be explained by a redistribution 
of the trimethylated H3K27 across certain loci.  
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Chapter 6. Biochemical characterisation of      
Pcl2-PRC2 in mouse ES cells 
 
6.1. Introduction 
6.1.1. Drosophila melanogaster Pcl complexes 
Drosophila Pcl was shown to be part of two distinct protein complexes; PRC2 
(Nekrasov et al., 2007; O'Connell et al., 2001; Tie et al., 2003) and a novel complex 
which is present at larval stages in Drosophila (Savla et al., 2008). In Drosophila 
embryos, Pcl is part of a 1 MDa complex with core PRC2 components and the HDAC1 
homologue, RPD3 (Tie et al., 2003). However, the recent biochemical purification of 
Pcl-PRC2 failed to detect RPD3 in this complex. Additionally, Pcl was shown to be 
essential to maximize PRC2 catalytic activity at PcG target genes (Nekrasov et al., 
2007). Nekrasov and colleagues reported that Pcl interacts exclusively with PRC2 
core components and that it constitutes an E(z) sub-stoichiometric complex. 
Interestingly, in Drosophila larvae, Pcl seems to function as a component of an 
additional distinct complex which acts upstream of PRC2 and PRC1 and mediates 
their binding to different chromosomal locations (Savla et al., 2008). This suggests 
that Pcl plays distinct roles in regulating PcG proteins and the expression of PcG 
targets by interacting with different protein complexes depending on the 
developmental stage.  
 
6.1.2. Mammalian Polycomblike containing complexes 
In mammals, hPHFH1 (Pcl1) has recently been co-purified independently by two 
groups within a PRC2 sub-complex from HeLa cell nuclear extracts (Cao et al., 2008; 
Sarma et al., 2008). This complex includes the core PRC2 proteins and no other 
candidate interactors, and has an approximate size of around 600 kDa, similar to the 
size of the main PRC2 complex identified in mammalian cells. Although being part of 
a sub-complex that is less abundant than the core PRC2 complex, Pcl1 was shown to 
enhance the catalytic activity of PRC2 and mediate repression of PcG target genes. 
Interestingly, Pcl1 was also found to be part of a protein complex that includes PRC2 
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proteins together with proteins involved in the response to DNA double-strand 
breaks, such as Rad50, DHX9, SMC1 and p53. Pcl1 was shown to be an important 
component of the double-strand DNA damage response, when incorporated into this 
newly described complex (Hong et al., 2008).  
 
Studies from our laboratory demonstrated that H3K27me3 HMT activity present in 
ES cells purifies as a major peak at 550 kDa and a minor peak at 1 MDa. Western 
analysis indicated that the Pcl homologue, Pcl2 is present in both peaks (Tanja 
Preissner, personal communication). The relationship between these two complexes 
is unclear. It is possible that the 1 MDa complex has additional subunits that confer it 
different functions. For example, Pcl2-PRC2 complexes in ES cells might associate 
with a histone deacetylase similarly to what was reported in Drosophila. It is also 
possible that, similar to what was found in Drosophila, these apparently distinct 
complexes are involved in different enzymatic processes. Pcl-PRC2 complexes were 
recently shown to be essential for high levels of H3K27me3 while core PRC2 
complexes were shown to be essential for H3K27me2 and -me1 activity (Nekrasov et 
al., 2007).  
 
To gain a better insight into the Pcl2-PRC2 complex and its function, I have used an 
affinity chromatography approach to biochemically purify Pcl2 complexes from 
mouse ES cells. 
  
6.2. Results 
6.2.1. Pcl2 stability is affected in other PRC2 mutants 
There are multiple Drosophila Pcl mammalian homologues which are differentially 
expressed in various tissues. Pcl2 is the Pcl homologue most highly expressed in ES 
cells. Pcl2 was shown to fractionate with PRC2 and to be present in fractions 
corresponding to 550-600 kDa and 1 MDa complexes with H3K27me3 activity (Tanja 
Preissner and Neil Brockdorff, personal communication). By comparing expression 
levels of the Pcl2 gene (Mtf2) in mouse ES cells and mouse fibroblasts, it was 
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observed that Pcl2 is expressed approximately 9 fold higher in ES cells when 
compared to a differentiated fibroblast cell line (MP cells) (Figure 6.1a).  
 
 
Figure 6.1. The Pcl2 gene is expressed at higher levels in ES cells than in fibroblast cells and Pcl2 
stability is affected in other PRC2 mutants. (a) Expression of two housekeeping genes (Hmbs and Idh) 
and the Pcl2 gene were compared by qRT-PCR in PGK12.1 ES cells and MP fibroblast cells. RT reactions 
were performed starting with the same quantity of total RNA for both cell lines, accurately measured 
by spectrophotometry. For each gene analysed, the expression level is arbitrarily set at 1 for the 
fibroblast cell line. Expression levels in ES cells are represented relative to MP cells. Graphs show the 
mean +/- standard deviation of the mean for each gene (n=3). (b) Nuclear extracts were prepared 
from various wild type (wt) and PRC2 mutant ES cell lines (see Materials and Methods, section 
2.1.1.1), separated by SDS-PAGE and analysed by western blotting using antibodies raised against 
LaminB and the PRC2 components Ezh2, Eed, Suz12 and Pcl2. The monoclonal Eed antibody 
reproducibly detects several bands corresponding to different isoforms of the protein (Kuzmichev et 
al., 2004). (c) Similarly, nuclear extracts were prepared from two Pcl2 knockdown clones (sh1 and sh2) 
and a control cell line. Levels of Suz12, Eed, Ezh2, Ring1B and Pcl2 were analysed by western blot. 
LaminB is used as a loading control. Molecular weight markers are indicated (kDa). 
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Interestingly, amongst PRC2 components Pcl2 seems to be one of the genes showing 
the biggest difference in expression levels between these two cell types (see section 
3.2.1). This strongly suggests that Pcl2 plays an important role in ES cells.  
 
Previous reports suggest that failure to form a PRC2 complex results in the 
destabilisation of individual PRC2 components (Montgomery et al., 2005; Pasini et 
al., 2004; Schoeftner et al., 2006). In order to determine whether Pcl2 can exist 
independently of a functional PRC2 complex, ES cells mutant for all the core PRC2 
components Eed, Suz12 and Ezh2 were analysed by western blotting. The data 
obtained showed that ES cells lacking any of the core PRC2 components strongly 
destabilises the other PRC2 core components (Figure 6.1b). Similarly, Pcl2 stability 
was markedly affected in all PRC2 ES cell mutants analysed. This observation 
suggests that in ES cells, the association of Pcl2 with the PRC2 complex is important 
for stability of the protein and is consistent with the idea that a significant 
proportion of Pcl2 is associated with the PRC2 complex. 
 
To determine if Pcl2 is important for stabilising the PRC2 complex, the impact of Pcl2 
depletion on PRC2 stability was evaluated. In two different Pcl2 knockdown ES 
clones where the Pcl2 protein is efficiently depleted, the levels of the PRC2 core 
components and Ring1B were analysed by western blot (Figure 6.1c). Unlike what 
was observed in ES cells mutant for any of the core PRC2 components, the 
knockdown of Pcl2 did not lead to a significant destabilisation of the core PRC2 
components analysed.  
 
6.2.2. Cloning and characterisation of Pcl2-FLAG ES cell lines 
The Drosophila Pcl protein was shown to directly interact with E(z) and this 
interaction was shown to be maintained by the human Pcl homologue, hPHF1, that 
binds to Ezh2 through its PHD fingers (O'Connell et al., 2001). To determine whether 
Pcl2 interacts with other PRC2 components in ES cells and to characterise the 
putative Pcl2 containing complex, full length Pcl2 cDNA was cloned in frame with 
either a double FLAG tag or a tandem affinity purification (TAP) tag in two different 
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mammalian expression vectors (see Materials and Methods, section 2.10.1). The 
successful use of expression vectors in ES cells depends on the promoters used for 
expression. In many instances, promoters can be inefficient at driving the expression 
of the cloned cDNA or will get silenced during cell passaging or ES cell differentiation. 
In order to circumvent this issue, Pcl2 was cloned in frame with a double FLAG tag 
under the control of the Chicken Beta Actin (CBA) promoter (pCBA-2xFLAG) and in 
frame with a TAP tag under the control of the human Cytomegalovirus (CMV) 
promoter (pGM-TAP). The CMV promoter is believed to be inefficient at driving 
expression of recombinant protein in ES cells but is known to be very efficient in 
other cell types, for example human 293T cells. Transient expression of both these 
vectors containing full length Pcl2 in 293T human cells has confirmed that the tagged 
proteins can be detected by western blotting using an antibody raised against the 
FLAG tag (M2 from Sigma) or an antibody directed against the calmodulin binding 
peptide of the TAP tag (Figure 6.2a and b). Probing the membrane with an antibody 
specific for Pcl2 detected the Pcl2 tagged protein, confirming that the two 
expression vectors are functional (Figure 6.2c).  
 
To determine the efficiency of expression of the tagged protein in ES cells, PGK12.1 
ES cells were transfected with the pCBA-Pcl2-2xFLAG vector and a control vector 
expressing solely the FLAG tag. ES cells that were successfully transfected were 
selected by culture in the presence of the antibiotic geneticin (G418) for 
approximately 2 weeks to allow for selection of individual clones and establishment 
of stable cell lines expressing the full-length FLAG-tagged Pcl2. A pool of transiently 
transfected cells was analysed to check expression of Pcl2-FLAG by western blotting. 
Using the anti-FLAG antibody the western blot analysis showed that a band 
migrating at around 70 kDa was present only in protein extracts from ES cells 
transfected with the Pcl2-FLAG vector (Figure 6.2d). This band migrates slightly faster 
than a non-specific band which migrates around 75 kDa present in all cell extracts. 
The 70 kDa band corresponds to the predicted size for Pcl2-FLAG as the full length 
Pcl2 protein has an expected size of 68 kDa and the molecular weight of the double 
FLAG tag is around 2 kDa. Western blot analysis using the FLAG antibody on pooled 
ES cells transfected with pCBA-Pcl2-2xFLAG and selected for over a week indicated 
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that positively transfected cells are selected efficiently (Figure 6.2e). Using an affinity 
antibody to Pcl2 it was not possible to easily distinguish endogenous from 
recombinant Pcl2 proteins in whole cell extracts (Figure 6.2f).  
 
 
Figure 6.2. Recombinant Pcl2 protein is stably expressed in 293T and ES cells. Whole cell extracts 
were prepared from 293T untransfected cells and 48h after transfection with pCBA-Pcl2-2xFLAG 
(293T Pcl2-FLAG) or pGM-Pcl2-TAP (293T Pcl2-TAP). Extracts were separated by SDS-PAGE and 
analysed by western-blotting using anti-CBP (a), anti-FLAG (b) or anti-Pcl2 (c) antibodies. Note that 
the band detected by the anti-FLAG antibody in 293T Pcl2-TAP cells is due to the very high expression 
of Pcl2-TAP in 293T cells. Similarly, PGK12.1 ES cells were transfected with pCBA-2xFLAG (PGK FLAG) 
or pCBA-Pcl2-2xFLAG (PGK Pcl2-FLAG) constructs. Cells were analysed after transient (48h) 
transfection and after 8 and 11 days of antibiotic (G418) selection. Whole cell extracts were prepared 
and analysed by western blotting for untransfected and transiently transfected ES cells using anti-
FLAG antibody (d); for transfected cells, selected for 8 and 11 days using anti-FLAG or anti-Pcl2 
antibodies (e, f). Recombinant Pcl2 is indicated by pointed arrows. Molecular weight markers are 
indicated on the left of each blot (kDa).  
 
 
To establish a stable cell line expressing the full length FLAG-tagged Pcl2, 96 
individual ES colonies were picked and analysed. Protein extracts from all clones 
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were analysed by western blotting to verify the presence of the FLAG tagged protein. 
Extracts were separated by SDS-PAGE, blotted onto PVDF membranes, and probed 
with M2 anti-FLAG antibody. The M2 anti-FLAG antibody recognises a non-specific 
band migrating at 75 kDa which is difficult to resolve from the specific 70 kDa band 
corresponding to Pcl2-FLAG. As a consequence, all clones where two bands could be 
resolved were selected. Additionally, where non-specific and specific bands could 
not be resolved, clones were selected based on the intensity of the band migrating 
at around 75 kDa. The results are shown in Figure 6.3a and selected clones are 
indicated with an asterisk. These clones were grown without selection and the 
expression of Pcl2-FLAG was assessed again to check for stability and levels of Pcl2-
FLAG expression (Figure 6.3b). From all the clones analysed, two clones were 
selected for subsequent analysis, clones B2 and E1, both of which showed bands 
corresponding to the Pcl2-FLAG recombinant protein. A more careful analysis of 
these two clones confirmed that both clones express levels of Pcl2-FLAG protein 
similar to endogenous levels that can be readily detected by analysing nuclear 
extracts for each clone. The Pcl2 antibody, which can detect the endogenous and 
recombinant Pcl2, revealed in nuclear extracts of clones B2 and E1 the existence of 
an additional band just above the 68 kDa Pcl2 band corresponding to the 
recombinant Pcl2-FLAG protein (Figure 6.3c).  
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Figure 6.3. Selection of ES cell lines showing stable expression of Pcl2-FLAG. (a) Whole cell extracts 
were prepared from 96 PGK Pcl2-FLAG clones selected with antibiotic and individually grown. Extracts 
were analysed by western blotting using the anti-FLAG antibody. Clones indicated with an asterisk 
were selected for subsequent analysis. (b) Clones selected in 6.3.a were grown without any selective 
drug and re-analysed by western blot to confirm stable expression of Pcl2-FLAG. Clones B2 and E1, 
indicated with an asterisk, were selected and analysed after a few passages for expression of Pcl2-
FLAG, using anti-FLAG or anti-Pcl2 antibodies (c). Recombinant Pcl2 is indicated by pointed arrows. 
Molecular weight markers are indicated on the left of each blot (kDa). 
 
 
To confirm that the recombinant Pcl2-FLAG behaves like the endogenous Pcl2 
protein, PGK Pcl2-FLAG and PGK FLAG cells were fractionated to separate proteins 
according to their cellular localisation (Figure 6.4a). The endogenous levels of Pcl2 
were analysed using an anti-Pcl2 antibody. Endogenous Pcl2 can be found in all the 
cellular fractions but is mostly found in the high salt nuclear fraction (S3). Using the 
anti-FLAG antibody, the non-specific band of 75 kDa can clearly be seen in the 
cytoplasmic S1 fraction of the PGK FLAG ES cells and PGK Pcl2-FLAG ES cells. 
Additionally, in PGK Pcl2-FLAG ES cells, a second band corresponding to the 70 kDa 
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band of Pcl2-FLAG could be detected in S1. Pcl2-FLAG is detected at very low levels 
in the low salt nuclear fraction S2 and is mainly detected in fraction S3. Some of the 
Pcl2-FLAG is also present in the chromatin bound fraction (C). These data indicate 
that the distribution of Pcl2-FLAG mimics that of endogenous Pcl2. Moreover, to 
verify whether the stability of expression was maintained in differentiating ES cells, 
PGK Pcl2-FLAG ES cells were induced to differentiate for 3 days and the expression of 
the protein was analysed by western blot. The results shown in Figure 6.4b indicate 
that expression of Pcl2-FLAG is maintained in both ES and differentiated cells in both 
clones analysed. 
 
 
 
Figure 6.4. Pcl2-FLAG is mainly found in the high salt nuclear fraction and remains stably expressed 
upon ES cell differentiation. (a) Cell fractionation analysis of PGK FLAG and PGK Pcl2-FLAG ES cells 
after two weeks of drug selection. Fractions were prepared as described in Materials and Methods 
(section 2.8.4), separated by SDS-PAGE, western blotted and probed with anti-FLAG or anti-Pcl2 
antibodies. S1 corresponds to cytoplasmic fraction, S2 to low salt nuclear extract, S3 to high salt 
nuclear extract and C to chromatin bound fraction. (b) PGK12.1 cells and ES cell clones B2 and E1 
were differentiated for 3 days. Whole cell extracts were then analysed for Pcl2-FLAG expression by 
western blot using anti-FLAG antibody. Recombinant Pcl2 is indicated by pointed arrows. Molecular 
weight markers are indicated (kDa). 
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6.2.3. Pcl2-FLAG co-immunoprecipitates with PRC2 core components 
The biochemical characterisation of Pcl2-FLAG complexes was carried out using PGK 
Pcl2-FLAG ES cell lines B2 and E1 by immunoprecipitation of Pcl2-FLAG using an anti-
FLAG antibody resin. Nuclear extracts of clones B2 and E1 were incubated with the 
anti-FLAG antibody covalently bound to agarose beads for 3-4 hours, followed by 
stringent washes to eliminate non-specific proteins. The Pcl2-FLAG complexes were 
eluted in 4 independent fractions, by the addition of FLAG tri-peptide which 
competes for binding of the Pcl2-FLAG to the anti-FLAG antibody. The majority of the 
Pcl2-FLAG protein was efficiently eluted in the first two fractions (E1 and E2) for 
clone E1 and B2, as can be seen on the western blot analysis of all fractions in Figure 
6.5a. Moreover, the flow through (Ft) fraction was depleted of Pcl2-FLAG indicating 
that the majority of the Pcl2-FLAG was bound to the beads. A residual amount of 
Pcl2-FLAG remained on the beads after elution, but relative to the eluted Pcl2-FLAG 
this proportion is minimal (Figure 6.5a). Using this technique, it was possible to 
efficiently immunoprecipitate and purify Pcl2-FLAG from the nuclear extracts of ES 
clones B2 and E1. The immunoprecipitated elutions were then used to characterise 
Pcl2-FLAG containing complexes.  
 
To confirm that PRC2 core components interact with Pcl2 in ES cells, the eluted 
fractions were used to detect the co-immunoprecipitation of Ezh2, Suz12 and Eed in 
two independent purification experiments (Figure 6.5b). As a control, an antibody to 
the YY1 protein, not known to interact with PRC2, was used. Additionally, 
untransfected ES cells (PGK12.1) were used as a negative control. The core proteins 
Ezh2 and Suz12 were found to co-immunoprecipitate with Pcl2-FLAG in the IP 
fractions of clone E1 in both experiments, although no depletion was observed in the 
flow through. Endogenous Pcl2 was also detected in the immunoprecipitate (Figure 
6.5b). As expected, the YY1 protein did not co-immunoprecipitate with Pcl2-FLAG, 
suggesting that the interactions observed are specific. Moreover, no proteins were 
detected in the corresponding IP fraction from the control ES cell line. Interestingly, 
although Eed was found to co-precipitate with Pcl2-FLAG, the levels of Eed protein 
detected appeared to be lower than the levels of Suz12 and Ezh2. On the IP fraction 
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for clone E1, only one band for Eed was observed contrasting with the multiple 
bands detected in the input (Figure 6.5b).  
 
The observation that neither PRC2 components analysed are depleted in the flow 
through fraction strongly suggests that the Pcl2-PRC2 complex represents a sub-
stoichiometric PRC2 complex that includes all PRC2 core components. The core PRC2 
components which are incorporated into this complex may include specific isoforms 
or modified PcG proteins as suggested by the Eed western blot analysis, as well as 
other proteins which can determine and regulate the function of the Pcl2-PRC2 
complex.  
 
 
 
 
 
 
 
 
 
154 
 
 
 
Figure 6.5. PRC2 core components co-immunoprecipitate with Pcl2-FLAG. (a) Nuclear extracts from 
PGK12.1 ES cells and PGK Pcl2-FLAG clones B2 and E1 were used for FLAG immunoprecipitation. Input 
fraction (I) corresponding to the initial nuclear extract, flow through (Ft), elution fractions (E1 to E4) 
and beads from FLAG purification were analysed by western blot using anti-FLAG antibody. (b) Input 
(I), flow through (Ft) and elution fraction E1 (IP) of two independent purification (IP1 and IP2) for 
clone E1 and PGK12.1 control cells were analysed by western blot using various antibody to assess for 
co-immunoprecipitation with Pcl2-FLAG (anti-Pcl2, anti-Ezh2, anti-Suz12, anti-Eed and anti-YY1). 
Molecular weight markers are indicated (kDa).  
 
 
6.2.4. Mass spectrometry of purified Pcl2-FLAG identifies novel 
candidate interactors 
The biochemically purified Pcl2-FLAG eluates were processed for nanoflow liquid 
chromatography-tandem mass spectrometry (Nano-LC-MS/MS) analysis to identify 
specific Pcl2-FLAG interactors. Database searches to assign proteins to the found 
peptide fragmentation spectra were performed using Mascot score. The criteria to 
select possible interactors were based on the Mascot score and number of unique 
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peptides detected for each protein identified. Mass spectrometry of three 
independent purifications revealed that all PRC2 core components, Ezh2, Suz12 and 
Eed, were found in purified fractions together with Pcl2 (Table 6.1). The presence of 
Eed protein is notable as western blot analysis indicated only low levels of Eed are 
present (Figure 6.5). Additionally, RBBP7 (Rbap46), also described as a core 
component of the PRC2 complex (Kuzmichev et al., 2002), was found in the 
immunoprecipitated fractions from PGK Pcl2-FLAG CL E1 Exp.1 but not in the mass 
spectrometry analysis of both immunoprecipitations from Exp.2 (Table 6.1). Other 
candidate interactor proteins found in the purified IP fractions from Pcl2-FLAG ES 
cells but not in the PGK12.1 control cell line or other control cell lines (Raymond 
Poot, personal communication) were also found. These generally had lower Mascot 
scores and fewer unique peptides. Amongst the candidates that fit this criteria is the 
recombining binding protein suppressor of hairless isoform 1 (Rbpj), a transducer of 
the Notch signalling pathway. Ring1B (Rnf2) was also found as a candidate 
interactor, as well as Pbrm1 (Baf180), a component of the SWI/SNF chromatin 
remodelling complex (Table 6.1). Additionally, several hnRNP (heterogeneous 
ribonucleoprotein) were identified in the different mass spectrometry experiments. 
hnRNP proteins are common contaminants in mass spectrometry analysis but the 
possible link between Pcl2-PRC2 and RNA means that they should probably not be 
disregarded at this stage. 
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Table 6.1. Mass spectrometry analysis of Pcl2-FLAG immunoprecipitates. For three independent 
FLAG purification experiment (CLE1 Exp1, CLE1 Exp2 and CLB2 Exp2) and PGK12.1 control cell line, 
elution 1 and 2 following FLAG IP were combined, concentrated by TCA precipitation and separated 
by SDS-PAGE. Gel lanes were cut and subjected to in-gel digestion with trypsin for mass spectrometry 
analysis. Database searches to assign proteins to the found peptides were performed using Mascot. A 
list of proteins characterised by a Mascot score above 50 and present in at least 2 independent IP 
experiment, but not in the PGK12.1 control cell line is shown. Note that Rbbp7 is only present in one 
mass spectrometry assay, although being identified as a PRC2 core complex (Kuzmichev et al., 2002).  
 
 
6.2.5. Pcl2-PRC2 complex has an approximate size of 600 kDa  
To further characterise the PRC2-like complex containing Pcl2, the Pcl2-FLAG purified 
complex was analysed by size exclusion chromatography on a Superose6 column. 
The Pcl2-FLAG protein was shown to fractionate with the PRC2 complex core 
proteins Ezh2 and Suz12 at approximately 600 kDa (Figure 6.6), corresponding 
approximately to the described mass for the PRC2 complex. This data together with 
the observation that Pcl2 is destabilised in the absence of a functional PRC2 
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complex, suggests that Pcl2 is in fact a bona fide component of a sub-complex of 
PRC2 that contains all the PRC2 core components. 
 
 
 
Figure 6.6. Superose 6 size exclusion chromatography analysis of Pcl2-PRC2 complex following FLAG 
immunoprecipitation. Nuclear extracts from PGK Pcl2-FLAG clone E1 were used for FLAG 
immunoprecipitation. Input (I), flow through (Ft) and a single elution fraction (IP) were analysed prior 
to gel filtration by western blot with anti-FLAG, anti-Ezh2 and anti-Suz12 antibodies to confirm 
efficient pull-down (left). IP fraction was loaded on a Superose 6 SMART column. Collected fractions 
(1 to 26) were analysed by western blotting with antibodies raised against FLAG, Ezh2 and Suz12. The 
molecular weights of marker proteins used to calibrate the column and the void volume are indicated 
at the top (right).  
 
 
6.3. Discussion 
The interaction of Pcl with components of the PRC2 complex, namely E(z), was first 
shown in Drosophila using a yeast two-hybrid screen (O'Connell et al., 2001). 
Subsequent studies revealed that in Drosophila embryo extracts, Pcl is present in a 1 
MDa protein complex together with core components of the ESC-E(Z) complex and a 
histone deacetylase, RPD3 (Tie et al., 2003). Recently, a Pcl complex was 
biochemically purified from Drosophila embryonic extracts and shown to form a 
distinct PRC2 sub-complex which has a critical role in H3K27 trimethylation at PcG 
target genes (Nekrasov et al., 2007). The results presented in this chapter 
demonstrate that Pcl2, one of the mouse homologues of Drosophila Pcl, is highly 
expressed in ES cells and requires the presence of other PRC2 core components for 
the stability of the Pcl2 protein. The use of a full length FLAG-tagged Pcl2 allowed the 
isolation and identification of a Pcl2-PRC2 sub-complex present in ES cells. This 
complex has similar properties to Pcl-PRC2 complexes in Drosophila and Pcl1-PRC2 
complexes in HeLa cells. It includes all core PRC2 components Ezh2, Suz12, Eed and 
has a native mass of around 600 kDa. 
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The Pcl2-PRC2 complex purified in this chapter is distinct from the larger 1 MDa 
PRC2 complex detected in Drosophila embryo extracts. This could be due to the fact 
that the Pcl2-PRC2 complex is missing some weakly associated components that 
dissociated from the complex during biochemical purification. As an example, RPD3 
was not detected in any of the mass spectrometry experiments performed. Likewise, 
the recent biochemical purification of Pcl from Drosophila embryos failed to detect 
RPD3 (Nekrasov et al., 2007). Moreover, the amino-terminal region of Drosophila 
ESC (Eed homologue) was shown to be phosphorylated and this mediates the 
dimerisation of PRC2 complexes (Tie et al., 2005). The treatment of native ESC 
complexes with alkaline phosphatase leads to the disruption of the 1 MDa ESC/E(z) 
complex but has no effect on the 600 kDa ESC/E(z) complex, suggesting that the 1 
MDa complex found in Drosophila embryos could be a multimeric complex (Tie et al., 
2005). This could account for the size difference observed between the 1 MDa 
complex seen in Drosophila and also by size fractionation of ES cell H3K27me3 
activity (Tanja Preissner and Neil Brockdorff, personal communication) and the 600 
kDa complex described here.  
 
The data presented in this chapter and the recent biochemical purifications from 
Drosophila embryos (Nekrasov et al., 2007) and human HeLa cells (Cao et al., 2008; 
Sarma et al., 2008), indicate that Pcl associates at sub-stoichiometric levels with the 
PRC2 complex forming a unique PRC2 sub-complex. The biochemical purification of 
Eed-FLAG PRC2 complexes from mouse ES cells confirmed that Pcl2 is only present at 
sub-stoichiometric levels, being part of a PRC2 sub-complex (Stephan Sauer, 
personal communication). The Pcl2-PRC2 sub-complex may form a separate 
complex, with specific functions and gene targets which are distinct from the major 
PRC2 complex. Otherwise, Pcl2 could be in a dynamic equilibrium with the rest of 
PRC2, binding less stably to the core PRC2 proteins and acting mainly as an accessory 
protein. Further studies will be needed to explore this hypothesis.  
 
The biochemical purification of Pcl2-FLAG from mouse ES cells identified Pcl2 in a 
PRC2 complex with the core proteins Ezh2, Suz12 and Eed. In mouse ES cells there 
are four different isoforms of Eed which arise from a single mRNA with different 
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translational start sites (Kuzmichev et al., 2004). These different isoforms were 
shown to be part of different Ezh2 containing complexes, PRC2, PRC3 and PRC4 and 
seem to be regulated throughout development in a cell specific manner conferring 
an increased capacity to PRC2/3/4 complexes to regulate gene expression 
(Kuzmichev et al., 2004; Kuzmichev et al., 2005). It has been suggested that these 
different Eed isoforms affect the substrate specificity of the Ezh2 HMT activity 
towards different histone residues, but this data was contradicted by a recent report 
which shows that different Eed isoforms do not alter the substrate specificity of 
reconstituted PRC2 complexes (Martin et al., 2006). Interestingly, the levels of the 
Eed protein purified were very low and only the most highly expressed isoform was 
detected after purification of the Pcl2-PRC2 complex in mouse ES cells. This result 
can have different interpretations: Pcl2 is present in an Ezh2 containing complex 
together with only one particular Eed isoform; or the Eed protein present in the Pcl2-
PRC2 complex is post-translationally modified, preventing its detection by the 
monoclonal antibody used.  
 
Although the 600 kDa Pcl2-PRC2 complex can be accounted by the presence of core 
PRC2 proteins (550 kDa) together with Pcl2, mass spectrometry did identify some 
additional proteins present, albeit with relatively low Mascot scores, in Pcl2-FLAG ES 
cell lines but not in control ES cell lines. Some of these potential interactors were 
present in independent purifications, notably Rbpj, Ring1B (Rnf2), BAF180 (Pbrm1) 
and several hnRNP proteins. The identification of these candidate interactors 
together with Pcl2-FLAG suggests a link between Pcl2 and PRC1 (via Ring1B), 
SWI/SNF chromatin remodelling complexes and the RNA processing machinery. 
Whether these proteins are true links or just the result of an artefact in the 
methodology used will have to be confirmed. The transcription factor Rbpj was one 
of the candidate interactors identified with the highest Mascot score and number of 
unique peptides (Table 6.1). Rbpj is a transducer of the Notch signalling pathway that 
has been implicated in maintaining neural progenitor cells, in B and T cell 
development, amongst other processes (Hori et al., 2008; Robert-Moreno et al., 
2005). This protein was shown to act essentially in DNA binding complexes, by 
activating or repressing genes downstream of a Notch signalling cascade. The 
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possible link between Pcl2-PRC2 complexes and Rbpj would confer to this complex 
the capability of specifically targeting genes involved in regulation of certain 
differentiation pathways, thus refining the mechanisms of PcG control in ES cell 
pluripotency and lineage determination. This would also suggest a link between PcG 
proteins and Notch signalling.  
 
To conclude, the collective analysis of my data and recent publications indicate that 
Polycomblike proteins regulate PRC2 function in multiple ways. Reports have shown 
that Pcl increases the catalytic activity of PRC2 and my work suggests a role in the 
recruitment of PRC2 to target regions of the genome. The recent discovery of the 
association of Pcl with different proteins, namely proteins involved in the DNA 
double-strand break response and Notch signalling, suggest that the role of Pcl might 
be more diverse than was initially thought.  
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Chapter 7. General discussion 
 
7.1. Regulation of pluripotency by Polycomb group proteins 
Pluripotency is defined as the ability of an individual cell to differentiate into all cell 
types of an organism, including the extraembryonic lineages, without the self-
organising ability to generate a whole organism (Niwa, 2007a). The mechanisms 
involved in the maintenance of pluripotency are diverse and recently two different 
models have been proposed. The first model describes an integrated network of 
transcription factors, including Nanog, Oct3/4 and Sox2, which bind to regions within 
the genome and maintain the correct gene expression profile of stem cells. This 
regulation of gene expression profiles is key for maintaining cells in a pluripotent 
state (Chamberlain et al., 2008; Niwa, 2007a; Smith, 2005). The second model 
describes the role of epigenetic mechanisms for example histone modifications such 
as H3K27me3 and H2Aub1, which maintain heritable gene expression profiles of cells 
and also play a key role in maintaining cells in a pluripotent state (Boyer et al., 
2006a; Pietersen and van Lohuizen, 2008). In this study I have explored the 
involvement of epigenetic mechanisms, more precisely PcG proteins, in the 
maintenance of pluripotency. My data shows that in ES cells, PcG proteins are under 
the positive transcriptional regulation of key transcription factors Oct4 and Sox2 
which promote high levels of PRC2 expression in ES cells. The transcription 
regulation or PRC2 genes is relaxed during ES cell differentiation. The removal of any 
of these key pluripotency transcriptional regulators from ES cells results in a rapid 
reduction in levels of the PcG genes analysed.  From the data presented in this thesis 
and other studies it is becoming evident that both transcriptional networks and 
epigenetic mechanisms contribute to a complex and integrated mechanism to 
regulate pluripotency.  
 
It is now believed that the role of PcG proteins in maintenance of pluripotency 
inferred from early studies was overestimated. Undeniably, ES cells lacking core 
PRC2 components were shown to mis-express several lineage associated genes 
(Azuara et al., 2006; Boyer et al., 2006b; Lee et al., 2006). However, the mis-
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expression of these lineage associated genes does not have an effect on the ability of 
the PRC2 deficient cells to self-renew and to be maintained in an undifferentiated 
state in culture (Montgomery et al., 2005; Pasini et al., 2007). These latter studies 
concluded that PRC2 is not essential for the maintenance of pluripotency. 
Interestingly, O’Carroll and colleagues were unable to derive Ezh2 deficient ES cells 
leading to the suggestion that Ezh2 is essential for pluripotency (O'Carroll et al., 
2001). More recent studies using ES cells where Ezh2 can be conditionally deleted 
show that ES cells can be maintained in an undifferentiated state in the absence of 
Ezh2 (Stephan Sauer and Amanda Fisher, personal communication). Taken together, 
this suggests that Ezh2 may be essential for ES cell derivation but not for 
maintenance of pluripotency and self renewal. Nevertheless, the tendency of Eed 
deficient ES cells to differentiate in culture observed in this work and in previous 
studies (Azuara et al., 2006; Boyer et al., 2006b) is probably linked to the aberrant 
expression of different developmentally regulated genes and it can be concluded 
that PRC2 helps to stabilise the pluripotent state in ES cells. Conversely, ES cells 
deficient for the PRC2 component Suz12 were shown to self-renew but are unable to 
properly differentiate in vitro, a consequence of a failure to silence pluripotency 
transcription factors after induction of differentiation (Pasini et al., 2007). This 
contrasts with Eed deficient ES cells and may indicate that Suz12 is present in an 
additional complex unrelated to PRC2. These findings suggest that ES cells are a 
unique entity where key pluripotency transcription factors, which act positively and 
dominantly to influence self-renewal co-exist with factors that are involved in ES cell 
differentiation. Thus it is plausible to suggest that a functional PRC2 complex acts by 
conferring stability to the pluripotent state by preventing an inappropriate response 
to different differentiation cues presented to ES cells (Figure 7.1).  
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Figure 7.1. A model for the role of PcG proteins in stabilisation of pluripotency. Key pluripotency 
factors (Oct4, Sox2, Nanog, Stat3) in ES cells are involved in direct transcriptional control of target 
genes, as represented on the upper part of the figure. This control is essential and sufficient to 
activate downstream effectors which will promote ES cell proliferation and self-renewal.  Pluripotency 
factors additionally directly or indirectly control the expression of epigenetic regulators, such as PRC2 
proteins. These epigenetic factors are thought to be involved in the stabilisation of expression 
patterns dominantly controlled by the pluripotency transcription factors (bottom part of the figure). 
Both epigenetic and pluripotency factors cooperate to prevent ES cells to respond inappropriately to 
differentiation cues.   
 
 
It has been suggested that PRC2 and PRC1 function in a hierarchical manner with the 
PRC2 complex initially targeted to specific regions within the genome, promoting the 
tri-methylation of histone H3K27. The H3K27me3 histone modification then provides 
a specific binding site for the chromodomain protein Pc, a core component of the 
PRC1 complex (Fischle et al., 2003; Min et al., 2003). PRC1 is therefore suggested to 
function as the effector of PcG mediated repression. A simplistic interpretation of 
this model predicts that the disruption of PRC1 and PRC2 would result in overlapping 
effects on the maintenance of ES cell pluripotency. However, in contrast to PRC2, 
Ring1A/B double knockout ES cells are unable to maintain pluripotency when 
cultured in vitro for a prolonged period of time (Endoh et al., 2008). Ring1A and 
Ring1B were shown to be required to maintain ES cells in an undifferentiated state 
by repressing the expression of developmental regulators that promote 
differentiation of ES cells (Endoh et al., 2008). Cells deficient for Ring1B alone can 
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however be maintained in culture in an undifferentiated state despite the fact that 
Ring1B is the homologue that contributes the most to H2A ubiquitylation in ES cells 
(de Napoles et al., 2004). Ring1A/B deficient ES cells show mis-expression of nearly 
1000 genes, whereas Ring1B knockout ES cells show deregulation of around 500 
genes. However, the deregulated genes in both Ring1A/B and Ring1B knockout ES 
cells closely overlap (Endoh et al., 2008). More importantly, the level of de-
repression of the affected genes was found to be much higher in Ring1A/B double-
knockout ES cells than in the Ring1B deficient ES cells. It was concluded that Ring1A 
and Ring1B act in a compensatory manner to repress the expression of 
developmental regulators in ES cells, thus contributing to the maintenance of 
pluripotency in ES cells (Endoh et al., 2008). In the same study, the link between the 
core transcriptional regulatory network in ES cells and PcG was investigated and the 
authors showed that Ring1A/B functions downstream of Oct4 and the recruitment of 
PRC1 complex to target genes is dependant on the presence of Oct4 (Endoh et al., 
2008). 
 
The contrasting data on the influence of PRC1 and PRC2 in ES cell pluripotency can 
be explained in a number of ways. One possible explanation for the differences 
observed is that during the derivation of PRC2 deficient ES cells, the cells may have 
acquired compensatory mechanisms to maintain pluripotency. In contrast there is 
insufficient opportunity for compensatory mechanisms to be selected/acquired in 
the conditional knockout of Ring1B in a Ring1A knockout background. An argument 
against this possibility however, is that Ezh2 conditional knockout ES cells can be 
maintained in an undifferentiated state (Stephan Sauer and Amanda Fisher, personal 
communication). Similarly, Eed conditional knockout ES cell lines have been recently 
characterised and shown to undergo morphological changes which are identical to 
the ones observed in the Eed deficient ES cell lines characterised in this thesis. 
Although the Eed knockout cell lines undergo morphological changes they can 
maintain the capability to self-renew in vitro and restoration of Eed expression 
reverses these changes giving rise to normal ES cell cultures (Ura et al., 2008). This 
suggests that both PRC1 and PRC2 have additional functions outside of the simplistic 
hierarchical model proposed for PcG. These differences can be explained in a 
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number of ways; Ring1A and Ring1B may contribute to complexes other than PRC1 
that do not contain the Pc subunit and hence, may have mechanisms of recruitment 
to genomic loci independent of PRC2. Examples of such complexes are the 
E2F6.com-1 complex (Ogawa et al., 2002; Trimarchi et al., 2001), which contains a 
subset of PcG proteins, transcription factors and an H3K9 histone methyltransferase 
or the BCOR complex, shown to contain several PcG proteins, Skp-Cullin-F-box (SCF) 
ubiquitin ligase components and a Jumonji C (Jmjc) domain containing histone 
demethylase (Gearhart et al., 2006). The disruption of PRC1 together with these 
other complexes could account for the differences observed in ES cells mutant for 
PRC2 and PRC1. Alternatively, although not mutually exclusive, PRC1 can be 
recruited to PRC2 target genes by other mechanisms independent of the presence of 
H3K27me3. Therefore, loss of PRC2 activity would not result in a loss of PRC1, and 
repression of these targets would be retained to some level. Supporting this idea, a 
recent report suggests that PRC1 can be recruited to the inactive X chromosome by 
mechanisms that are independent of PRC2 and H3K27me3 (Leeb and Wutz, 2007). 
This suggests that PRC1 complex can hypothetically have a distinct subset of targets 
from those of PRC2, which could account for the differences observed in PRC2 and 
PRC1 deficient ES cells. 
 
To distinguish between these possibilities, analysis of the distribution of the PRC1 
histone modification H2Aub1 by ChIP in PRC2 conditional knockout ES cells will 
reveal how the distribution of H2Aub1 and hence PRC1 recruitment is immediately 
affected in the absence of PRC2. Genome-wide studies of the redistribution of PRC1 
in PRC2 mutant ES cells will also clarify if PRC2 independent mechanisms are 
involved in the recruitment of PRC1 complex to its targets and if PRC1 is, in fact, 
indispensable for maintaining ES cells in a pluripotent state.  
 
7.2. Mechanisms of silencing by Polycomb group proteins  
The mechanisms by which PcG proteins induce gene silencing are poorly understood. 
In this thesis I present evidence for the role of PRC1 in the maintenance of silencing 
at bivalent loci in ES cells. The PRC1 complex is important for restraining the RNA 
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polymerase II (RNAPII) at the promoters of bivalent genes and thus maintains them 
in a silenced state (Stock et al., 2007). The removal of PRC1 from ES cells leads to the 
release of poised RNAPII from the promoters of bivalent genes resulting in the up-
regulation of these genes, which ultimately results in a failure to maintain 
pluripotency.  
 
The suggestion that a poised form of RNAPII localises to the promoter of silenced 
genes is not recent and was first described in Drosophila for heat shock genes (Lis, 
1998). Recently, it has been shown that RNAPII localises to the promoters of most 
genes in the human and Drosophila genome (Guenther et al., 2007; Muse et al., 
2007; Zeitlinger et al., 2007). Interestingly, the poised RNAPII found at the promoters 
of bivalent genes in ES cells is not efficiently recognised by an antibody used for 
detection of the stalled form of RNAPII (8WG16) in other cell types. This may be 
explained by the following hypothesis; in ES cells the stalled RNAPII bound to a 
bivalent promoter may adopt a particular conformation which prevents the efficient 
detection of the epitope by the 8WG16 antibody. The inability of the 8WG16 to 
detect the stalled RNAPII in ES cells may be a result of the RNAPII being in an 
uncharacterised phosphorylated form, or being associated with DNA in a different 
conformation and finally, by potentially being associated with other factors that 
mask the epitope recognised by the antibody.  
 
Multiple PcG target genes in ES cells were shown to exist in a bivalent conformation, 
a chromatin state characterised by the dual presence of both active histone marks 
(H3K4me3 and acetylated histones) and repressive histone marks (H3K27me3 and 
H2Aub1) (Bernstein et al., 2006). Initially, bivalency was proposed to be a chromatin 
signature unique to ES cells which poises genes for differentiation-coupled activation 
(Bernstein et al., 2007). Recently, this idea has been challenged by the observation 
that upon ES cell differentiation to fibroblasts, a number of these bivalent domains 
retain the characteristic “dual” histone configuration (Mikkelsen et al., 2007). 
Additionally a more recent study showed evidence for the de novo formation of 
bivalent domains in progenitor and terminally differentiated cell lines (Mohn et al., 
2008). Given these observations, it would be interesting to study the conformation 
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of RNAPII at bivalent promoters in progenitor and terminally differentiated cells in 
order to understand whether the characteristic conformation of RNAPII observed in 
ES cells is reproduced in other cell types or whether it is characteristic of progenitor 
cells. Additionally it would be interesting to dissect further the novel RNAPII 
conformation and determine whether it is in fact a novel phosphorylated form or 
structural conformation.  
 
The role of H2Aub1 in restraining poised RNAPII at bivalent promoters as described 
here is in contrast with recent data by Nakagawa and colleagues that show that 
H2Aub1 impacts on transcription by inhibiting H3K4me2 and –me3 methylation 
(Nakagawa et al., 2008). This seems paradoxical as bivalent genes have both PcG 
mediated histone modifications and H3K4 methylation. Different explanations could 
account for this. First, the different histone marks may exist on proximal or adjactent 
nucleosomes. However sequential-ChIP experiments suggest that this is not the case 
(Bernstein et al., 2006). A second possibility is that these histone modification marks 
are highly dynamic as suggested by the recent discovery that the UTX H3K27 
demethylase is associated with trithorax/MLL complexes which are responsible for 
H3K4me3  (Lee et al., 2007). Additionally an H3K4 demethylase, Rbp2 (Jarid1a) was 
shown to be recruited by PRC2 to a large number of PcG target genes (Pasini et al., 
2008). The recent discovery of several deubiquitylases (DUBs) for H2Aub1 and the 
role they play in gene regulation increases the dynamic potential of both active and 
repressive histone modification marks and states of transcription (Vissers et al., 
2008).  
 
In contrast to the role of PRC1 in directly influencing transcription as presented in 
this thesis, PRC1 has also been suggested to repress ATP-dependent nucleosome 
remodelling by the SWI/SNF complex in vitro (Shao et al., 1999) in addition to being 
able to condense chromatin in a Psc-dependent manner and in the absence of 
histone modifications (Francis et al, 2004). These studies would suggest that the 
PRC1 complex plays a structural role in limiting the accessibility of the transcriptional 
machinery to PcG targets. Whatever the mechanism(s) of silencing employed by 
PRC1 complex might be, this complex is essential for the transcriptional repression 
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mediated by PcG proteins in Drosophila and mammals. Paradoxically, no PRC1-like 
complexes or detectable H2Aub1 have been described in Arabidopsis or C. elegans 
(Kohler and Villar, 2008), suggesting that mechanisms of silencing mediated by PcG 
proteins may exist in the absence of PRC1. The absence of PRC1 from these 
organisms was initially suggested to be a direct consequence of evolution and to the 
degree to which these different organisms commit to cellular differentiation. PRC1 
was suggested to be dispensable as cells from these organisms need to retain their 
competence to de-differentiate. Consequently, a complex that stably silences genes 
was not favoured by evolution. This leaves us with the question of how silencing is 
achieved in the absence of PRC1. It is possible that PRC2 mediated H3K27me3 might 
directly repress transcription, for instance by inhibiting some steps involved in 
transcriptional activation or by preventing the deposition of histone marks 
associated with gene activation. However, in plants and worms, H3K27me3 may still 
be essential for creating binding sites that can be bound by different effector 
proteins that possess a chromodomain. An example of this is the recently discovered 
chromodomain protein, LIKE HETEROCHROMATIN PROTEIN 1 (LHP1), which is 
present in plants. The LHP1 protein was suggested to be a functional PRC1 analogue 
(Sung et al., 2006; Turck et al., 2007; Zhang et al., 2007). A recent report by Sanchez-
Pulido and colleagues reveals the identification of a new ubiquitin-like domain, the 
RAWUL domain, present in PRC1 Ring domain proteins (Sanchez-Pulido et al., 2008). 
The identification of this domain unveiled the presence of putative PRC1 Ring finger-
like proteins in plant and worms, suggesting that PRC1-like complexes may in fact be 
involved in PcG-mediated gene silencing mechanisms. Further studies are required 
to test these candidates. 
 
7.3. Mechanisms of Polycomb group protein recruitment – Is 
Polycomblike the missing link? 
The targeting of PcG proteins to specific regions within the genome is important to 
establish the precise patterns of gene expression that are involved in the 
maintenance of cellular identity and developmental potential. In flies, the way PcG 
proteins are targeted to different regions is thought to involve cis-acting DNA 
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elements, the Polycomb response elements (PREs). To date no PREs or PcG 
components that specifically bind DNA have been identified in mammalian cells and 
the mechanism of recruitment of PcG complexes to specific regions within the 
genome remains poorly understood. In this thesis I present data which confirms the 
existence of a Pcl2-PRC2 complex in mouse ES cells. Furthermore, the Pcl2 subunit 
was shown to be important for the efficient recruitment of core PRC2 components 
to the promoters of bivalent genes and the inactive X chromosome, during X-
chromosome inactivation. The Pcl2-PRC2 complex present in ES cells shares 
similarities with the recently characterised Pcl-PRC2 complex in Drosophila 
(Nekrasov et al., 2007) and the Pcl1-PRC2 complexes isolated from human HeLa cells 
(Cao et al., 2008; Sarma et al., 2008). Both the Drosophila Pcl and human Pcl1 
subunit promote the activity of the PRC2 complex, and are involved in maintaining 
high levels of H3K27me3 at target regions within the genome. Both studies by 
Nekrasov et al. and Cao et al. provide evidence that whilst the global levels of 
H3K27me3 are largely unaffected in the absence of Pcl, the recruitment of the PRC2 
components to PcG target genes is slightly reduced.  This reduction in recruitment 
translates into a mild decrease in the levels of H3K27me3 at target promoters (Cao 
et al., 2008; Nekrasov et al., 2007). 
 
Contrasting with the data presented in this thesis and the above mentioned studies, 
Sarma and colleagues reported that in HeLa cells, the knockdown of Pcl1 has no 
effect on the recruitment of PRC2 components to target promoters (Sarma et al., 
2008). These results can be explained by different technical approaches used in the 
different studies. Sarma and colleagues used a vector-based RNA interference 
approach to knockdown Pcl1 in HeLa cells. The efficiency of depletion of the target 
Pcl1 mRNAs observed in this study is low and the Pcl1 mRNA is only reduced to 
around 50% of the initial mRNA levels. The reduction in Pcl1 levels to 50% may not 
be sufficient to destabilise the Pcl1-PRC2 complex thus masking any real effects. 
Consistent with this interpretation, Cao and colleagues have shown that in an 
immortalized mouse male germ cell line, GC1Spg, with a reduction of 80% Pcl1 
mRNA, a subtle but consistent, decrease in the binding of Suz12 to the promoter 
region of HOXA10 is observed (Cao et al., 2008). Additionally, given the structural 
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similarity of the multiple Pcl homologues and the association of these homologues 
with PRC2 complexes, different Pcl homologues likely play compensatory roles. In 
mouse ES cells, where Pcl2 is the predominant Pcl homologue expressed, 
compensatory mechanisms are unlikely to be important and this is consistent with 
findings reported here. In contrast, HeLa cells have similar levels of Pcl1 and Pcl2 
expression (Sarma et al., 2008) and there is a strong possibility that these proteins 
might functionally compensate one another. In order to clarify these issues, 
strategies to combine knockout of the different Pcl homologues would test the 
existence of a compensatory mechanism.  
 
The knockdown of Pcl2 in ES cells has a less severe effect on H3K27me3 levels at 
PRC2 target promoters compared to the effects of knocking down Pcl in Drosophila 
or Pcl1 in HeLa cells, which additionally lead to expression changes of several of 
these target genes. However, Pcl2 knockdown had a more pronounced effect on the 
efficient recruitment of PRC2 and H3K27me3 to the inactive X chromosome during 
ES cell differentiation, compared to the promoters of PRC2 target genes in 
undifferentiated ES cells. These observations can be reconciled by considering the 
high levels of PRC2 proteins expressed in undifferentiated ES cells compared to 
differentiated cells. It can be hypothesised that the levels of PRC2 in ES cells are in 
excess and that even a significant reduction in the levels of PRC2 at target regions is 
not sufficient to cause any dramatic effect on the levels of H3K27me3 and hence, 
gene silencing. The knockdown of Pcl1 in HeLa cells or the knockdown of Pcl2 in 
differentiating ES cells where starting level of PRC2 proteins are relatively low will 
have more severe effects on PRC2 activity and gene silencing. Specifically, a 
reduction below a threshold level must occur for H3K27me3 to be reduced. To 
explore these issues further, the expression dynamics of Pcl2 and Pcl1 throughout ES 
cell differentiation and in distinct cell types (including human HeLa cells) has to be 
studied.  
    
A key unresolved question is the function of both the Tudor and PHD domains of Pcl 
proteins. One possibility is that these domains interact with methylated proteins, 
and particularly methylated histones. A number of Tudor domain containing proteins 
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have been shown to bind methylated histones (Brahms et al., 2001; Cote and 
Richard, 2005; Huyen et al., 2004; Kim et al., 2006; Sprangers et al., 2003). 
Specifically, the Tudor domain of 53BP1 was shown to bind histone H3K79me2 in 
addition to H4K20me2 (Botuyan et al., 2006; Huyen et al., 2004). PHD fingers have 
also been shown to be important for mediating the binding of diverse proteins to 
methylated histones (Bienz, 2006; Mellor, 2006). The PHD finger of the ING2 protein 
was shown to bind H3K4me3 (Shi et al., 2006). In Drosophila, depletion of Pcl leads 
to a slight increase in the levels of H3K27me2 and -me1 associated with PcG targets 
(Nekrasov et al., 2007). Similarly, Sarma and colleagues show that although global 
levels are not changed, the local levels of H3K27me2 at PcG target genes are 
increased (Sarma et al., 2008). Considering that H3K27me2 is present in about 40 to 
60% of total histone H3, it is possible that this mark acts as a binding site for Pcl, and 
thus recruiting the PRC2 complex to PcG targets. Another possibility is that PRC2 
devoid of a Pcl component is able to establish low levels of H3K27me3 which are 
required for the stabilisation of the Pcl-PRC2 complex. This stabilisation could 
potentially promote higher levels of H3K27me3 at target loci (Figure 7.2). To delve 
deeper into the recruitment of PRC2 complexes, it will be important to study the 
binding affinity of Pcl2 for different methylated histone residues. In addition, 
examining how the Tudor and PHD domains are involved in the potential binding to 
methylated histones has to be addressed. Moreover, understanding the dynamics of 
Pcl proteins and how Pcl-PRC2 might interact with other PRC2 complexes will give us 
a better insight into the diverse roles of PcG proteins. 
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Figure 7.2. A model for the function of the Pcl2-PRC2 sub-complex. The PRC2 core complex is 
composed of Eed, Suz12, Ezh2 and RbAP which are necessary and sufficient for the H3K27me3 activity 
of the complex. It is currently unclear how PRC2 interact with its target sequences. In addition to the 
core PRC2 complex, there are sub-stoichiometric forms of PRC2 which contain different accessory 
proteins. These accessory proteins may be involved in targeting the PRC2 complex to a subset of 
genes which are involved in different differentiation pathways. The Pcl2-PRC2 represents one of these 
sub-complexes and is thought to interact with chromatin either through binding of Pcl2 to methylated 
histone residues or by means of other accessory proteins. Pcl2 could act by increasing the H3K27 
methyltransferase activity of PRC2 at target genes and/or by promoting the recruitment of the PRC2 
complex to a subset of target genes. Pcl2 may additionally be involved in stabilisation of the 
recruitment of the core PRC2 complex, which might be essential for establishing high levels of 
H3K27me3 at PRC2 target genes.  
 
 
Recruitment of Pcl2-PRC2 to target loci may be mediated through the PHD and Tudor 
domains, as proposed above, but it may additionally involve other recruiting factors, 
either proteins or non coding RNAs. With this in mind, work presented in this thesis 
describes the biochemical purification of the Pcl2-PRC2 complex from mouse ES cells 
and presents evidence that Pcl2 is in a complex with PRC2 core components Ezh2, 
Eed and Suz12. This association is necessary to stabilise the Pcl2 protein. The analysis 
indicates that Pcl2 is associated with a small proportion of the total PRC2 complex 
present in ES cells. Additionally, the Pcl2-PRC2 complex may include a specific form 
of the PRC2 core protein Eed, which might correspond to either a single Eed isoform 
or a post-translationally modified form of the protein. Different post-translational 
modifications have been identified for PRC2 components, namely phosphorylation of 
Ezh2 and Eed (Cha et al., 2005; Tie et al., 2005) and sumoylation of Ezh2 and Suz12 
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(Riising et al., 2008). In Drosophila and mammals, Eed was shown to be 
phosphorylated in vivo but only contributed a small fraction of the total PRC2 
complex within cells (Tie et al., 2005). The phosphorylation of Esc/Eed was shown to 
influence the stability and assembly of the Eed containing complex and suggested to 
be important for targeting PRC2 to its targets (Tie et al., 2005). Interestingly, in 
Drosophila, the 1 MDa Pcl-PRC2 complex but not the 600 kDa complex was shown to 
be disrupted by alkaline phosphatase (AP) treatment (Tie et al., 2005). Taken 
together, these observations indicate that it is possible that Pcl2 (and other Pcl 
homologues) associates specifically with a phosphorylated form of Eed in a PRC2 
sub-complex or that Pcl2 may be required for Eed phosphorylation. To test this, 
further studies analysing the presence of different post-translational modifications 
present in the Eed protein found co-immunoprecipitating with Pcl2-FLAG could be 
carried out.  
 
The analysis of the mass spectrometry data obtained from the purified Pcl2-PRC2 
complexes from ES cells identifies new candidate partners that may suggest novel 
functions or recruitment mechanisms for the PRC2 complex. Amongst these putative 
candidates, Rbpj, Ring1B (Rnf2) and Pbrm1 were found to be present in at least 2 out 
of 3 immunoprecipitation experiments and are interesting candidates, suggesting 
potential links with PRC1 of which Ring1B is a core component, SWI/SNF chromatin 
remodelling complexes of which Pbrm1 (BAF180) is a subunit (Xue et al., 2000) and 
Notch effector complexes that have Rbpj as the main transcriptional effector 
(Jarriault et al., 1995; Lai, 2002). All of these candidates will need to be investigated 
further, for example carrying out reciprocal affinity tag purifications. The Mascot 
scores for Ring1B and Pbrm1 were relatively low and no other PRC1 or SWI/SNF 
components were found, perhaps indicating that these interactions are weak or non-
specific. Rbpj was identified as a strong candidate interactor, with 8 unique peptides 
identified and a high Mascot score in one of the immunoprecipitation, and was 
found to be present in the two other immunoprecipitations, albeit with lower 
Mascot scores and number of unique peptides identified. Rbpj is a transcriptional 
repressor that specifically binds certain consensus DNA sequences and which, in the 
absence of Notch-1 activation, forms a repressor complex together with other 
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proteins, like Skip, SMRT/N-CoR and the histone deacetylase HDAC1 (Lai, 2002). 
Once activated, intracytoplasmic Notch-1 displaces Rbpj repressive complex and 
creates an Rbpj activating complex by promoting its interactions with MAML, CBP-
p300 and histone acetyltransferases (Hsieh et al., 1999; Jarriault et al., 1995; Wu and 
Griffin, 2004). In mammals, Notch regulates numerous cell fate decisions during 
hematopoiesis, neurogenesis and many other tissue-developing processes. Notch 
signalling has two contrasting functions; depending on the developmental stage, it 
either suppresses or facilitates differentiation. The potential involvement of Rbpj 
with the Pcl2-PRC2 complex is interesting and may define a novel layer of regulation 
that depends on the crosstalk between epigenetics and cell signalling, speficially 
Notch pathway activation. None of the mammalian core PcG proteins have been 
shown to directly bind DNA. The confirmation of Rbpj as a true Pcl2-PRC2 interactor 
would therefore reveal a novel DNA based mechanism for recruitment of PcG 
proteins.  
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Appendix 
 
 
Gene   Primer Sequence Ta 
Oct4 
F GGAGGGATGGCATACTGTGG 
60°C 
R CTCATTGTTGTCGGCTTCCTC 
Nanog 
F TTACAAGGGTCTGCTACTGAG 
57°C 
R CAATGGATGCTGGGATACTC 
Fgf4 
F GAGTGGCCAGCCGGTTCTTC 
65°C 
R TTCTTGGTCCGCCCGTTCTTAC 
Cdx2 
F TCAACCTCGCCACAACCTTCCC 
60°C 
R TGGCTCAGCCTGGGATTGCT 
Hand1 
F ACGTGCTGGCCAAGGATGCA 
60°C 
R TGGTTTAGCTCCAGCGCCCA 
Errb 
F CCCGGCCACCAATGAATGT 
64°C 
R GGTACACGATGCCCAAGATG 
Gata6 
F GACTCCTACTTCCTCTTCTTCTAATTCAGA 
60°C 
R ACCTGAATACTTGAGGTCACTGTTCTC 
FoxA 
F CCATCAGCCCCACAAAATG 
60°C 
R CCAAGCTGCCTGGCATG 
Sox7 
F CCGTGGACCGAGGGACTGGA 
62°C 
R GAGGGAGCTGAGGAGGAAG 
Afp 
F ATCGACCTCACCGGGAAGAT 
60°C 
R GAGTTCACAGGGCTTGCTTCA 
T 
F TTCATCTGCTTGTCTGTCCA 
60°C 
R CGTGTCATACTGGCTGTCA 
Gapdh 
F AACTCGGCCCCCAACACT 
60°C 
R CCTAGGCCCCTCCTGTTATTATG 
Table A1. Semi-quantitative RT-PCR primer sequences and corresponding 
annealing temperatures.   
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Primer name Primer sequence 
 
Gapdh F TGCACCACCAACTGCTTAGC 
 
Gapdh R GGCATGGACTGTGGTCATGAG 
 
Idh F AGAAAATGTGGAAGAGCCCTAACG 
 
Idh R TGCCAGCTCGATCTACCACAAAAT 
 
hmbs F CTGTACCTGACTGGTGGAGTCTGGAGTC 
 
hmbs R TGATGCCCAGGTTCTCAGCAGCT 
 
B2M F ACCCGCCTCACATTGAAATCC 
 
B2M R CGATCCCAGTAGACGGTCTTG 
 
B-actin F GATATCGCTGCGCTGGTCGT 
 
B-actin R AGATCTTCTCCATGTCGTCC 
 
mHPRT F         TTGAAATTCCAGACAAGTTTGTTGTTGG  
 
mHPRT R          CCTGCTAATTTTACTGGCAACATCAACA      
 
Pcl2 F1/2 AGGGGTGGTGCGCTTAAGAAAG 
 
Pcl2 R1 GGCATTGGACACAAGCTTCATGA 
 
Pcl2 R2 CATTGGCTTCTGAAGGCATTGGA 
 
Pcl1 F GTGGACAGTGCTCGAGAGGTGTGT 
 
Pcl1 R ATGCGCCCTCTCCTTCTCCA 
 
Pcl3 F GTTACCACCAACAGTGCCACATCC 
 
Pcl3 R TTCACTGCCTGCAGCGTCTTGG 
 
Eed F1 CAAATGTGTGAACAGCCTCAAGGAA 
 
Eed R1 GCATCAGCATCTACATAGGACTGCAA 
 
Ezh2 F1 CTGGAGTCAAAGGATACAGACAGTGACA 
 
Ezh2 R1 TCAGCACCACTCCACTCCACATT 
 
Suz12 F2 TTTGAGACATTTTCTCAGGGACCTACA 
 
Suz12 R2 TGTAGTCAGCGTCTCCTTAACAGCAAT 
 
Oct4 F CGTGGAGACTTTGCAGCCTG 
 
Oct4 R GCTTGGCAAACTGTTCTAGCTCCT 
 
Nanog F GAACTATTCTTGCTTACAAGGGTCTGC   
 
Nanog R     GCATCTTCTGCTTCCTGGCAA    
 
Rex1 F GAGCTGAACTCCTAGCCGCCTAGATT 
 
Rex1 R TTTGGTCAGTGGTATTTGGGGAGA 
 
Cdx2 F TCAACCTCGCCACAACCTTCCC  
 
Cdx2 R TGGCTCAGCCTGGGATTGCT    
 
Hand1 F ACGTGCTGGCCAAGGATGCA 
 
Hand1 R TGGTTTAGCTCCAGCGCCCA 
 
Gata6 F GACTCCTACTTCCTCTTCTTCTAATTCAGA 
 
Gata6 R ACCTGAATACTTGAGGTCACTGTTCTC 
 
Hnf4 F AATGGACAGATGTGTGAGTGGCC 
 
Hnf4 R CCAGCAGCTTGCTAGATGGC 
 
Eomes F TTCACCTTCTCAGAGACACAGTTCAT 
 
Eomes R GAGTTAACCTGTCATTTTCTGAAGCC 
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HoxA7 F AGTTCAGGACCCGACAGGAA 
 
HoxA7 R TTGATCTGGCGCTCAGTGAG 
 
Gata4 F GAGGCTCAGCCGCAGTTGCAG 
 
Gata4 R CGGCTAAAGAAGCCTAGTCCTTGCTT 
 
MyoD F CTGCTTTCTTCACCACACCTCTG 
 
MyoD R TCAACCCAAGCCGTGAGAGT 
 
Flk-1 F AGGGGAACTGAAGACAGGCTA  
 
Flk-1 R GATGCTCCAAGGTCAGGAAGT 
 
Nkx2.2 F TGTGCAGAGCCTGCCCCTTAA 
 
Nkx2.2 R GCCCTGGGTCTCCTTGTCAT 
 
Msx1 F GCCTCTCGGCCATTTCTCAG 
 
Msx1 R CGGTTGGTCTTGTGCTTGCC 
 
Math1 F GGAGAAGCTTCGTTGCACGC 
 
Math1 R GGACATCGCACTGCAATGG 
 
Sox1 F TGAACGCCTTCATGGTGTGGTC 
 
Sox1 R GCGCGGCCGGTACTTGTAAT 
 
Ikaros F TCGGGAGAGAAAATGAATGG 
 
Ikaros R AGGCCGTTCACCAGTATGAC 
 
   Table A2. List of primers used for real-time PCR in expression 
analyses, in 5' to 3' orientation.   
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Primer name Primer sequence 
 β-actin promoter F  GCAGGCCTAGTAACCGAGACA 
 β-actin promoter R  AGTTTTGGCGATGGGTGCT 
 β-actin coding F  TCCTGGCCTCACTGTCCAC 
 β-actin coding R  GTCCGCCTAGAAGCACTTGC 
 Oct4 promoter F  GGCTCTCCAGAGGATGGCTGAG 
 Oct4 promoter R  TCGGATGCCCCATCGCA 
 Oct4 coding F  CCTGCAGAAGGAGCTAGAACA 
 Oct4 coding R  TGTGGAGAAGCAGCTCCTAAG 
 Sox2 promoter F  CCATCCACCCTTATGTATCCAAG 
 Sox2 promoter R  CGAAGGAAGTGGGTAAACAGCAC 
 Sox2 coding F  GGAGCAACGGCAGCTA 
 Sox2 coding R  GTAGCGGTGCATCGGT 
 Math1 promoter F  CCTTCTTTGACTGGGCAGAC 
 Math1 promoter R  ACTCGGAGATCGCACACC 
 Math1 coding F  CCAGTTGCCATTGCTTTAT 
 Math1 coding R  AGGATACTAGATTTGCAACATTCTT 
 Nkx2.2 promoter F  CAGGTTCGTGAGTGGAGCCC 
 Nkx2.2 promoter R  GCGCGGCCTCAGTTTGTAAC 
 Nkx2.2 coding F  AGAGCCCTCGGCTGACGAGT 
 Nkx2.2 coding R  CGTGAGACGGATGAGGCTGG 
 Msx1 promoter F  ACAGAAAGAAATAGCACAGACCATAAGA 
 Msx1 promoter R  TTCTACCAAGTTCCAGAGGGACTTT 
 Msx1 coding F  AGATGGCCGCGAAAC 
 Msx1 coding R  CCAGAGGCACTGTAGAGTGA 
 Nkx2.9 promoter F  TGGCACCTTCCGGACTTG 
 Nkx2.9 promoter R  AAGTGCGAGGCGCTCG 
 Nkx2.9 coding F  AGCTCTGGTCTCCTGGAACT 
 Nkx2.9 coding R  GTGTGTGTTTGCCGGTTAG 
 Mash1 promoter F  CCAGGCTGGAGCAAGGGA 
 Mash1 promoter R  CGGTTGGCTTCGGGAGC 
 Mash1 coding F  CCAGAATGACTTCAGCACCA 
 Mash1 coding R  AGGCAACCTATGGGAACCAA 
 Cdx2 promoter F  GGACTCCGCGAGCCAA 
 Cdx2 promoter R  CTCAGCCCACGGTGCTC 
 Cdx2 coding F  CCAATGACTGATGGATTGTAGTT 
 Cdx2 coding R  GCTCACTTTTCCTCCTGATG 
 HoxA7 promoter F  GAGAGGTGGGCAAAGAGTGG 
 HoxA7 promoter R  CCGACAACCTCATACCTATTCCTG 
 HoxA7 coding F  CTGGACCTTGATGCTTCTAACT 
 HoxA7 coding R  AGCCAGAGAAAGAGGGATTCTA 
 Flk1 promoter F  CCACCCCTCCCGGTAA 
 Flk1 promoter R  GGTCCGCGCGATCTAA 
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Flk1 coding F  TTCATGGACCCAAAGACTAC 
 Flk1 coding R  GTTCTCGGTGATGTACACG 
 Gata4 promoter F  AAGAGCGCTTGCGTCTCTA 
 Gata4 promoter R  TTGCTAGCCTCAGATCTACGG 
 Gata4 coding F  TTGCACATTAACACCACACGTATA 
 Gata4 coding R  CCACCATTCAATTTTTAAGTCAAGTA 
 Gata1 promoter F  AGAGGAGGGAGAAGGTGAGTG 
 Gata1 promoter R  AGCCACCTTAGTGGTATGACG 
 Gata1 coding F  TGGATTTTCCTGGTCTAGGG 
 Gata1 coding R  GTAGGCCTCAGCTTCTCTGTAGTA 
 Myf5 promoter F  GGAGATCCGTGCGTTAAGAATCC 
 Myf5 promoter R  CGGTAGCAAGACATTAAAGTTCCGTA 
 Myf5 coding F  GATTGCTTGTCCAGCATTGT 
 Myf5 coding R  AGTGATCATCGGGAGAGAGTT 
 λ5 HS2  ACCCAGTAAGCAAGTTTTCA 
 λ5 HS2  ATAAGCTCTCCTCCCTCAAG 
 B2M_promoter_F1 GCATCAACAGCTAGGGACTGGTGAC 
 B2M_promoter_R1 CCGAGTAGCAGCCACTGAAATGAG 
 Ikaros promoter F TCGGGGAACACGGGACAC 
 Ikaros promoter R CCAGTTTCAGGGACTCGGCT 
 Hnf4 promoter F AAAGAAGGTACTGGGTTTCCTGGA 
 Hnf4 promoter R AATTAAGCCTTGAGCCAAAGGAGT 
 FGF5 promoter F TTCCCAGGCTCCAGATGGC 
 FGF5 promoter R CATGTGTCCCAGCCAACTCACT 
 Gata 6 promoter F GACTCCTACTTCCTCTTCTTCTAATTCAGA 
 Gata 6 promoter R ACCTGAATACTTGAGGTCACTGTTCTC 
 Nanog promoter F CCCAGGTTTCCCAATGTGAAG 
 Nanog promoter R AAAGAGTCAGACCTTGCTGCCA 
 Rex1 promoter F TTGCGGGAATCCAGCAGT 
 Rex1 promoter R CGTCCCATCGCCACTCTAGAC 
 Hand1 promoter F GGCCTAGCCTACTTCCCTGCT 
 Hand1 promoter R CAGCATTCCTGAACCCGAACT 
 Sox1 promoter F ACAAGAGGAGGCAGCGAACC 
 Sox1 promoter R TCGCAGGTGGAAAGTTTCTCC 
 
   Table A3. List of primers used for real-time PCR in ChIP analyses, in 5' to 3' orientation. Region of the 
gene amplified by the primer pair (promotor or coding region) is indicated. 
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Table A4. List of primary antibodies used throughout this study, in chromatin immunoprecipitation 
(ChIP), western blot (WB) and immunofluorescence (IF). For each antibody, is indicated the type of 
antibody, the supplier, reference and dilutions used for each application. 
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Table A5. List of secondary antibodies and corresponding dilutions used in this study for various 
applications (immunofluorescense (IF), western blot (WB) and RNA Fluorescence in-situ hybridization 
(FISH)). 
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Table A6. List of oligonucleotides used for shRNA cloning for Pcl2 knockdown. Sequences for the 
BamHI-XhoI cloning are shown in red. shRNA linker sequences are shown in green. 
 
 
